04 Immunosuppressive Therapy For Aplastic

{\rtf\ansi\deff0{\fonttbl{\f0 Garamond;}{\f1 Times New Roman;}{\f2 Segoe UI;}{\f
3 Palatino Linotype;}{\f4 Helvetica;}}{\colortbl\red0\green0\blue0;\red255\green

255\blue255;}\paperw12132\paperh15987\margl0\margr0\margt0\margb0\sectd\sbknone\
sected\cols2\colno1\colw3390\colsr10\colno2\colw8720\pard\plain\sl-200\par\pard\
plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-207\par\pard\plain\li1021\s
l-228\f0\fs18\cf0\b0\i0\ul0\strike0 16\f0\fs12\cf0\b0\i0\ul0\strike0 \par\pard\
column\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\s
l-262\par\pard\plain\li0\sl-152\f0\fs12\cf0\b0\i0\ul0\strike0 supplement to Jour
nal of the association of physicians of india \u183? published on 1st of every m
onth 1st march, 2015\par\sect\sected\sbknone\cols1\colno1\colw12120\pard\plain\s
l-359\par\pard\plain\li1021\sl-576\f1\fs48\cf0\b0\i0\ul\strike0 Immunosuppressiv
e Therapy for Aplastic Anaemia\par\pard\plain\li1021\sl-473\f1\fs26\cf0\b0\i0\ul
0\strike0 S\f1\fs26\cf0\b0\i0\ul0\strike0 Damodar\f1\fs14\cf0\b0\i0\ul0\strike0
*\par\pard\plain\sl-369\par\pard\plain\li1492\sl-297\f2\fs24\cf0\b\i0\ul0\strik
e0 Abstract\par\pard\plain\li1492\sl-290\f1\fs20\cf0\b0\i0\ul0\strike0 Immunosup
pressive\f1\fs20\cf0\b0\i0\ul0\strike0 therapy\f1\fs20\cf0\b0\i0\ul0\strike0 i
s\f1\fs20\cf0\b0\i0\ul0\strike0 the\f1\fs20\cf0\b0\i0\ul0\strike0 standard\f1\
fs20\cf0\b0\i0\ul0\strike0 of\f1\fs20\cf0\b0\i0\ul0\strike0 care\f1\fs20\cf0\b
0\i0\ul0\strike0 in\f1\fs20\cf0\b0\i0\ul0\strike0 aplastic\f1\fs20\cf0\b0\i0\u
l0\strike0 anaemia\f1\fs20\cf0\b0\i0\ul0\strike0 in\f1\fs20\cf0\b0\i0\ul0\stri
ke0 younger\f1\fs20\cf0\b0\i0\ul0\strike0 patients\f1\fs20\cf0\b0\i0\ul0\strik
e0 who\f1\fs20\cf0\b0\i0\ul0\strike0 do\par\pard\plain\li1492\sl-240\f1\fs20\c
f0\b0\i0\ul0\strike0 not\f1\fs20\cf0\b0\i0\ul0\strike0 have\f1\fs20\cf0\b0\i0\u
l0\strike0 a\f1\fs20\cf0\b0\i0\ul0\strike0 matched\f1\fs20\cf0\b0\i0\ul0\strik
e0 sibling\f1\fs20\cf0\b0\i0\ul0\strike0 donor,\f1\fs20\cf0\b0\i0\ul0\strike0
and\f1\fs20\cf0\b0\i0\ul0\strike0 also\f1\fs20\cf0\b0\i0\ul0\strike0 in\f1\fs
20\cf0\b0\i0\ul0\strike0 adults\f1\fs20\cf0\b0\i0\ul0\strike0 and\f1\fs20\cf0\
b0\i0\ul0\strike0 older\f1\fs20\cf0\b0\i0\ul0\strike0 patients.\f1\fs20\cf0\b0
\i0\ul0\strike0 Hence,\f1\fs20\cf0\b0\i0\ul0\strike0 a\f1\fs20\cf0\b0\i0\ul0\s
trike0 large\f1\fs20\cf0\b0\i0\ul0\strike0 population\f1\fs20\cf0\b0\i0\ul0\st
rike0 of\par\pard\plain\li1492\sl-240\f1\fs20\cf0\b0\i0\ul0\strike0 patients\f1
\fs20\cf0\b0\i0\ul0\strike0 with\f1\fs20\cf0\b0\i0\ul0\strike0 aplastic\f1\fs2
0\cf0\b0\i0\ul0\strike0 anaemia\f1\fs20\cf0\b0\i0\ul0\strike0 undergo\f1\fs20\
cf0\b0\i0\ul0\strike0 this\f1\fs20\cf0\b0\i0\ul0\strike0 treatment.\f1\fs20\cf
0\b0\i0\ul0\strike0 In\f1\fs20\cf0\b0\i0\ul0\strike0 patients\f1\fs20\cf0\b0\i
0\ul0\strike0 who\f1\fs20\cf0\b0\i0\ul0\strike0 have\f1\fs20\cf0\b0\i0\ul0\str
ike0 responded\f1\fs20\cf0\b0\i0\ul0\strike0 to\f1\fs20\cf0\b0\i0\ul0\strike0
the\f1\fs20\cf0\b0\i0\ul0\strike0 first\f1\fs20\cf0\b0\i0\ul0\strike0 course\
par\pard\plain\li1492\sl-240\f1\fs20\cf0\b0\i0\ul0\strike0 of\f1\fs20\cf0\b0\i0\
ul0\strike0 ATG,\f1\fs20\cf0\b0\i0\ul0\strike0 and\f1\fs20\cf0\b0\i0\ul0\strik
e0 have\f1\fs20\cf0\b0\i0\ul0\strike0 had\f1\fs20\cf0\b0\i0\ul0\strike0 a\f1\
fs20\cf0\b0\i0\ul0\strike0 relapse,\f1\fs20\cf0\b0\i0\ul0\strike0 a\f1\fs20\cf
0\b0\i0\ul0\strike0 second\f1\fs20\cf0\b0\i0\ul0\strike0 course\f1\fs20\cf0\b0
\i0\ul0\strike0 of\f1\fs20\cf0\b0\i0\ul0\strike0 ATG\f1\fs20\cf0\b0\i0\ul0\str
ike0 can\f1\fs20\cf0\b0\i0\ul0\strike0 be\f1\fs20\cf0\b0\i0\ul0\strike0 admin
istered\f1\fs20\cf0\b0\i0\ul0\strike0 with\f1\fs20\cf0\b0\i0\ul0\strike0 reaso
nable\f1\fs20\cf0\b0\i0\ul0\strike0 response\par\pard\plain\li1492\sl-240\f1\fs
20\cf0\b0\i0\ul0\strike0 rates.\f1\fs20\cf0\b0\i0\ul0\strike0 Response\f1\fs20\
cf0\b0\i0\ul0\strike0 rates\f1\fs20\cf0\b0\i0\ul0\strike0 to\f1\fs20\cf0\b0\i0
\ul0\strike0 first\f1\fs20\cf0\b0\i0\ul0\strike0 course\f1\fs20\cf0\b0\i0\ul0\
strike0 of\f1\fs20\cf0\b0\i0\ul0\strike0 ATG\f1\fs20\cf0\b0\i0\ul0\strike0 va
ry\f1\fs20\cf0\b0\i0\ul0\strike0 from\f1\fs20\cf0\b0\i0\ul0\strike0 50-85%\f1\
fs20\cf0\b0\i0\ul0\strike0 in\f1\fs20\cf0\b0\i0\ul0\strike0 both\f1\fs20\cf0\b
0\i0\ul0\strike0 children\f1\fs20\cf0\b0\i0\ul0\strike0 and\f1\fs20\cf0\b0\i0\
ul0\strike0 adult.\f1\fs20\cf0\b0\i0\ul0\strike0 Indian\f1\fs20\cf0\b0\i0\ul0\
strike0 data\f1\fs20\cf0\b0\i0\ul0\strike0 also\par\pard\plain\li1492\sl-240\f
1\fs20\cf0\b0\i0\ul0\strike0 suggests\f1\fs20\cf0\b0\i0\ul0\strike0 similar\f1\
fs20\cf0\b0\i0\ul0\strike0 response\f1\fs20\cf0\b0\i0\ul0\strike0 rates.\par\s
ect\sected\sbknone\cols3\colno1\colw3330\colsr10\colno2\colw4110\colsr10\colno3\
colw4660\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\
plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\p
ar\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\
sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\par
d\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200
\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plai
n\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\p
ard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-2
00\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\pl
ain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par
\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl
-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\
plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\p
ar\pard\plain\sl-296\par\pard\plain\li1580\sl-98\f1\fs8\cf0\b0\i0\ul0\strike0 *\
par\pard\plain\li1613\sl-261\f1\fs14\cf0\b0\i0\ul0\strike0 Narayana\f1\fs14\cf0\
b0\i0\ul0\strike0 Health\f1\fs14\cf0\b0\i0\ul0\strike0 city\f1\fs14\cf0\b0\i0\
ul0\strike0 /\par\pard\plain\li1488\sl-200\f1\fs14\cf0\b0\i0\ul0\strike0 Mazumd
ar\f1\fs14\cf0\b0\i0\ul0\strike0 Shaw\f1\fs14\cf0\b0\i0\ul0\strike0 Cancer\par
\pard\plain\li1224\sl-200\f1\fs14\cf0\b0\i0\ul0\strike0 Centre,\f1\fs14\cf0\b0\i
0\ul0\strike0 258/A\f1\fs14\cf0\b0\i0\ul0\strike0 Bommasandra\par\pard\plain\l
i1247\sl-200\f1\fs14\cf0\b0\i0\ul0\strike0 industrial\f1\fs14\cf0\b0\i0\ul0\stri
ke0 area,\f1\fs14\cf0\b0\i0\ul0\strike0 Anekal\f1\fs14\cf0\b0\i0\ul0\strike0
Taluk,\par\pard\plain\li1825\sl-200\f1\fs14\cf0\b0\i0\ul0\strike0 Bangalore-5600
99\par\pard\column\plain\sl-232\par\pard\plain\li0\sl-322\f2\fs26\cf0\b\i0\ul0\s
trike0 Introduction\par\pard\plain\li325\sl-383\f3\fs18\cf0\b0\i0\ul0\strike0 he
rapy\f3\fs18\cf0\b0\i0\ul0\strike0 for\f3\fs18\cf0\b0\i0\ul0\strike0 aplastic\
f3\fs18\cf0\b0\i0\ul0\strike0 anaemia\par\pard\plain\li325\sl-220\f3\fs18\cf0\b
0\i0\ul0\strike0 (\f3\fs18\cf0\b0\i0\ul0\strike0 A\f3\fs18\cf0\b0\i0\ul0\strike
0 A)\f3\fs18\cf0\b0\i0\ul0\strike0 e\f3\fs18\cf0\b0\i0\ul0\strike0 s\f3\fs18\
cf0\b0\i0\ul0\strike0 s\f3\fs18\cf0\b0\i0\ul0\strike0 e\f3\fs18\cf0\b0\i0\ul0\
strike0 n\f3\fs18\cf0\b0\i0\ul0\strike0 t\f3\fs18\cf0\b0\i0\ul0\strike0 i\f3\
fs18\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\b0\i0\ul0\strike0 l\f3\fs18\cf0\b0\i0
\ul0\strike0 l\f3\fs18\cf0\b0\i0\ul0\strike0 y\f3\fs18\cf0\b0\i0\ul0\strike0
c\f3\fs18\cf0\b0\i0\ul0\strike0 o\f3\fs18\cf0\b0\i0\ul0\strike0 n\f3\fs18\cf0\
b0\i0\ul0\strike0 s\f3\fs18\cf0\b0\i0\ul0\strike0 i\f3\fs18\cf0\b0\i0\ul0\stri
ke0 s\f3\fs18\cf0\b0\i0\ul0\strike0 t\f3\fs18\cf0\b0\i0\ul0\strike0 s\f3\fs18
\cf0\b0\i0\ul0\strike0 o\f3\fs18\cf0\b0\i0\ul0\strike0 f\f3\fs18\cf0\b0\i0\ul0
\strike0 3\par\pard\plain\li0\sl-220\f3\fs18\cf0\b0\i0\ul0\strike0 modalities\f
3\fs18\cf0\b0\i0\ul0\strike0 \u8211?\f3\fs18\cf0\b0\i0\ul0\strike0 stem\f3\fs1
8\cf0\b0\i0\ul0\strike0 cell\f3\fs18\cf0\b0\i0\ul0\strike0 transplant\f3\fs18\
cf0\b0\i0\ul0\strike0 (SCT),\par\pard\plain\li0\sl-220\f3\fs18\cf0\b0\i0\ul0\st
rike0 immunosuppressive\f3\fs18\cf0\b0\i0\ul0\strike0 therapy\f3\fs18\cf0\b0\i0
\ul0\strike0 (IST)\f3\fs18\cf0\b0\i0\ul0\strike0 and\par\pard\plain\li0\sl-220
\f3\fs18\cf0\b0\i0\ul0\strike0 supportive\f3\fs18\cf0\b0\i0\ul0\strike0 care\f3
\fs18\cf0\b0\i0\ul0\strike0 only.\f3\fs18\cf0\b0\i0\ul0\strike0 Supportive\f3\
fs18\cf0\b0\i0\ul0\strike0 care\f3\fs18\cf0\b0\i0\ul0\strike0 is\par\pard\plai
n\li0\sl-220\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 ba
re\f3\fs18\cf0\b0\i0\ul0\strike0 minimum,\f3\fs18\cf0\b0\i0\ul0\strike0 which\
f3\fs18\cf0\b0\i0\ul0\strike0 is\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0
\b0\i0\ul0\strike0 common\par\pard\plain\li0\sl-220\f3\fs18\cf0\b0\i0\ul0\strik
e0 factor\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 any\f
3\fs18\cf0\b0\i0\ul0\strike0 treatment.\f3\fs18\cf0\b0\i0\ul0\strike0 We\f3\fs
18\cf0\b0\i0\ul0\strike0 will\f3\fs18\cf0\b0\i0\ul0\strike0 discuss\par\pard\p
lain\li0\sl-220\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0
option\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 immunos
uppressive\f3\fs18\cf0\b0\i0\ul0\strike0 therapy\par\pard\plain\li0\sl-220\f3\f
s18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 relation\f3\fs18\cf0
\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 its\f3\fs18\cf0\b0\i0\ul0\
strike0 feasibility\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\str
ike0 our\f3\fs18\cf0\b0\i0\ul0\strike0 country.\par\pard\plain\li0\sl-424\f2\f
s26\cf0\b\i0\ul0\strike0 History\f2\fs26\cf0\b\i0\ul0\strike0 of\f2\fs26\cf0\b\
i0\ul0\strike0 IST\f2\fs26\cf0\b\i0\ul0\strike0 for\f2\fs26\cf0\b\i0\ul0\strik

e0 Aplastic\par\pard\plain\li0\sl-312\f2\fs26\cf0\b\i0\ul0\strike0 Anemia\par\p
ard\plain\li239\sl-393\f3\fs18\cf0\b0\i0\ul0\strike0 The\f3\fs18\cf0\b0\i0\ul0\s
trike0 first\f3\fs18\cf0\b0\i0\ul0\strike0 reports\f3\fs18\cf0\b0\i0\ul0\strik
e0 of\f3\fs18\cf0\b0\i0\ul0\strike0 IST\f3\fs18\cf0\b0\i0\ul0\strike0 working
\f3\fs18\cf0\b0\i0\ul0\strike0 in\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\u
l0\strike0 AA\f3\fs18\cf0\b0\i0\ul0\strike0 came\f3\fs18\cf0\b0\i0\ul0\strike0
from\f3\fs18\cf0\b0\i0\ul0\strike0 patients\f3\fs18\cf0\b0\i0\ul0\strike0 who
\f3\fs18\cf0\b0\i0\ul0\strike0 received\par\pard\plain\li0\sl-230\f3\fs18\cf0\b
0\i0\ul0\strike0 conditioning\f3\fs18\cf0\b0\i0\ul0\strike0 therapy\f3\fs18\cf0
\b0\i0\ul0\strike0 for\f3\fs18\cf0\b0\i0\ul0\strike0 stem\f3\fs18\cf0\b0\i0\ul
0\strike0 cell\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 transpla
nt\f3\fs18\cf0\b0\i0\ul0\strike0 but\f3\fs18\cf0\b0\i0\ul0\strike0 failed\f3\f
s18\cf0\b0\i0\ul0\strike0 donor\f3\fs18\cf0\b0\i0\ul0\strike0 engraftment\par\
pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 and\f3\fs18\cf0\b0\i0\ul0\st
rike0 had\f3\fs18\cf0\b0\i0\ul0\strike0 autologous\f3\fs18\cf0\b0\i0\ul0\strik
e0 recovery\f3\fs18\cf0\b0\i0\ul0\strike0 of\par\pard\plain\li0\sl-230\f3\fs18
\cf0\b0\i0\ul0\strike0 hematopoiesis.\f3\fs10\cf0\b0\i0\ul0\strike0 1,2\f3\fs18
\cf0\b0\i0\ul0\strike0 This\f3\fs18\cf0\b0\i0\ul0\strike0 leads\f3\fs18\cf0\b0
\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\str
ike0 theory\par\pard\plain\li0\sl-229\f3\fs18\cf0\b0\i0\ul0\strike0 that\f3\fs1
8\cf0\b0\i0\ul0\strike0 immunosuppression\f3\fs18\cf0\b0\i0\ul0\strike0 itself
\f3\fs18\cf0\b0\i0\ul0\strike0 may\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\
ul0\strike0 be\f3\fs18\cf0\b0\i0\ul0\strike0 sufficient\f3\fs18\cf0\b0\i0\ul0\s
trike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 some\f3\fs18\cf0\b0\i0\ul0\strike0 pa
tients\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 allow\pa
r\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 hematopoietic\f3\fs18\cf0\
b0\i0\ul0\strike0 recovery.\f3\fs18\cf0\b0\i0\ul0\strike0 Subsequent\par\pard\
plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 studies\f3\fs18\cf0\b0\i0\ul0\str
ike0 then\f3\fs18\cf0\b0\i0\ul0\strike0 showed\f3\fs18\cf0\b0\i0\ul0\strike0
that\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 infusion\
f3\fs18\cf0\b0\i0\ul0\strike0 of\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul
0\strike0 Anti-lymphocyte\f3\fs18\cf0\b0\i0\ul0\strike0 globulin\f3\fs18\cf0\b0
\i0\ul0\strike0 (ALG)\f3\fs18\cf0\b0\i0\ul0\strike0 alone\par\pard\plain\li0\s
l-230\f3\fs18\cf0\b0\i0\ul0\strike0 lead\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs
18\cf0\b0\i0\ul0\strike0 hematopoietic\f3\fs18\cf0\b0\i0\ul0\strike0 recovery\
f3\fs18\cf0\b0\i0\ul0\strike0 and\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\u
l0\strike0 based\f3\fs18\cf0\b0\i0\ul0\strike0 on\f3\fs18\cf0\b0\i0\ul0\strike0
the\f3\fs18\cf0\b0\i0\ul0\strike0 results\f3\fs18\cf0\b0\i0\ul0\strike0 of\f
3\fs18\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\b0\i0\ul0\strike0 prospective\par\p
ard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 randomised\f3\fs18\cf0\b0\i0\
ul0\strike0 trial,\f3\fs10\cf0\b0\i0\ul0\strike0 3\f3\fs18\cf0\b0\i0\ul0\strik
e0 IST\f3\fs18\cf0\b0\i0\ul0\strike0 became\f3\fs18\cf0\b0\i0\ul0\strike0 the
\par\pard\plain\li0\sl-229\f3\fs18\cf0\b0\i0\ul0\strike0 standard\f3\fs18\cf0\b0
\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 care\f3\fs18\cf0\b0\i0\ul0\st
rike0 for\f3\fs18\cf0\b0\i0\ul0\strike0 AA\f3\fs18\cf0\b0\i0\ul0\strike0 pati
ents\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 whom\par\p
ard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 transplant\f3\fs18\cf0\b0\i0\
ul0\strike0 was\f3\fs18\cf0\b0\i0\ul0\strike0 not\f3\fs18\cf0\b0\i0\ul0\strike
0 a\f3\fs18\cf0\b0\i0\ul0\strike0 feasible\f3\fs18\cf0\b0\i0\ul0\strike0 opti
on.\f3\fs18\cf0\b0\i0\ul0\strike0 This\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0
\i0\ul0\strike0 study\f3\fs18\cf0\b0\i0\ul0\strike0 clearly\f3\fs18\cf0\b0\i0\u
l0\strike0 demonstrated\f3\fs18\cf0\b0\i0\ul0\strike0 that\f3\fs18\cf0\b0\i0\u
l0\strike0 anti-\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 thymoc
yte\f3\fs18\cf0\b0\i0\ul0\strike0 globulin\f3\fs18\cf0\b0\i0\ul0\strike0 (ATG)
\f3\fs18\cf0\b0\i0\ul0\strike0 was\f3\fs18\cf0\b0\i0\ul0\strike0 superior\par\
pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\str
ike0 best\f3\fs18\cf0\b0\i0\ul0\strike0 supportive\f3\fs18\cf0\b0\i0\ul0\strik
e0 care\f3\fs18\cf0\b0\i0\ul0\strike0 (response\f3\fs18\cf0\b0\i0\ul0\strike0
rates\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 were\f3\fs18\cf0\
b0\i0\ul0\strike0 52%\f3\fs18\cf0\b0\i0\ul0\strike0 and\f3\fs18\cf0\b0\i0\ul0\

strike0 0%\f3\fs18\cf0\b0\i0\ul0\strike0 respectively\f3\fs18\cf0\b0\i0\ul0\st
rike0 with\f3\fs18\cf0\b0\i0\ul0\strike0 an\par\pard\plain\li0\sl-230\f3\fs18\
cf0\b0\i0\ul0\strike0 additional\f3\fs18\cf0\b0\i0\ul0\strike0 50%\f3\fs18\cf0\
b0\i0\ul0\strike0 response\f3\fs18\cf0\b0\i0\ul0\strike0 after\f3\fs18\cf0\b0\
i0\ul0\strike0 cross-\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 o
ver\f3\fs18\cf0\b0\i0\ul0\strike0 ),\f3\fs18\cf0\b0\i0\ul0\strike0 even\f3\fs1
8\cf0\b0\i0\ul0\strike0 if\f3\fs18\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\b0\i0\u
l0\strike0 complete\f3\fs18\cf0\b0\i0\ul0\strike0 normalisation\par\pard\plain
\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 bloo
d\f3\fs18\cf0\b0\i0\ul0\strike0 counts\f3\fs18\cf0\b0\i0\ul0\strike0 was\f3\fs
18\cf0\b0\i0\ul0\strike0 not\f3\fs18\cf0\b0\i0\ul0\strike0 achieved\f3\fs18\cf
0\b0\i0\ul0\strike0 in\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0
many\f3\fs18\cf0\b0\i0\ul0\strike0 responders.\f3\fs18\cf0\b0\i0\ul0\strike0 R
esponse\f3\fs18\cf0\b0\i0\ul0\strike0 rates\f3\fs18\cf0\b0\i0\ul0\strike0 usin
g\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 ATG\f3\fs18\cf0\b0\i0\
ul0\strike0 or\f3\fs18\cf0\b0\i0\ul0\strike0 ALG\f3\fs18\cf0\b0\i0\ul0\strike0
ranged\f3\fs18\cf0\b0\i0\ul0\strike0 between\f3\fs18\cf0\b0\i0\ul0\strike0 3
0%\f3\fs18\cf0\b0\i0\ul0\strike0 and\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i
0\ul0\strike0 70%\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\strike
0 larger\f3\fs18\cf0\b0\i0\ul0\strike0 series\f3\fs18\cf0\b0\i0\ul0\strike0 f
rom\f3\fs18\cf0\b0\i0\ul0\strike0 other\f3\fs18\cf0\b0\i0\ul0\strike0 groups,\
par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 which\f3\fs18\cf0\b0\i0\
ul0\strike0 also\f3\fs18\cf0\b0\i0\ul0\strike0 pointed\f3\fs18\cf0\b0\i0\ul0\s
trike0 out\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 ri
sk\f3\fs18\cf0\b0\i0\ul0\strike0 of\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0
\ul0\strike0 late\f3\fs18\cf0\b0\i0\ul0\strike0 treatment\f3\fs18\cf0\b0\i0\ul0
\strike0 failure\f3\fs18\cf0\b0\i0\ul0\strike0 due\f3\fs18\cf0\b0\i0\ul0\strik
e0 to\f3\fs18\cf0\b0\i0\ul0\strike0 disease\par\pard\plain\li0\sl-230\f3\fs18\
cf0\b0\i0\ul0\strike0 relapse.\f3\fs10\cf0\b0\i0\ul0\strike0 4,5\f3\fs18\cf0\b0
\i0\ul0\strike0 Thus,\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\
strike0 subsequent\f3\fs18\cf0\b0\i0\ul0\strike0 aim\f3\fs18\cf0\b0\i0\ul0\str
ike0 for\par\pard\plain\li0\sl-228\f3\fs18\cf0\b0\i0\ul0\strike0 investigators\
f3\fs18\cf0\b0\i0\ul0\strike0 was\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0
\b0\i0\ul0\strike0 increase\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i
0\ul0\strike0 response\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0
rate\f3\fs18\cf0\b0\i0\ul0\strike0 and\f3\fs18\cf0\b0\i0\ul0\strike0 sustain\f
3\fs18\cf0\b0\i0\ul0\strike0 such\f3\fs18\cf0\b0\i0\ul0\strike0 responses\f3\f
s18\cf0\b0\i0\ul0\strike0 for\par\pard\column\plain\sl-234\par\pard\plain\li0\s
l-254\f3\fs18\cf0\b0\i0\ul0\strike0 longer,\f3\fs18\cf0\b0\i0\ul0\strike0 preve
nting\f3\fs18\cf0\b0\i0\ul0\strike0 subsequent\f3\fs18\cf0\b0\i0\ul0\strike0 r
elapses.\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 A\f3\fs18\cf0\b
0\i0\ul0\strike0 number\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0
\strike0 immunosuppressive\f3\fs18\cf0\b0\i0\ul0\strike0 agents\par\pard\plain
\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 were\f3\fs18\cf0\b0\i0\ul0\strike0 in
itially\f3\fs18\cf0\b0\i0\ul0\strike0 combined\f3\fs18\cf0\b0\i0\ul0\strike0 w
ith\f3\fs18\cf0\b0\i0\ul0\strike0 ATG\f3\fs18\cf0\b0\i0\ul0\strike0 or\par\par
d\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 ALG,\f3\fs18\cf0\b0\i0\ul0\stri
ke0 including\f3\fs18\cf0\b0\i0\ul0\strike0 corticosteroids\f3\fs18\cf0\b0\i0\
ul0\strike0 (i.e.\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 m\f3\
fs18\cf0\b0\i0\ul0\strike0 e\f3\fs18\cf0\b0\i0\ul0\strike0 t\f3\fs18\cf0\b0\i0
\ul0\strike0 h\f3\fs18\cf0\b0\i0\ul0\strike0 yl\f3\fs18\cf0\b0\i0\ul0\strike0
p\f3\fs18\cf0\b0\i0\ul0\strike0 r\f3\fs18\cf0\b0\i0\ul0\strike0 e\f3\fs18\cf0
\b0\i0\ul0\strike0 d\f3\fs18\cf0\b0\i0\ul0\strike0 n\f3\fs18\cf0\b0\i0\ul0\str
ike0 i\f3\fs18\cf0\b0\i0\ul0\strike0 s\f3\fs18\cf0\b0\i0\ul0\strike0 o\f3\fs1
8\cf0\b0\i0\ul0\strike0 l\f3\fs18\cf0\b0\i0\ul0\strike0 o\f3\fs18\cf0\b0\i0\ul
0\strike0 n\f3\fs18\cf0\b0\i0\ul0\strike0 e\f3\fs18\cf0\b0\i0\ul0\strike0 )\f
3\fs18\cf0\b0\i0\ul0\strike0 ,\f3\fs10\cf0\b0\i0\ul0\strike0 6\f3\fs18\cf0\b0\
i0\ul0\strike0 a\f3\fs18\cf0\b0\i0\ul0\strike0 n\f3\fs18\cf0\b0\i0\ul0\strike0
d\f3\fs18\cf0\b0\i0\ul0\strike0 r\f3\fs18\cf0\b0\i0\ul0\strike0 o\f3\fs18\cf
0\b0\i0\ul0\strike0 g\f3\fs18\cf0\b0\i0\ul0\strike0 e\f3\fs18\cf0\b0\i0\ul0\st

rike0 n\f3\fs18\cf0\b0\i0\ul0\strike0 s\f3\fs10\cf0\b0\i0\ul0\strike0 7\f3\fs
10\cf0\b0\i0\ul0\strike0 ,\f3\fs10\cf0\b0\i0\ul0\strike0 8\par\pard\plain\li0\
sl-229\f3\fs18\cf0\b0\i0\ul0\strike0 and\f3\fs18\cf0\b0\i0\ul0\strike0 Cyclospo
rin\f3\fs18\cf0\b0\i0\ul0\strike0 A\f3\fs18\cf0\b0\i0\ul0\strike0 (CyA).\f3\fs
18\cf0\b0\i0\ul0\strike0 Only\f3\fs18\cf0\b0\i0\ul0\strike0 CyA,\f3\fs18\cf0\b
0\i0\ul0\strike0 a\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 calc
ineurin\f3\fs18\cf0\b0\i0\ul0\strike0 inhibitor\f3\fs18\cf0\b0\i0\ul0\strike0
(CNI)\f3\fs18\cf0\b0\i0\ul0\strike0 that\f3\fs18\cf0\b0\i0\ul0\strike0 impairs
\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 i\f3\fs18\cf0\b0\i0\ul0
\strike0 n\f3\fs18\cf0\b0\i0\ul0\strike0 t\f3\fs18\cf0\b0\i0\ul0\strike0 e\f3
\fs18\cf0\b0\i0\ul0\strike0 r\f3\fs18\cf0\b0\i0\ul0\strike0 l\f3\fs18\cf0\b0\i
0\ul0\strike0 e\f3\fs18\cf0\b0\i0\ul0\strike0 u\f3\fs18\cf0\b0\i0\ul0\strike0
k\f3\fs18\cf0\b0\i0\ul0\strike0 i\f3\fs18\cf0\b0\i0\ul0\strike0 n\f3\fs18\cf0
\b0\i0\ul0\strike0 (\f3\fs18\cf0\b0\i0\ul0\strike0 I\f3\fs18\cf0\b0\i0\ul0\str
ike0 L)\f3\fs18\cf0\b0\i0\ul0\strike0 -\f3\fs18\cf0\b0\i0\ul0\strike0 2\f3\fs
18\cf0\b0\i0\ul0\strike0 -\f3\fs18\cf0\b0\i0\ul0\strike0 d\f3\fs18\cf0\b0\i0\u
l0\strike0 e\f3\fs18\cf0\b0\i0\ul0\strike0 p\f3\fs18\cf0\b0\i0\ul0\strike0 e\
f3\fs18\cf0\b0\i0\ul0\strike0 n\f3\fs18\cf0\b0\i0\ul0\strike0 d\f3\fs18\cf0\b0
\i0\ul0\strike0 e\f3\fs18\cf0\b0\i0\ul0\strike0 n\f3\fs18\cf0\b0\i0\ul0\strike
0 t\f3\fs18\cf0\b0\i0\ul0\strike0 T\f3\fs18\cf0\b0\i0\ul0\strike0 c\f3\fs18\c
f0\b0\i0\ul0\strike0 e\f3\fs18\cf0\b0\i0\ul0\strike0 l\f3\fs18\cf0\b0\i0\ul0\s
trike0 l\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 activation\f3\
fs18\cf0\b0\i0\ul0\strike0 and\f3\fs18\cf0\b0\i0\ul0\strike0 differentiation,\
f3\fs18\cf0\b0\i0\ul0\strike0 has\f3\fs18\cf0\b0\i0\ul0\strike0 proven\par\par
d\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 effective\f3\fs18\cf0\b0\i0\ul0
\strike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 increasing\f3\fs18\cf0\b0\i0\ul0\str
ike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 response\f3\fs18\cf0\b0\i0\ul0\strike0
rate,\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 as\f3\fs18\cf0\b0
\i0\ul0\strike0 initially\f3\fs18\cf0\b0\i0\ul0\strike0 demonstrated\f3\fs18\c
f0\b0\i0\ul0\strike0 by\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul
0\strike0 German\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 Aplast
ic\f3\fs18\cf0\b0\i0\ul0\strike0 Anaemia\f3\fs18\cf0\b0\i0\ul0\strike0 Group\f
3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\b0
\i0\ul0\strike0 randomised\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\stri
ke0 trial\f3\fs10\cf0\b0\i0\ul0\strike0 9\f3\fs18\cf0\b0\i0\ul0\strike0 .\f3\fs
18\cf0\b0\i0\ul0\strike0 In\f3\fs18\cf0\b0\i0\ul0\strike0 fact,\f3\fs18\cf0\b0
\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 addition\f3\fs18\cf0\b0\i0\u
l0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 CyA\f3\fs18\cf0\b0\i0\ul0\strike0
to\par\pard\plain\li0\sl-229\f3\fs18\cf0\b0\i0\ul0\strike0 ATG\f3\fs18\cf0\b0\i
0\ul0\strike0 and\f3\fs18\cf0\b0\i0\ul0\strike0 high\f3\fs18\cf0\b0\i0\ul0\str
ike0 dose\f3\fs18\cf0\b0\i0\ul0\strike0 steroids\f3\fs18\cf0\b0\i0\ul0\strike0
(utilised\f3\fs18\cf0\b0\i0\ul0\strike0 as\par\pard\plain\li0\sl-230\f3\fs18\
cf0\b0\i0\ul0\strike0 prophylaxis\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\
b0\i0\ul0\strike0 serum-sickness)\f3\fs18\cf0\b0\i0\ul0\strike0 increased\par\
pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\st
rike0 6-month\f3\fs18\cf0\b0\i0\ul0\strike0 overall\f3\fs18\cf0\b0\i0\ul0\stri
ke0 response\f3\fs18\cf0\b0\i0\ul0\strike0 rate\f3\fs18\cf0\b0\i0\ul0\strike0
from\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 46%\f3\fs18\cf0\b0
\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 70%\f3\fs18\cf0\b0\i0\ul0\str
ike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 all\f3\fs18\cf0\b0\i0\ul0\strike0 AA\f3
\fs18\cf0\b0\i0\ul0\strike0 patients\f3\fs18\cf0\b0\i0\ul0\strike0 (from\f3\fs
18\cf0\b0\i0\ul0\strike0 31%\f3\fs18\cf0\b0\i0\ul0\strike0 to\par\pard\plain\l
i0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 65%\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3
\fs18\cf0\b0\i0\ul0\strike0 severe\f3\fs18\cf0\b0\i0\ul0\strike0 or\f3\fs18\cf
0\b0\i0\ul0\strike0 very\f3\fs18\cf0\b0\i0\ul0\strike0 severe\f3\fs18\cf0\b0\i
0\ul0\strike0 forms\f3\fs18\cf0\b0\i0\ul0\strike0 only),\par\pard\plain\li0\sl
-230\f3\fs18\cf0\b0\i0\ul0\strike0 possibly\f3\fs18\cf0\b0\i0\ul0\strike0 impac
ting\f3\fs18\cf0\b0\i0\ul0\strike0 long\f3\fs18\cf0\b0\i0\ul0\strike0 term\f3\
fs18\cf0\b0\i0\ul0\strike0 survival\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0
\ul0\strike0 (\f3\fs18\cf0\b0\i0\ul0\strike0 e\f3\fs18\cf0\b0\i0\ul0\strike0 v

e\f3\fs18\cf0\b0\i0\ul0\strike0 n\f3\fs18\cf0\b0\i0\ul0\strike0 i\f3\fs18\cf0\
b0\i0\ul0\strike0 f\f3\fs18\cf0\b0\i0\ul0\strike0 n\f3\fs18\cf0\b0\i0\ul0\stri
ke0 o\f3\fs18\cf0\b0\i0\ul0\strike0 s\f3\fs18\cf0\b0\i0\ul0\strike0 t\f3\fs18
\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\b0\i0\ul0\strike0 t\f3\fs18\cf0\b0\i0\ul0
\strike0 i\f3\fs18\cf0\b0\i0\ul0\strike0 s\f3\fs18\cf0\b0\i0\ul0\strike0 t\f3
\fs18\cf0\b0\i0\ul0\strike0 i\f3\fs18\cf0\b0\i0\ul0\strike0 c\f3\fs18\cf0\b0\i
0\ul0\strike0 a\f3\fs18\cf0\b0\i0\ul0\strike0 l\f3\fs18\cf0\b0\i0\ul0\strike0
l\f3\fs18\cf0\b0\i0\ul0\strike0 y\f3\fs18\cf0\b0\i0\ul0\strike0 s\f3\fs18\cf0
\b0\i0\ul0\strike0 i\f3\fs18\cf0\b0\i0\ul0\strike0 g\f3\fs18\cf0\b0\i0\ul0\str
ike0 n\f3\fs18\cf0\b0\i0\ul0\strike0 i\f3\fs18\cf0\b0\i0\ul0\strike0 f\f3\fs1
8\cf0\b0\i0\ul0\strike0 i\f3\fs18\cf0\b0\i0\ul0\strike0 c\f3\fs18\cf0\b0\i0\ul
0\strike0 a\f3\fs18\cf0\b0\i0\ul0\strike0 n\f3\fs18\cf0\b0\i0\ul0\strike0 t\p
ar\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 difference\f3\fs18\cf0\b0
\i0\ul0\strike0 was\f3\fs18\cf0\b0\i0\ul0\strike0 shown\f3\fs18\cf0\b0\i0\ul0\
strike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 this\f3\fs18\cf0\b0\i0\ul0\strike0 i
nitial\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 cohort).\f3\fs18\
cf0\b0\i0\ul0\strike0 This\f3\fs18\cf0\b0\i0\ul0\strike0 study\f3\fs18\cf0\b0\
i0\ul0\strike0 leads\f3\fs18\cf0\b0\i0\ul0\strike0 us\f3\fs18\cf0\b0\i0\ul0\st
rike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 pres
ent\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 day;\f3\fs18\cf0\b0\
i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 fact,\f3\fs18\cf0\b0\i0\ul0\st
rike0 based\f3\fs18\cf0\b0\i0\ul0\strike0 on\f3\fs18\cf0\b0\i0\ul0\strike0 th
ese\f3\fs18\cf0\b0\i0\ul0\strike0 results,\f3\fs18\cf0\b0\i0\ul0\strike0 ATG\p
ar\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 +\f3\fs18\cf0\b0\i0\ul0\s
trike0 CyA\f3\fs18\cf0\b0\i0\ul0\strike0 has\f3\fs18\cf0\b0\i0\ul0\strike0 be
en\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 most\f3\fs1
8\cf0\b0\i0\ul0\strike0 utilised\f3\fs18\cf0\b0\i0\ul0\strike0 IST\f3\fs18\cf0
\b0\i0\ul0\strike0 for\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0
AA\f3\fs18\cf0\b0\i0\ul0\strike0 patients\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\
fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 past\f3\fs18\cf0\
b0\i0\ul0\strike0 two\f3\fs18\cf0\b0\i0\ul0\strike0 decades\f3\fs18\cf0\b0\i0\
ul0\strike0 in\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 Western\
f3\fs18\cf0\b0\i0\ul0\strike0 countries.\f3\fs18\cf0\b0\i0\ul0\strike0 Unfortu
nately,\f3\fs18\cf0\b0\i0\ul0\strike0 the\par\pard\plain\li0\sl-230\f3\fs18\cf0
\b0\i0\ul0\strike0 access\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul
0\strike0 such\f3\fs18\cf0\b0\i0\ul0\strike0 treatment\f3\fs18\cf0\b0\i0\ul0\s
trike0 still\f3\fs18\cf0\b0\i0\ul0\strike0 represents\f3\fs18\cf0\b0\i0\ul0\st
rike0 a\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 problem\f3\fs18
\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 developing\f3\fs18\cf0
\b0\i0\ul0\strike0 countries,\f3\fs18\cf0\b0\i0\ul0\strike0 mainly\par\pard\pl
ain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 due\f3\fs18\cf0\b0\i0\ul0\strike0
to\f3\fs18\cf0\b0\i0\ul0\strike0 economic\f3\fs18\cf0\b0\i0\ul0\strike0 reason
s.\f3\fs10\cf0\b0\i0\ul0\strike0 10\par\pard\plain\li0\sl-433\f2\fs26\cf0\b\i0\
ul0\strike0 When\f2\fs26\cf0\b\i0\ul0\strike0 and\f2\fs26\cf0\b\i0\ul0\strike0
Whom\f2\fs26\cf0\b\i0\ul0\strike0 to\f2\fs26\cf0\b\i0\ul0\strike0 Treat\par\p
ard\plain\li239\sl-393\f3\fs18\cf0\b0\i0\ul0\strike0 Patients\f3\fs18\cf0\b0\i0\
ul0\strike0 who\f3\fs18\cf0\b0\i0\ul0\strike0 are\f3\fs18\cf0\b0\i0\ul0\strike
0 transfusion\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 independe
nt\f3\fs18\cf0\b0\i0\ul0\strike0 or\f3\fs18\cf0\b0\i0\ul0\strike0 moderate\f3\
fs18\cf0\b0\i0\ul0\strike0 aplastic\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0
\ul0\strike0 anaemia,\f3\fs18\cf0\b0\i0\ul0\strike0 observation\f3\fs18\cf0\b0\
i0\ul0\strike0 would\f3\fs18\cf0\b0\i0\ul0\strike0 be\f3\fs18\cf0\b0\i0\ul0\st
rike0 the\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 appropriate\f
3\fs18\cf0\b0\i0\ul0\strike0 treatment.\f3\fs18\cf0\b0\i0\ul0\strike0 Many\f3\
fs18\cf0\b0\i0\ul0\strike0 patients\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0
\ul0\strike0 with\f3\fs18\cf0\b0\i0\ul0\strike0 AA\f3\fs18\cf0\b0\i0\ul0\strike
0 may\f3\fs18\cf0\b0\i0\ul0\strike0 present\f3\fs18\cf0\b0\i0\ul0\strike0 sta
ble\f3\fs18\cf0\b0\i0\ul0\strike0 blood\f3\fs18\cf0\b0\i0\ul0\strike0 counts\p
ar\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 for\f3\fs18\cf0\b0\i0\ul0
\strike0 years,\f3\fs18\cf0\b0\i0\ul0\strike0 but\f3\fs18\cf0\b0\i0\ul0\strike

0 pancytopenia\f3\fs18\cf0\b0\i0\ul0\strike0 may\f3\fs18\cf0\b0\i0\ul0\strike0
worsen\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 over\f3\fs18\cf
0\b0\i0\ul0\strike0 time\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul
0\strike0 some.\f3\fs10\cf0\b0\i0\ul0\strike0 11\f3\fs18\cf0\b0\i0\ul0\strike0
Patients\f3\fs18\cf0\b0\i0\ul0\strike0 who\f3\fs18\cf0\b0\i0\ul0\strike0 prog
ress\par\pard\plain\li0\sl-229\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i
0\ul0\strike0 severe\f3\fs18\cf0\b0\i0\ul0\strike0 pancytopenia\f3\fs18\cf0\b0
\i0\ul0\strike0 and\f3\fs18\cf0\b0\i0\ul0\strike0 meet\f3\fs18\cf0\b0\i0\ul0\s
trike0 the\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 criteria\f3\
fs18\cf0\b0\i0\ul0\strike0 for\f3\fs18\cf0\b0\i0\ul0\strike0 SAA\f3\fs18\cf0\b
0\i0\ul0\strike0 or\f3\fs18\cf0\b0\i0\ul0\strike0 become\f3\fs18\cf0\b0\i0\ul0
\strike0 transfusion-\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 d
ependent,\f3\fs18\cf0\b0\i0\ul0\strike0 can\f3\fs18\cf0\b0\i0\ul0\strike0 then
\f3\fs18\cf0\b0\i0\ul0\strike0 be\f3\fs18\cf0\b0\i0\ul0\strike0 treated\f3\fs1
8\cf0\b0\i0\ul0\strike0 according\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\u
l0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 current\f3\fs18\cf0\b0\i0\ul0\strik
e0 algorithms\f3\fs18\cf0\b0\i0\ul0\strike0 (Figure\f3\fs18\cf0\b0\i0\ul0\stri
ke0 1).\f3\fs18\cf0\b0\i0\ul0\strike0 Elderly,\par\pard\plain\li0\sl-230\f3\fs
18\cf0\b0\i0\ul0\strike0 feeble,\f3\fs18\cf0\b0\i0\ul0\strike0 or\f3\fs18\cf0\b
0\i0\ul0\strike0 patients\f3\fs18\cf0\b0\i0\ul0\strike0 experiencing\f3\fs18\c
f0\b0\i0\ul0\strike0 severe\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\str
ike0 comorbidities\f3\fs18\cf0\b0\i0\ul0\strike0 might\f3\fs18\cf0\b0\i0\ul0\st
rike0 not\f3\fs18\cf0\b0\i0\ul0\strike0 benefit\f3\fs18\cf0\b0\i0\ul0\strike0
from\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 more\f3\fs18\cf0\b
0\i0\ul0\strike0 aggressive\f3\fs18\cf0\b0\i0\ul0\strike0 treatment\f3\fs18\cf
0\b0\i0\ul0\strike0 approaches,
{\shp{\*\shpinst\shpleft1022\shptop2532\shpright11110\shpbottom2532
\shpfhdr0\shpbxpage\shpbypage
\shpwr3\shpwrk0\shpfblwtxt1\shpz43\shplid32994
{\sp{\sn shapeType}{\sv 20}}
{\sp{\sn fFlipH}{\sv 0}}
{\sp{\sn fFlipV}{\sv 0}}
{\sp{\sn shapePath}{\sv 4}}
{\sp{\sn fFillOK}{\sv 0}}
{\sp{\sn fLayoutInCell}{\sv 1}}
{\sp{\sn lineColor}{\sv 10000019}}
{\sp{\sn lineWidth}{\sv 12700}}
{\sp{\sn lineDashing}{\sv 0}}
{\sp{\sn posrelh}{\sv 1}}
{\sp{\sn posrelv}{\sv 1}}
{\sp{\sn fArrowheadsOK}{\sv 1}}
{\sp{\sn fBehindDocument}{\sv 1}}
}}
}}
}}
}}
}}
{\sp{\sn geoRight}{\sv 9600}}
{\sp{\sn geoBottom}{\sv 2005}}

{\sp{\sn pVerticies}{\sv 8;5;(0,2005);(9600,2005);(9600,0);(0,0);(0,2005)}}
{\sp{\sn pSegmentInfo}{\sv 2;12;16384;45824;1;45824;1;45824;1;45824;1;45824;2457
7;32768}}
{\sp{\sn fFilled}{\sv 1}}
{\sp{\sn fillColor}{\sv 14936281}}
{\sp{\sn fLine}{\sv 0}}
}}
{\sp{\sn geoRight}{\sv 9600}}
{\sp{\sn geoBottom}{\sv 2005}}
{\sp{\sn pVerticies}{\sv 8;5;(0,2005);(9600,2005);(9600,0);(0,0);(0,2005)}}
{\sp{\sn pSegmentInfo}{\sv 2;12;16384;45824;1;45824;1;45824;1;45824;1;45824;2457
7;32768}}
{\sp{\sn fillColor}{\sv 0}}
{\sp{\sn fillOpacity}{\sv 0}}
}}
{\sp{\sn dxTextLeft}{\sv 0}}
{\sp{\sn dyTextTop}{\sv 0}}
{\sp{\sn dxTextRight}{\sv 0}}
{\sp{\sn dyTextBottom}{\sv 0}}
{\sp{\sn fBehindDocument}{\sv 1}}{\shptxt\pard\plain\li0\sl-168\f1\fs14\charscal
ex98\cf0\b0\i0\ul0\strike0 Dept\f1\fs14\charscalex98\cf0\b0\i0\ul0\strike0 of\f
1\fs14\charscalex98\cf0\b0\i0\ul0\strike0 Haematology,\par}}}
{\sp{\sn fBehindDocument}{\sv 1}}{\shptxt\pard\plain\li0\sl-678\f3\fs50\charscal
ex96\cf0\b0\i0\ul0\strike0 T\par}}}\sect\sectd\sbkpage\pgwsxn12132\pghsxn15987\s
ected\cols2\colno1\colw10910\colsr10\colno2\colw1200\pard\plain\sl-200\par\pard\
plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-262\par\pard\plain\li1022\s
l-152\f0\fs12\cf0\b0\i0\ul0\strike0 supplement to Journal of the association of
physicians of india \u183? published on 1st of every month 1st march, 2015\par\p
ard\column\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\pla
in\sl-207\par\pard\plain\li0\sl-228\f0\fs18\cf0\b0\i0\ul0\strike0 17\par\sect\se
cted\sbknone\cols1\colno1\colw12120\pard\plain\sl-200\par\pard\plain\sl-200\par\
pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\p
lain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\pa
r\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-298\par\pard\plain\l
i1021\sl-214\f3\fs16\cf0\b0\i0\ul0\strike0 HSCT-haematopoietic\f3\fs16\cf0\b0\i0
\ul0\strike0 stem\f3\fs16\cf0\b0\i0\ul0\strike0 cell\f3\fs16\cf0\b0\i0\ul0\str
ike0 transplant,\f3\fs16\cf0\b0\i0\ul0\strike0 MUD-\f3\fs16\cf0\b0\i0\ul0\stri
ke0 matched\f3\fs16\cf0\b0\i0\ul0\strike0 unrelated\f3\fs16\cf0\b0\i0\ul0\stri
ke0 donor,\f3\fs16\cf0\b0\i0\ul0\strike0 EXP\f3\fs16\cf0\b0\i0\ul0\strike0 \u
8211?experimental\f3\fs16\cf0\b0\i0\ul0\strike0 therapy,\f3\fs16\cf0\b0\i0\ul0\
strike0 IST\f3\fs16\cf0\b0\i0\ul0\strike0 \u8211?\f3\fs16\cf0\b0\i0\ul0\strike
0 immunosuppressive\f3\fs16\cf0\b0\i0\ul0\strike0 therapy,\par\pard\plain\li10
21\sl-192\f3\fs16\cf0\b0\i0\ul0\strike0 BST\f3\fs16\cf0\b0\i0\ul0\strike0 \u821
1?best\f3\fs16\cf0\b0\i0\ul0\strike0 supportive\f3\fs16\cf0\b0\i0\ul0\strike0
care\par\pard\plain\li1021\sl-304\f2\fs18\cf0\b\i0\ul0\strike0 Fig.\f2\fs18\cf0\
b\i0\ul0\strike0 1\f2\fs18\cf0\b\i0\ul0\strike0 :\f2\fs18\cf0\b\i0\ul0\strike0
Algorithm\f2\fs18\cf0\b\i0\ul0\strike0 for\f2\fs18\cf0\b\i0\ul0\strike0 appr
oach\f2\fs18\cf0\b\i0\ul0\strike0 to\f2\fs18\cf0\b\i0\ul0\strike0 aplastic\f2\
fs18\cf0\b\i0\ul0\strike0 Anaemia\par\sect\sected\sbknone\cols2\colno1\colw6290
\colsr10\colno2\colw5820\pard\plain\li1021\sl-262\f3\fs18\cf0\b0\i0\ul0\strike0
particularly\f3\fs18\cf0\b0\i0\ul0\strike0 if\f3\fs18\cf0\b0\i0\ul0\strike0 th
ey\f3\fs18\cf0\b0\i0\ul0\strike0 are\f3\fs18\cf0\b0\i0\ul0\strike0 not\f3\fs18
\cf0\b0\i0\ul0\strike0 bleeding\f3\fs18\cf0\b0\i0\ul0\strike0 and\f3\fs18\cf0\
b0\i0\ul0\strike0 have\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strik
e0 neutrophil\f3\fs18\cf0\b0\i0\ul0\strike0 counts\f3\fs18\cf0\b0\i0\ul0\strike
0 (generally\f3\fs18\cf0\b0\i0\ul0\strike0 between\f3\fs18\cf0\b0\i0\ul0\strik
e0 >200\f3\fs18\cf0\b0\i0\ul0\strike0 -400/L)\f3\fs18\cf0\b0\i0\ul0\strike0 t
hat\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 defend\f3\fs18\cf
0\b0\i0\ul0\strike0 them\f3\fs18\cf0\b0\i0\ul0\strike0 from\f3\fs18\cf0\b0\i0\
ul0\strike0 serious\f3\fs18\cf0\b0\i0\ul0\strike0 infections.\par\pard\plain\l
i1021\sl-434\f2\fs26\cf0\b\i0\ul0\strike0 Standard\f2\fs26\cf0\b\i0\ul0\strike0
Immunosuppression\par\pard\plain\li1261\sl-393\f3\fs18\cf0\b0\i0\ul0\strike0 S\
f3\fs18\cf0\b0\i0\ul0\strike0 i\f3\fs18\cf0\b0\i0\ul0\strike0 n\f3\fs18\cf0\b0
\i0\ul0\strike0 c\f3\fs18\cf0\b0\i0\ul0\strike0 e\f3\fs18\cf0\b0\i0\ul0\strike
0 t\f3\fs18\cf0\b0\i0\ul0\strike0 h\f3\fs18\cf0\b0\i0\ul0\strike0 e\f3\fs18\c
f0\b0\i0\ul0\strike0 e\f3\fs18\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\b0\i0\ul0\s
trike0 r\f3\fs18\cf0\b0\i0\ul0\strike0 l\f3\fs18\cf0\b0\i0\ul0\strike0 y\f3\f
s18\cf0\b0\i0\ul0\strike0 1\f3\fs18\cf0\b0\i0\ul0\strike0 9\f3\fs18\cf0\b0\i0\
ul0\strike0 9\f3\fs18\cf0\b0\i0\ul0\strike0 0\f3\fs18\cf0\b0\i0\ul0\strike0 s
\f3\fs18\cf0\b0\i0\ul0\strike0 ,\f3\fs18\cf0\b0\i0\ul0\strike0 AT\f3\fs18\cf0\

b0\i0\ul0\strike0 G\f3\fs18\cf0\b0\i0\ul0\strike0 +\f3\fs18\cf0\b0\i0\ul0\stri
ke0 C\f3\fs18\cf0\b0\i0\ul0\strike0 y\f3\fs18\cf0\b0\i0\ul0\strike0 A\f3\fs18
\cf0\b0\i0\ul0\strike0 h\f3\fs18\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\b0\i0\ul0
\strike0 s\f3\fs18\cf0\b0\i0\ul0\strike0 b\f3\fs18\cf0\b0\i0\ul0\strike0 e\f3
\fs18\cf0\b0\i0\ul0\strike0 e\f3\fs18\cf0\b0\i0\ul0\strike0 n\par\pard\plain\l
i1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 considered\f3\fs18\cf0\b0\i0\ul0\stri
ke0 the\f3\fs18\cf0\b0\i0\ul0\strike0 standard\f3\fs18\cf0\b0\i0\ul0\strike0
IST\f3\fs18\cf0\b0\i0\ul0\strike0 for\f3\fs18\cf0\b0\i0\ul0\strike0 AA\f3\fs18
\cf0\b0\i0\ul0\strike0 patients,\f3\fs18\cf0\b0\i0\ul0\strike0 with\par\pard\p
lain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 an\f3\fs18\cf0\b0\i0\ul0\strike
0 expected\f3\fs18\cf0\b0\i0\ul0\strike0 50\f3\fs18\cf0\b0\i0\ul0\strike0 \u8
211?60%\f3\fs18\cf0\b0\i0\ul0\strike0 probability\f3\fs18\cf0\b0\i0\ul0\strike0
of\f3\fs18\cf0\b0\i0\ul0\strike0 response\f3\fs18\cf0\b0\i0\ul0\strike0 and\
par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 60%\f3\fs18\cf0\b0\i0
\ul0\strike0 overall\f3\fs18\cf0\b0\i0\ul0\strike0 survival\f3\fs18\cf0\b0\i0\
ul0\strike0 at\f3\fs18\cf0\b0\i0\ul0\strike0 1\f3\fs18\cf0\b0\i0\ul0\strike0
year.\f3\fs10\cf0\b0\i0\ul0\strike0 12-14\f3\fs18\cf0\b0\i0\ul0\strike0 A\f3\f
s18\cf0\b0\i0\ul0\strike0 heterogeneous\par\pard\plain\li1021\sl-229\f3\fs18\cf
0\b0\i0\ul0\strike0 definition\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\
i0\ul0\strike0 clinical\f3\fs18\cf0\b0\i0\ul0\strike0 response\f3\fs18\cf0\b0\
i0\ul0\strike0 may\f3\fs18\cf0\b0\i0\ul0\strike0 account\f3\fs18\cf0\b0\i0\ul0
\strike0 for\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 differe
nces\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 response\f
3\fs18\cf0\b0\i0\ul0\strike0 rates\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf
0\b0\i0\ul0\strike0 distinct\f3\fs18\cf0\b0\i0\ul0\strike0 studies,\f3\fs18\cf
0\b0\i0\ul0\strike0 thus\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\str
ike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 use\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3
\fs18\cf0\b0\i0\ul0\strike0 common\f3\fs18\cf0\b0\i0\ul0\strike0 response\f3\f
s18\cf0\b0\i0\ul0\strike0 criteria\f3\fs18\cf0\b0\i0\ul0\strike0 is\f3\fs18\cf
0\b0\i0\ul0\strike0 encouraged,\f3\fs10\cf0\b0\i0\ul0\strike0 15\par\pard\plai
n\li1021\sl-229\f3\fs18\cf0\b0\i0\ul0\strike0 even\f3\fs18\cf0\b0\i0\ul0\strike0
more\f3\fs18\cf0\b0\i0\ul0\strike0 so\f3\fs18\cf0\b0\i0\ul0\strike0 because\
f3\fs18\cf0\b0\i0\ul0\strike0 such\f3\fs18\cf0\b0\i0\ul0\strike0 criteria\f3\f
s18\cf0\b0\i0\ul0\strike0 clearly\f3\fs18\cf0\b0\i0\ul0\strike0 predict\par\pa
rd\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\s
trike0 long-term\f3\fs18\cf0\b0\i0\ul0\strike0 survival\f3\fs18\cf0\b0\i0\ul0\
strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 AA\f3\fs18\cf0\b0\i0\ul0\strike0 pat
ients.\f3\fs10\cf0\b0\i0\ul0\strike0 16\f3\fs18\cf0\b0\i0\ul0\strike0 Most\f3\
fs18\cf0\b0\i0\ul0\strike0 studies\par\pard\plain\li1021\sl-229\f3\fs18\cf0\b0\
i0\ul0\strike0 reported\f3\fs18\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\b0\i0\ul0\s
trike0 response\f3\fs18\cf0\b0\i0\ul0\strike0 rate\f3\fs18\cf0\b0\i0\ul0\strik
e0 [complete\f3\fs18\cf0\b0\i0\ul0\strike0 response\f3\fs18\cf0\b0\i0\ul0\stri
ke0 (CR)\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 +\f3\fs18\c
f0\b0\i0\ul0\strike0 partial\f3\fs18\cf0\b0\i0\ul0\strike0 response\f3\fs18\cf
0\b0\i0\ul0\strike0 (PR)]\f3\fs18\cf0\b0\i0\ul0\strike0 ranging\f3\fs18\cf0\b0
\i0\ul0\strike0 from\f3\fs18\cf0\b0\i0\ul0\strike0 50%\f3\fs18\cf0\b0\i0\ul0\s
trike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 70%,\par\pard\plain\li1021\sl-230\f3\f
s18\cf0\b0\i0\ul0\strike0 without\f3\fs18\cf0\b0\i0\ul0\strike0 any\f3\fs18\cf0
\b0\i0\ul0\strike0 improvement\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0
\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 past\f3\fs18\cf0\b0\i0\ul0\s
trike0 two\f3\fs18\cf0\b0\i0\ul0\strike0 decades.\par\pard\plain\li1021\sl-230
\f3\fs18\cf0\b0\i0\ul0\strike0 However,\f3\fs18\cf0\b0\i0\ul0\strike0 most\f3\f
s18\cf0\b0\i0\ul0\strike0 recent\f3\fs18\cf0\b0\i0\ul0\strike0 studies\f3\fs18
\cf0\b0\i0\ul0\strike0 have\f3\fs18\cf0\b0\i0\ul0\strike0 shown\f3\fs18\cf0\b0
\i0\ul0\strike0 improved\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\str
ike0 overall\f3\fs18\cf0\b0\i0\ul0\strike0 survival\f3\fs18\cf0\b0\i0\ul0\strik
e0 (above\f3\fs18\cf0\b0\i0\ul0\strike0 80%\f3\fs18\cf0\b0\i0\ul0\strike0 at\
f3\fs18\cf0\b0\i0\ul0\strike0 1\f3\fs18\cf0\b0\i0\ul0\strike0 year\f3\fs18\cf0
\b0\i0\ul0\strike0 ),\f3\fs18\cf0\b0\i0\ul0\strike0 regardless\f3\fs18\cf0\b0\
i0\ul0\strike0 of\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 th
e\f3\fs18\cf0\b0\i0\ul0\strike0 initial\f3\fs18\cf0\b0\i0\ul0\strike0 response
\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 IST,\f3\fs10\c
f0\b0\i0\ul0\strike0 16-18\f3\fs18\cf0\b0\i0\ul0\strike0 probably\f3\fs18\cf0\
b0\i0\ul0\strike0 due\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\s
trike0 better\par\pard\plain\li1021\sl-229\f3\fs18\cf0\b0\i0\ul0\strike0 suppor
tive\f3\fs18\cf0\b0\i0\ul0\strike0 care\f3\fs18\cf0\b0\i0\ul0\strike0 and\f3\f
s18\cf0\b0\i0\ul0\strike0 salvage\f3\fs18\cf0\b0\i0\ul0\strike0 treatment\f3\f
s18\cf0\b0\i0\ul0\strike0 (mainly\f3\fs18\cf0\b0\i0\ul0\strike0 HSCT).\par\par
d\plain\li1021\sl-434\f2\fs26\cf0\b\i0\ul0\strike0 ATG\f2\fs26\cf0\b\i0\ul0\stri
ke0 Preparations\par\pard\plain\li1261\sl-393\f3\fs18\cf0\b0\i0\ul0\strike0 ATG
\f3\fs18\cf0\b0\i0\ul0\strike0 is\f3\fs18\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\
b0\i0\ul0\strike0 heterologous\f3\fs18\cf0\b0\i0\ul0\strike0 anti-serum\f3\fs1
8\cf0\b0\i0\ul0\strike0 obtained\f3\fs18\cf0\b0\i0\ul0\strike0 by\par\pard\pla
in\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 injecting\f3\fs18\cf0\b0\i0\ul0\s
trike0 human\f3\fs18\cf0\b0\i0\ul0\strike0 lymphocytes\f3\fs18\cf0\b0\i0\ul0\s
trike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 animals;\f3\fs18\cf0\b0\i0\ul0\strike0
various\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 ATG\f3\fs18
\cf0\b0\i0\ul0\strike0 preparations\f3\fs18\cf0\b0\i0\ul0\strike0 exist,\f3\fs
18\cf0\b0\i0\ul0\strike0 which\f3\fs18\cf0\b0\i0\ul0\strike0 differ\f3\fs18\cf
0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 stimulating\par\pard\plai
n\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 antigens\f3\fs18\cf0\b0\i0\ul0\str
ike0 (peripheral\f3\fs18\cf0\b0\i0\ul0\strike0 lymphocytes,\f3\fs18\cf0\b0\i0\
ul0\strike0 thymocytes\f3\fs18\cf0\b0\i0\ul0\strike0 or\f3\fs18\cf0\b0\i0\ul0\
strike0 even\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 T\f3\fs
18\cf0\b0\i0\ul0\strike0 cell\f3\fs18\cf0\b0\i0\ul0\strike0 lines),\f3\fs18\cf
0\b0\i0\ul0\strike0 and/or\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\
ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 host\f3\fs18\cf0\b0\i0\ul0\strik
e0 animal\f3\fs18\cf0\b0\i0\ul0\strike0 (either\f3\fs18\cf0\b0\i0\ul0\strike0
horse\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 or\f3\fs18\cf0
\b0\i0\ul0\strike0 rabbit).\f3\fs18\cf0\b0\i0\ul0\strike0 In\f3\fs18\cf0\b0\i0
\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 last\f3\fs18\cf0\b0\i0\ul0\stri
ke0 two\f3\fs18\cf0\b0\i0\ul0\strike0 decades\f3\fs18\cf0\b0\i0\ul0\strike0 p
hysicians\f3\fs18\cf0\b0\i0\ul0\strike0 have\par\pard\plain\li1021\sl-230\f3\fs
18\cf0\b0\i0\ul0\strike0 utilised\f3\fs18\cf0\b0\i0\ul0\strike0 any\f3\fs18\cf0
\b0\i0\ul0\strike0 commercially\f3\fs18\cf0\b0\i0\ul0\strike0 available\f3\fs1
8\cf0\b0\i0\ul0\strike0 ATG\f3\fs18\cf0\b0\i0\ul0\strike0 preparation\par\pard
\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 without\f3\fs18\cf0\b0\i0\ul0
\strike0 distinction.\f3\fs18\cf0\b0\i0\ul0\strike0 Most\f3\fs18\cf0\b0\i0\ul0
\strike0 available\f3\fs18\cf0\b0\i0\ul0\strike0 data\f3\fs18\cf0\b0\i0\ul0\st
rike0 from\f3\fs18\cf0\b0\i0\ul0\strike0 large\par\pard\plain\li1021\sl-230\f3
\fs18\cf0\b0\i0\ul0\strike0 randomised\f3\fs18\cf0\b0\i0\ul0\strike0 clinical\f
3\fs18\cf0\b0\i0\ul0\strike0 trials\f3\fs18\cf0\b0\i0\ul0\strike0 refer\f3\fs1
8\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 polyclonal\f3\fs18\cf
0\b0\i0\ul0\strike0 ATGs\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\str
ike0 obtained\f3\fs18\cf0\b0\i0\ul0\strike0 from\f3\fs18\cf0\b0\i0\ul0\strike0
horse\f3\fs18\cf0\b0\i0\ul0\strike0 (h),\f3\fs18\cf0\b0\i0\ul0\strike0 which\
f3\fs18\cf0\b0\i0\ul0\strike0 have\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf
0\b0\i0\ul0\strike0 be\f3\fs18\cf0\b0\i0\ul0\strike0 considered\par\pard\plain
\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0
gold\f3\fs18\cf0\b0\i0\ul0\strike0 standard\f3\fs18\cf0\b0\i0\ul0\strike0 for\
f3\fs18\cf0\b0\i0\ul0\strike0 AA\f3\fs18\cf0\b0\i0\ul0\strike0 treatment.\f3\f
s18\cf0\b0\i0\ul0\strike0 Of\f3\fs18\cf0\b0\i0\ul0\strike0 note,\f3\fs18\cf0\b
0\i0\ul0\strike0 U.S.\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike
0 and\f3\fs18\cf0\b0\i0\ul0\strike0 Japanese\f3\fs18\cf0\b0\i0\ul0\strike0 inv
estigators\f3\fs18\cf0\b0\i0\ul0\strike0 utilised\f3\fs18\cf0\b0\i0\ul0\strike0
hATG\f3\fs18\cf0\b0\i0\ul0\strike0 (40\f3\fs18\cf0\b0\i0\ul0\strike0 mg/kg\p
ar\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 per\f3\fs18\cf0\b0\i0\
ul0\strike0 day\f3\fs18\cf0\b0\i0\ul0\strike0 for\f3\fs18\cf0\b0\i0\ul0\strike
0 4\f3\fs18\cf0\b0\i0\ul0\strike0 days,\f3\fs18\cf0\b0\i0\ul0\strike0 ATGAM;\
f3\fs18\cf0\b0\i0\ul0\strike0 Pharmacia\f3\fs18\cf0\b0\i0\ul0\strike0 and\f3\f

s18\cf0\b0\i0\ul0\strike0 Upjohn,\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i
0\ul0\strike0 New\f3\fs18\cf0\b0\i0\ul0\strike0 York,\f3\fs18\cf0\b0\i0\ul0\str
ike0 NY,\f3\fs18\cf0\b0\i0\ul0\strike0 U.S.),\f3\fs10\cf0\b0\i0\ul0\strike0 1
6,18\f3\fs18\cf0\b0\i0\ul0\strike0 which\f3\fs18\cf0\b0\i0\ul0\strike0 is\f3\f
s18\cf0\b0\i0\ul0\strike0 different\f3\fs18\cf0\b0\i0\ul0\strike0 from\f3\fs18
\cf0\b0\i0\ul0\strike0 the\par\pard\plain\li1021\sl-228\f3\fs18\cf0\b0\i0\ul0\s
trike0 hATG\f3\fs18\cf0\b0\i0\ul0\strike0 preparation\f3\fs18\cf0\b0\i0\ul0\str
ike0 used\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 Euro
pe\f3\fs18\cf0\b0\i0\ul0\strike0 (15\f3\fs18\cf0\b0\i0\ul0\strike0 mg/\f3\fs18
\cf0\b0\i0\ul0\strike0 kg\f3\fs18\cf0\b0\i0\ul0\strike0 per\f3\fs18\cf0\b0\i0\
ul0\strike0 day\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 for\
f3\fs18\cf0\b0\i0\ul0\strike0 5\f3\fs18\cf0\b0\i0\ul0\strike0 days,\f3\fs18\cf
0\b0\i0\ul0\strike0 Lymphoglobuline;\f3\fs18\cf0\b0\i0\ul0\strike0 Genzyme,\f3
\fs18\cf0\b0\i0\ul0\strike0 Cambridge,\par\pard\plain\li1021\sl-230\f3\fs18\cf0
\b0\i0\ul0\strike0 MA,\f3\fs18\cf0\b0\i0\ul0\strike0 U.S.;\f3\fs18\cf0\b0\i0\ul
0\strike0 Fresenius\f3\fs18\cf0\b0\i0\ul0\strike0 Biotech,\f3\fs18\cf0\b0\i0\u
l0\strike0 Munich,\f3\fs18\cf0\b0\i0\ul0\strike0 Germany)\f3\fs10\cf0\b0\i0\ul
0\strike0 19\f3\fs18\cf0\b0\i0\ul0\strike0 .\par\pard\plain\li1021\sl-229\f3\fs
18\cf0\b0\i0\ul0\strike0 Thus,\f3\fs18\cf0\b0\i0\ul0\strike0 both\f3\fs18\cf0\b
0\i0\ul0\strike0 preparations\f3\fs18\cf0\b0\i0\ul0\strike0 can\f3\fs18\cf0\b0
\i0\ul0\strike0 be\f3\fs18\cf0\b0\i0\ul0\strike0 considered\f3\fs18\cf0\b0\i0\
ul0\strike0 equivalent\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strik
e0 as\f3\fs18\cf0\b0\i0\ul0\strike0 standard\f3\fs18\cf0\b0\i0\ul0\strike0 IST
\f3\fs18\cf0\b0\i0\ul0\strike0 for\f3\fs18\cf0\b0\i0\ul0\strike0 AA;\f3\fs18\c
f0\b0\i0\ul0\strike0 however,\f3\fs18\cf0\b0\i0\ul0\strike0 Lymphoglobuline\pa
r\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 is\f3\fs18\cf0\b0\i0\ul
0\strike0 no\f3\fs18\cf0\b0\i0\ul0\strike0 longer\f3\fs18\cf0\b0\i0\ul0\strike
0 available.\f3\fs18\cf0\b0\i0\ul0\strike0 Alternative\f3\fs18\cf0\b0\i0\ul0\s
trike0 polyclonal\f3\fs18\cf0\b0\i0\ul0\strike0 ATGs\par\pard\plain\li0\sl-262
\column\f3\fs18\cf0\b0\i0\ul0\strike0 may\f3\fs18\cf0\b0\i0\ul0\strike0 be\f3\f
s18\cf0\b0\i0\ul0\strike0 obtained\f3\fs18\cf0\b0\i0\ul0\strike0 from\f3\fs18\
cf0\b0\i0\ul0\strike0 rabbits\f3\fs18\cf0\b0\i0\ul0\strike0 (r\f3\fs18\cf0\b0\
i0\ul0\strike0 );\f3\fs18\cf0\b0\i0\ul0\strike0 two\f3\fs18\cf0\b0\i0\ul0\stri
ke0 rATGs\f3\fs18\cf0\b0\i0\ul0\strike0 are\par\pard\plain\li0\sl-230\f3\fs18\
cf0\b0\i0\ul0\strike0 currently\f3\fs18\cf0\b0\i0\ul0\strike0 available\f3\fs18
\cf0\b0\i0\ul0\strike0 (Thymoglobuline,\f3\fs18\cf0\b0\i0\ul0\strike0 Genzyme;
\f3\fs18\cf0\b0\i0\ul0\strike0 ATG-\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0
\ul0\strike0 Fresenius),\f3\fs18\cf0\b0\i0\ul0\strike0 but\f3\fs18\cf0\b0\i0\ul
0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 date\f3\fs18\cf0\b0\i0\ul0\strike0
the\f3\fs18\cf0\b0\i0\ul0\strike0 clinical\f3\fs18\cf0\b0\i0\ul0\strike0 resu
lts\f3\fs18\cf0\b0\i0\ul0\strike0 with\f3\fs18\cf0\b0\i0\ul0\strike0 these\par
\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 agents\f3\fs18\cf0\b0\i0\ul
0\strike0 are\f3\fs18\cf0\b0\i0\ul0\strike0 less\f3\fs18\cf0\b0\i0\ul0\strike0
robust\f3\fs18\cf0\b0\i0\ul0\strike0 for\f3\fs18\cf0\b0\i0\ul0\strike0 the\f
3\fs18\cf0\b0\i0\ul0\strike0 lack\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0
\b0\i0\ul0\strike0 large\f3\fs18\cf0\b0\i0\ul0\strike0 randomised\par\pard\pla
in\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 trials.\f3\fs18\cf0\b0\i0\ul0\strike
0 However,\f3\fs18\cf0\b0\i0\ul0\strike0 hATG\f3\fs18\cf0\b0\i0\ul0\strike0 (
ATGAM)\f3\fs18\cf0\b0\i0\ul0\strike0 is\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\f
s18\cf0\b0\i0\ul0\strike0 recommended\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\
i0\ul0\strike0 first\f3\fs18\cf0\b0\i0\ul0\strike0 line\f3\fs18\cf0\b0\i0\ul0\s
trike0 IST\f3\fs18\cf0\b0\i0\ul0\strike0 for\f3\fs18\cf0\b0\i0\ul0\strike0 pa
tients\f3\fs18\cf0\b0\i0\ul0\strike0 ineligible\f3\fs18\cf0\b0\i0\ul0\strike0
for\f3\fs18\cf0\b0\i0\ul0\strike0 HLA\f3\fs18\cf0\b0\i0\ul0\strike0 identical\
par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 sibling\f3\fs18\cf0\b0\i
0\ul0\strike0 haemopoietic\f3\fs18\cf0\b0\i0\ul0\strike0 stem\f3\fs18\cf0\b0\i
0\ul0\strike0 cell\f3\fs18\cf0\b0\i0\ul0\strike0 transplantation\f3\fs18\cf0\b
0\i0\ul0\strike0 (HSCT)\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0
as\f3\fs18\cf0\b0\i0\ul0\strike0 stated\f3\fs18\cf0\b0\i0\ul0\strike0 by\f3\f
s18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 British\f3\fs18\cf

0\b0\i0\ul0\strike0 Committee\f3\fs18\cf0\b0\i0\ul0\strike0 for\f3\fs18\cf0\b0
\i0\ul0\strike0 Standards\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strik
e0 in\f3\fs18\cf0\b0\i0\ul0\strike0 Haematology\f3\fs18\cf0\b0\i0\ul0\strike0
(BCSH)\f3\fs18\cf0\b0\i0\ul0\strike0 guidance\f3\fs18\cf0\b0\i0\ul0\strike0 fo
llowing\f3\fs18\cf0\b0\i0\ul0\strike0 the\par\pard\plain\li0\sl-230\f3\fs18\cf0
\b0\i0\ul0\strike0 results\f3\fs18\cf0\b0\i0\ul0\strike0 obtained\f3\fs18\cf0\b
0\i0\ul0\strike0 from\f3\fs18\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\b0\i0\ul0\st
rike0 prospective\f3\fs18\cf0\b0\i0\ul0\strike0 randomised\f3\fs18\cf0\b0\i0\u
l0\strike0 trial\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 compar
ing\f3\fs18\cf0\b0\i0\ul0\strike0 hATG\f3\fs18\cf0\b0\i0\ul0\strike0 versus\f3
\fs18\cf0\b0\i0\ul0\strike0 rATG\f3\fs18\cf0\b0\i0\ul0\strike0 for\f3\fs18\cf0
\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 treatment\f3\fs18\cf0\b0\
i0\ul0\strike0 of\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 AA.\f
3\fs10\cf0\b0\i0\ul0\strike0 20\f3\fs18\cf0\b0\i0\ul0\strike0 rATG\f3\fs18\cf0
\b0\i0\ul0\strike0 is\f3\fs18\cf0\b0\i0\ul0\strike0 more\f3\fs18\cf0\b0\i0\ul0
\strike0 immunosuppressive\f3\fs18\cf0\b0\i0\ul0\strike0 than\f3\fs18\cf0\b0\i
0\ul0\strike0 hATG\par\pard\plain\li0\sl-229\f3\fs18\cf0\b0\i0\ul0\strike0 but\
f3\fs18\cf0\b0\i0\ul0\strike0 does\f3\fs18\cf0\b0\i0\ul0\strike0 not\f3\fs18\c
f0\b0\i0\ul0\strike0 improve\f3\fs18\cf0\b0\i0\ul0\strike0 haematological\f3\f
s18\cf0\b0\i0\ul0\strike0 recovery\f3\fs18\cf0\b0\i0\ul0\strike0 as\par\pard\p
lain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 compared\f3\fs18\cf0\b0\i0\ul0\str
ike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 hATG.\f3\fs18\cf0\b0\i0\ul0\strike0 rAT
G\f3\fs18\cf0\b0\i0\ul0\strike0 is\f3\fs18\cf0\b0\i0\ul0\strike0 used\f3\fs18\
cf0\b0\i0\ul0\strike0 successfully\f3\fs18\cf0\b0\i0\ul0\strike0 to\par\pard\p
lain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 salvage\f3\fs18\cf0\b0\i0\ul0\stri
ke0 patients\f3\fs18\cf0\b0\i0\ul0\strike0 with\f3\fs18\cf0\b0\i0\ul0\strike0
refractory\f3\fs18\cf0\b0\i0\ul0\strike0 or\f3\fs18\cf0\b0\i0\ul0\strike0 rel
apsed\f3\fs18\cf0\b0\i0\ul0\strike0 SAA\par\pard\plain\li0\sl-230\f3\fs18\cf0\b
0\i0\ul0\strike0 following\f3\fs18\cf0\b0\i0\ul0\strike0 initial\f3\fs18\cf0\b0
\i0\ul0\strike0 hATG.\f3\fs10\cf0\b0\i0\ul0\strike0 11\par\pard\plain\li0\sl-4
34\f2\fs26\cf0\b\i0\ul0\strike0 Immunosuppression\f2\fs26\cf0\b\i0\ul0\strike0
Administration\par\pard\plain\li0\sl-368\f2\fs18\cf0\b\i0\ul0\strike0 ATG\par\pa
rd\plain\li239\sl-300\f3\fs18\cf0\b0\i0\ul0\strike0 During\f3\fs18\cf0\b0\i0\ul0
\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 administration\f3\fs18\cf0\b0\i0\ul
0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 ATG,\f3\fs18\cf0\b0\i0\ul0\strike0
referral\f3\fs18\cf0\b0\i0\ul0\strike0 to\par\pard\plain\li0\sl-230\f3\fs18\cf
0\b0\i0\ul0\strike0 hospitals\f3\fs18\cf0\b0\i0\ul0\strike0 with\f3\fs18\cf0\b0
\i0\ul0\strike0 experience\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\
ul0\strike0 treating\f3\fs18\cf0\b0\i0\ul0\strike0 SAA\f3\fs18\cf0\b0\i0\ul0\s
trike0 or\f3\fs18\cf0\b0\i0\ul0\strike0 enrolment\par\pard\plain\li0\sl-230\f3
\fs18\cf0\b0\i0\ul0\strike0 into\f3\fs18\cf0\b0\i0\ul0\strike0 research\f3\fs18
\cf0\b0\i0\ul0\strike0 trials\f3\fs18\cf0\b0\i0\ul0\strike0 should\f3\fs18\cf0
\b0\i0\ul0\strike0 be\f3\fs18\cf0\b0\i0\ul0\strike0 encouraged,\f3\fs18\cf0\b0
\i0\ul0\strike0 owing\f3\fs18\cf0\b0\i0\ul0\strike0 to\par\pard\plain\li0\sl-2
30\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 unfamiliarit
y\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\c
f0\b0\i0\ul0\strike0 administration\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\c
f0\b0\i0\ul0\strike0 polyclonal\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0
\strike0 antibodies\f3\fs18\cf0\b0\i0\ul0\strike0 and\f3\fs18\cf0\b0\i0\ul0\str
ike0 its\f3\fs18\cf0\b0\i0\ul0\strike0 immediate\f3\fs18\cf0\b0\i0\ul0\strike0
toxicities,\f3\fs18\cf0\b0\i0\ul0\strike0 such\f3\fs18\cf0\b0\i0\ul0\strike0
as\f3\fs18\cf0\b0\i0\ul0\strike0 ATG,\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0
\i0\ul0\strike0 amongst\f3\fs18\cf0\b0\i0\ul0\strike0 inexperienced\f3\fs18\cf0
\b0\i0\ul0\strike0 nurses\f3\fs18\cf0\b0\i0\ul0\strike0 and\f3\fs18\cf0\b0\i0\
ul0\strike0 physicians.\f3\fs18\cf0\b0\i0\ul0\strike0 To\par\pard\plain\li0\sl
-230\f3\fs18\cf0\b0\i0\ul0\strike0 test\f3\fs18\cf0\b0\i0\ul0\strike0 for\f3\fs
18\cf0\b0\i0\ul0\strike0 hypersensitivity\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\
fs18\cf0\b0\i0\ul0\strike0 horse\f3\fs18\cf0\b0\i0\ul0\strike0 serum\f3\fs18\c
f0\b0\i0\ul0\strike0 an\f3\fs18\cf0\b0\i0\ul0\strike0 ATG\f3\fs18\cf0\b0\i0\ul
0\strike0 skin\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 test\f3\

fs18\cf0\b0\i0\ul0\strike0 should\f3\fs18\cf0\b0\i0\ul0\strike0 be\f3\fs18\cf0
\b0\i0\ul0\strike0 performed.\f3\fs10\cf0\b0\i0\ul0\strike0 11\f3\fs18\cf0\b0\
i0\ul0\strike0 Furthermore,\f3\fs18\cf0\b0\i0\ul0\strike0 ease\f3\fs18\cf0\b0\
i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 drug\par\pard\plain\li0\sl-229
\f3\fs18\cf0\b0\i0\ul0\strike0 delivery\f3\fs18\cf0\b0\i0\ul0\strike0 and\f3\fs
18\cf0\b0\i0\ul0\strike0 transfusions\f3\fs18\cf0\b0\i0\ul0\strike0 can\f3\fs1
8\cf0\b0\i0\ul0\strike0 be\f3\fs18\cf0\b0\i0\ul0\strike0 improved\f3\fs18\cf0\
b0\i0\ul0\strike0 with\f3\fs18\cf0\b0\i0\ul0\strike0 the\par\pard\plain\li0\sl
-230\f3\fs18\cf0\b0\i0\ul0\strike0 use\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18
\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\b0\i0\ul0\strike0 double\f3\fs18\cf0\b0\i
0\ul0\strike0 lumen\f3\fs18\cf0\b0\i0\ul0\strike0 central\f3\fs18\cf0\b0\i0\ul
0\strike0 line.\f3\fs18\cf0\b0\i0\ul0\strike0 Scheinberg\f3\fs18\cf0\b0\i0\ul0
\strike0 and\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 Young\f3\f
s18\cf0\b0\i0\ul0\strike0 recommend\f3\fs18\cf0\b0\i0\ul0\strike0 maintaining\
f3\fs18\cf0\b0\i0\ul0\strike0 platelets\f3\fs18\cf0\b0\i0\ul0\strike0 at\f3\fs
18\cf0\b0\i0\ul0\strike0 more\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\s
trike0 than\f3\fs18\cf0\b0\i0\ul0\strike0 20000/L\f3\fs18\cf0\b0\i0\ul0\strike0
during\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 ATG\f
3\fs18\cf0\b0\i0\ul0\strike0 administration\f3\fs18\cf0\b0\i0\ul0\strike0 peri
od.\f3\fs10\cf0\b0\i0\ul0\strike0 11\par\pard\plain\li0\sl-229\f3\fs18\cf0\b0\i
0\ul0\strike0 In\f3\fs18\cf0\b0\i0\ul0\strike0 cases\f3\fs18\cf0\b0\i0\ul0\stri
ke0 of\f3\fs18\cf0\b0\i0\ul0\strike0 platelet\f3\fs18\cf0\b0\i0\ul0\strike0 r
efractoriness,\f3\fs18\cf0\b0\i0\ul0\strike0 they\f3\fs18\cf0\b0\i0\ul0\strike0
recommend\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 testing\f3\f
s18\cf0\b0\i0\ul0\strike0 for\f3\fs18\cf0\b0\i0\ul0\strike0 alloantibodies\f3\
fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 determine\f3\fs18\
cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 need\f3\fs18\cf0\b0\i0
\ul0\strike0 for\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 best\f
3\fs18\cf0\b0\i0\ul0\strike0 matched\f3\fs18\cf0\b0\i0\ul0\strike0 platelet\f3
\fs18\cf0\b0\i0\ul0\strike0 products\f3\fs18\cf0\b0\i0\ul0\strike0 and\f3\fs18
\cf0\b0\i0\ul0\strike0 using\f3\fs18\cf0\b0\i0\ul0\strike0 universal\par\pard\
plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 filtration\f3\fs18\cf0\b0\i0\ul0\
strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 blood\f3\fs18\cf0\b0\i0\ul0\strike0
products\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 preven
t\f3\fs18\cf0\b0\i0\ul0\strike0 alloantibody\par\pard\plain\li0\sl-230\f3\fs18\
cf0\b0\i0\ul0\strike0 formation.\f3\fs18\cf0\b0\i0\ul0\strike0 While\f3\fs18\cf
0\b0\i0\ul0\strike0 there\f3\fs18\cf0\b0\i0\ul0\strike0 is\f3\fs18\cf0\b0\i0\u
l0\strike0 no\f3\fs18\cf0\b0\i0\ul0\strike0 formal\f3\fs18\cf0\b0\i0\ul0\strik
e0 recommendation\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 regar
ding\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 use\f3\fs
18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 irradiated\f3\fs18\c
f0\b0\i0\ul0\strike0 products\f3\fs18\cf0\b0\i0\ul0\strike0 after\f3\fs18\cf0\
b0\i0\ul0\strike0 hATG\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0
in\f3\fs18\cf0\b0\i0\ul0\strike0 SAA\f3\fs18\cf0\b0\i0\ul0\strike0 patients,\f
3\fs18\cf0\b0\i0\ul0\strike0 their\f3\fs18\cf0\b0\i0\ul0\strike0 practice\f3\f
s18\cf0\b0\i0\ul0\strike0 has\f3\fs18\cf0\b0\i0\ul0\strike0 been\f3\fs18\cf0\b
0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 apply\par\pard\plain\li0\sl230\f3\fs18\cf0\b0\i0\ul0\strike0 universal\f3\fs18\cf0\b0\i0\ul0\strike0 irrad
iation\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 their\f3
\fs18\cf0\b0\i0\ul0\strike0 protocols,\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs1
8\cf0\b0\i0\ul0\strike0 accordance\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\
ul0\strike0 with\f3\fs18\cf0\b0\i0\ul0\strike0 recommendations\f3\fs18\cf0\b0\i
0\ul0\strike0 from\f3\fs18\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\b0\i0\ul0\strik
e0 European\f3\fs18\cf0\b0\i0\ul0\strike0 study\par\pard\plain\li0\sl-230\f3\f
s18\cf0\b0\i0\ul0\strike0 survey.\f3\fs10\cf0\b0\i0\ul0\strike0 21\f3\fs18\cf0\
b0\i0\ul0\strike0 Establishing\f3\fs18\cf0\b0\i0\ul0\strike0 responsiveness\f3
\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 antibiotic\par\pa
rd\plain\li0\sl-229\f3\fs18\cf0\b0\i0\ul0\strike0 therapy\f3\fs18\cf0\b0\i0\ul0\
strike0 for\f3\fs18\cf0\b0\i0\ul0\strike0 bacterial\f3\fs18\cf0\b0\i0\ul0\stri
ke0 infections\f3\fs18\cf0\b0\i0\ul0\strike0 is\f3\fs18\cf0\b0\i0\ul0\strike0

preferred,\f3\fs18\cf0\b0\i0\ul0\strike0 even\par\pard\plain\li0\sl-230\f3\fs1
8\cf0\b0\i0\ul0\strike0 though\f3\fs18\cf0\b0\i0\ul0\strike0 patients\f3\fs18\c
f0\b0\i0\ul0\strike0 need\f3\fs18\cf0\b0\i0\ul0\strike0 not\f3\fs18\cf0\b0\i0\
ul0\strike0 be\f3\fs18\cf0\b0\i0\ul0\strike0 free\f3\fs18\cf0\b0\i0\ul0\strike
0 of\f3\fs18\cf0\b0\i0\ul0\strike0 infection\f3\fs18\cf0\b0\i0\ul0\strike0 be
fore
}}
}}
}}
{\sp{\sn lTxid}{\sv 28236}}
{\shptxt\pard\li5\sl240\slmult1\sb34\f3\fs21\b0\expnd0\expndtw1\charscalex100
\trowd\irow0\trgaph0\trrh-204\trql\trleft0
\clvertalt\clbrdrt\brdrs\brdrw12\brdrcf0\clbrdrl\brdrs\brdrw12\brdrcf0\clbrdrr\b
rdrs\brdrw12\brdrcf0\clbrdrb\brdrs\brdrw12\brdrcf0\clcbpat1\cltxlrtb\cellx4031
\pard\plain\intbl\li1633\sl-207\f3\fs16\cf0\b0\i0\ul0\strike0 <\f3\fs16\cf0\b0\i
0\ul0\strike0 40\f3\fs16\cf0\b0\i0\ul0\strike0 years\cell
\pard\plain\intbl\li1102\sl-207\f3\fs16\cf0\b0\i0\ul0\strike0 40-60\f3\fs16\cf0\
b0\i0\ul0\strike0 years\cell
\pard\plain\intbl\li1149\sl-207\f3\fs16\cf0\b0\i0\ul0\strike0 >\f3\fs16\cf0\b0\i
0\ul0\strike0 60\f3\fs16\cf0\b0\i0\ul0\strike0 years\cell
\row
\clvmgf\clvertalt\clbrdrt\brdrs\brdrw12\brdrcf0\clbrdrl\brdrs\brdrw12\brdrcf0\cl
brdrr\brdrs\brdrw12\brdrcf0\clbrdrb\brdrs\brdrw12\brdrcf0\clcbpat1\cltxlrtb\cell
x7056
x10080
\pard\plain\intbl\li6\sl-207\f3\fs16\cf0\b0\i0\ul0\strike0 Sibling\f3\fs16\cf0\b
0\i0\ul0\strike0 donor\cell
\pard\plain\intbl\li892\sl-207\f3\fs16\cf0\b0\i0\ul0\strike0 No\f3\fs16\cf0\b0\i
0\ul0\strike0 sibling\f3\fs16\cf0\b0\i0\ul0\strike0 donor\cell
\pard\plain\intbl\li1015\sl-323\f3\fs16\cf0\b0\i0\ul0\strike0 H-ATG\f3\fs16\cf0\
b0\i0\ul0\strike0 +CSA\cell
\pard\plain\intbl\li995\sl-323\f3\fs16\cf0\b0\i0\ul0\strike0 H-ATG\f3\fs16\cf0\b
0\i0\ul0\strike0 +\f3\fs16\cf0\b0\i0\ul0\strike0 CSA\cell
\row
x1008
\clvmrg\clvertalt\clbrdrt\brdrs\brdrw12\brdrcf0\clbrdrl\brdrs\brdrw12\brdrcf0\cl
x7056
x10080
\cell
\pard\plain\intbl\li975\sl-221\f3\fs16\cf0\b0\i0\ul0\strike0 H\f3\fs16\cf0\b0\i0
\ul0\strike0 -ATG\f3\fs16\cf0\b0\i0\ul0\strike0 +\f3\fs16\cf0\b0\i0\ul0\strike
0 CSA\cell
\pard\plain\intbl\li1015\sl-323\f3\fs16\cf0\b0\i0\ul0\strike0 H-ATG\f3\fs16\cf0\
b0\i0\ul0\strike0 +CSA\cell
\pard\plain\intbl\li995\sl-323\f3\fs16\cf0\b0\i0\ul0\strike0 H-ATG\f3\fs16\cf0\b
0\i0\ul0\strike0 +\f3\fs16\cf0\b0\i0\ul0\strike0 CSA\cell
\row
x1008
\cell
0\ul0\strike0 response\cell
\pard\plain\intbl\li152\sl-221\f3\fs16\cf0\b0\i0\ul0\strike0 Response\cell
\pard\plain\intbl\li173\sl-221\f3\fs16\cf0\b0\i0\ul0\strike0 response\cell
\row
x1008
x9072
\cell
\pard\plain\intbl\li82\sl-325\f3\fs16\cf0\b0\i0\ul0\strike0 MUD\f3\fs16\cf0\b0\i
0\ul0\strike0 10/10\cell
\pard\plain\intbl\li139\sl-325\f3\fs16\cf0\b0\i0\ul0\strike0 NO\f3\fs16\cf0\b0\i
0\ul0\strike0 MUD\cell
\cell
0\i0\ul0\strike0 donor\cell
0\ul0\strike0 donor\cell
\cell
\cell
\cell
\row
x1008
x2016
x5040
x9072
\cell
\cell
\cell
\pard\plain\intbl\li234\sl-207\f3\fs16\cf0\b0\i0\ul0\strike0 relapse\cell
\cell
\cell
\cell
\row
x1008
x2016
x5040
\cell
\cell
\pard\plain\intbl\li978\sl-134\f3\fs8\cf0\b0\i0\ul0\strike0 nd\par\pard\plain\in
tbl\li898\sl-72\f3\fs16\cf0\b0\i0\ul0\strike0 2\f3\fs16\cf0\b0\i0\ul0\strike0 I
ST\cell
\cell
\pard\plain\intbl\li998\sl-134\f3\fs8\cf0\b0\i0\ul0\strike0 nd\par\pard\plain\in
ST\cell
\pard\plain\intbl\li1562\sl-134\f3\fs8\cf0\b0\i0\ul0\strike0 nd\par\pard\plain\i
ntbl\li1482\sl-72\f3\fs16\cf0\b0\i0\ul0\strike0 2\f3\fs16\cf0\b0\i0\ul0\strike0
IST\cell
\row
x1008
x2016
x5040
\cell
\cell
\pard\plain\intbl\li239\sl-207\f3\fs16\cf0\b0\i0\ul0\strike0 Failure\cell
\cell
\pard\plain\intbl\li257\sl-207\f3\fs16\cf0\b0\i0\ul0\strike0 failure\cell
\pard\plain\intbl\li152\sl-207\f3\fs16\cf0\b0\i0\ul0\strike0 Response\cell
\pard\plain\intbl\li761\sl-207\f3\fs16\cf0\b0\i0\ul0\strike0 failure\cell
\row
x2016
x3024
x5040
x6048
x8064
x9072
\pard\plain\intbl\li765\sl-544\f3\fs16\cf0\b\i0\ul0\strike0 HSCT\cell
\pard\plain\intbl\li323\sl-182\f3\fs8\cf0\b0\i0\ul0\strike0 RD\par\pard\plain\in
ST\par\pard\plain\intbl\li122\sl-191\f3\fs16\cf0\b0\i0\ul0\strike0 9/10\f3\fs16\
cf0\b0\i0\ul0\strike0 MUD\par\pard\plain\intbl\li199\sl-192\f3\fs16\cf0\b0\i0\u
l0\strike0 HAPLO\par\pard\plain\intbl\li253\sl-192\f3\fs16\cf0\b0\i0\ul0\strike0
CORD\cell
\cell
\pard\plain\intbl\li343\sl-182\f3\fs8\cf0\b0\i0\ul0\strike0 rd\par\pard\plain\in
ST\par\pard\plain\intbl\li288\sl-191\f3\fs16\cf0\b0\i0\ul0\strike0 MUD\par\pard\
plain\intbl\li150\sl-192\f3\fs16\cf0\b0\i0\ul0\strike0 HALPLO\par\pard\plain\int
bl\li253\sl-192\f3\fs16\cf0\b0\i0\ul0\strike0 CORD\cell
\cell
0\i0\ul0\strike0 donor\par\pard\plain\intbl\li274\sl-191\f3\fs16\cf0\b0\i0\ul0\
strike0 HSCT\cell
\pard\plain\intbl\li337\sl-447\f3\fs16\cf0\b0\i0\ul0\strike0 EXP\par\pard\plain\
intbl\li348\sl-191\f3\fs16\cf0\b0\i0\ul0\strike0 BST\cell
\cell
\row
x2016
x3024
x4032
x5040
x6048
x7056
x8064
x9072
CORD\cell
strike0 HSCT\cell
\pard\plain\intbl\li212\sl-206\f3\fs16\cf0\b0\i0\ul0\strike0 Relapse\cell
\row
x2016
x3024
x4032
x5040
x6048
x7056
x8064
x9072
CORD\cell
strike0 HSCT\cell
\pard\plain\intbl\li348\sl-221\f3\fs16\cf0\b0\i0\ul0\strike0 BST\cell
\row
}{\par}
}}\sect\sectd\sbkpage\pgwsxn12132\pghsxn15987\sected\cols2\colno1\colw3390\colsr
10\colno2\colw8720\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200
\par\pard\plain\sl-207\par\pard\plain\li1021\sl-228\f0\fs18\cf0\b0\i0\ul0\strike
0 18\f0\fs12\cf0\b0\i0\ul0\strike0 \par\pard\column\plain\sl-200\par\pard\plain
\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-262\par\pard\plain\li0\sl-152\f0
\fs12\cf0\b0\i0\ul0\strike0 supplement to Journal of the association of physicia
ns of india \u183? published on 1st of every month 1st march, 2015\par\sect\sect
ed\sbknone\cols2\colno1\colw6290\colsr10\colno2\colw5820\pard\plain\sl-396\par\p
ard\plain\li1021\sl-254\f3\fs18\cf0\b0\i0\ul0\strike0 starting\f3\fs18\cf0\b0\i0
\ul0\strike0 ATG.\f3\fs10\cf0\b0\i0\ul0\strike0 11\f3\fs18\cf0\b0\i0\ul0\strik
e0 However,\f3\fs18\cf0\b0\i0\ul0\strike0 it\f3\fs18\cf0\b0\i0\ul0\strike0 is
\f3\fs18\cf0\b0\i0\ul0\strike0 important\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\f
s18\cf0\b0\i0\ul0\strike0 note\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\u
l0\strike0 that\f3\fs18\cf0\b0\i0\ul0\strike0 prolonged\f3\fs18\cf0\b0\i0\ul0\s
trike0 attempts\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0
clear\f3\fs18\cf0\b0\i0\ul0\strike0 fungal\f3\fs18\cf0\b0\i0\ul0\strike0 inf
ections\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 or\f3\fs18\cf
0\b0\i0\ul0\strike0 extensive\f3\fs18\cf0\b0\i0\ul0\strike0 bacterial\f3\fs18\
cf0\b0\i0\ul0\strike0 infections\f3\fs18\cf0\b0\i0\ul0\strike0 can\f3\fs18\cf0
\b0\i0\ul0\strike0 defer\f3\fs18\cf0\b0\i0\ul0\strike0 definitive\par\pard\pla
in\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 IST\f3\fs18\cf0\b0\i0\ul0\strike0
or\f3\fs18\cf0\b0\i0\ul0\strike0 HSCT\f3\fs18\cf0\b0\i0\ul0\strike0 therapie
s.\f3\fs18\cf0\b0\i0\ul0\strike0 b-blockers\f3\fs18\cf0\b0\i0\ul0\strike0 may\
f3\fs18\cf0\b0\i0\ul0\strike0 be\f3\fs18\cf0\b0\i0\ul0\strike0 withheld\par\pa
rd\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 before\f3\fs18\cf0\b0\i0\ul
0\strike0 ATG\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0
evade\f3\fs18\cf0\b0\i0\ul0\strike0 suppression\f3\fs18\cf0\b0\i0\ul0\strike0
of\f3\fs18\cf0\b0\i0\ul0\strike0 physiologic\par\pard\plain\li1021\sl-230\f3\fs
18\cf0\b0\i0\ul0\strike0 compensatory\f3\fs18\cf0\b0\i0\ul0\strike0 responses\f
3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 anaphylaxis.\f3\
fs18\cf0\b0\i0\ul0\strike0 It\f3\fs18\cf0\b0\i0\ul0\strike0 is\f3\fs18\cf0\b0\
i0\ul0\strike0 also\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0
advisable\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 not\f
3\fs18\cf0\b0\i0\ul0\strike0 initiate\f3\fs18\cf0\b0\i0\ul0\strike0 ATG\f3\fs1
8\cf0\b0\i0\ul0\strike0 late\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i
0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 day\f3\fs18\cf0\b0\i0\ul0\stri
ke0 or\f3\fs18\cf0\b0\i0\ul0\strike0 on\par\pard\plain\li1021\sl-230\f3\fs18\c
f0\b0\i0\ul0\strike0 weekends\f3\fs18\cf0\b0\i0\ul0\strike0 when\f3\fs18\cf0\b0
\i0\ul0\strike0 hospitals\f3\fs18\cf0\b0\i0\ul0\strike0 may\f3\fs18\cf0\b0\i0\
ul0\strike0 be\f3\fs18\cf0\b0\i0\ul0\strike0 understaffed.\f3\fs10\cf0\b0\i0\u
l0\strike0 11\par\pard\plain\li1261\sl-282\f3\fs18\cf0\b0\i0\ul0\strike0 The\f3
\fs18\cf0\b0\i0\ul0\strike0 normal\f3\fs18\cf0\b0\i0\ul0\strike0 daily\f3\fs18
\cf0\b0\i0\ul0\strike0 dose\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0
\ul0\strike0 ATG\f3\fs18\cf0\b0\i0\ul0\strike0 is\f3\fs18\cf0\b0\i0\ul0\strike
0 40mg/kg\f3\fs18\cf0\b0\i0\ul0\strike0 over\par\pard\plain\li1021\sl-230\f3\f
s18\cf0\b0\i0\ul0\strike0 4\f3\fs18\cf0\b0\i0\ul0\strike0 hours,\f3\fs18\cf0\b0
\i0\ul0\strike0 for\f3\fs18\cf0\b0\i0\ul0\strike0 4\f3\fs18\cf0\b0\i0\ul0\stri
ke0 days.\f3\fs18\cf0\b0\i0\ul0\strike0 Prophylactic\f3\fs18\cf0\b0\i0\ul0\str
ike0 treatment\f3\fs18\cf0\b0\i0\ul0\strike0 for\par\pard\plain\li1021\sl-230\
f3\fs18\cf0\b0\i0\ul0\strike0 serum\f3\fs18\cf0\b0\i0\ul0\strike0 sickness\f3\f
s18\cf0\b0\i0\ul0\strike0 may\f3\fs18\cf0\b0\i0\ul0\strike0 be\f3\fs18\cf0\b0\
i0\ul0\strike0 initiated\f3\fs18\cf0\b0\i0\ul0\strike0 on\f3\fs18\cf0\b0\i0\ul

0\strike0 day\f3\fs18\cf0\b0\i0\ul0\strike0 1\f3\fs18\cf0\b0\i0\ul0\strike0 w
ith\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 Prednisone\f3\fs1
8\cf0\b0\i0\ul0\strike0 1\f3\fs18\cf0\b0\i0\ul0\strike0 mg/kg,\f3\fs18\cf0\b0\
i0\ul0\strike0 which\f3\fs18\cf0\b0\i0\ul0\strike0 may\f3\fs18\cf0\b0\i0\ul0\s
trike0 be\f3\fs18\cf0\b0\i0\ul0\strike0 continued\par\pard\plain\li1021\sl-230
\f3\fs18\cf0\b0\i0\ul0\strike0 for\f3\fs18\cf0\b0\i0\ul0\strike0 2\f3\fs18\cf0\
b0\i0\ul0\strike0 weeks.\f3\fs18\cf0\b0\i0\ul0\strike0 Conventional\f3\fs18\cf
0\b0\i0\ul0\strike0 premedication\f3\fs18\cf0\b0\i0\ul0\strike0 prior\par\pard
\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\stri
ke0 every\f3\fs18\cf0\b0\i0\ul0\strike0 ATG\f3\fs18\cf0\b0\i0\ul0\strike0 dos
e\f3\fs18\cf0\b0\i0\ul0\strike0 involves\f3\fs18\cf0\b0\i0\ul0\strike0 acetami
nophen\f3\fs18\cf0\b0\i0\ul0\strike0 and\par\pard\plain\li1021\sl-230\f3\fs18\c
f0\b0\i0\ul0\strike0 diphenhydramine.\f3\fs18\cf0\b0\i0\ul0\strike0 Furthermore
,\f3\fs18\cf0\b0\i0\ul0\strike0 symptomatic\par\pard\plain\li1021\sl-230\f3\fs1
8\cf0\b0\i0\ul0\strike0 management\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0
\b0\i0\ul0\strike0 common\f3\fs18\cf0\b0\i0\ul0\strike0 infusion\f3\fs18\cf0\b
0\i0\ul0\strike0 reactions\f3\fs18\cf0\b0\i0\ul0\strike0 may\par\pard\plain\li
1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 comprise\f3\fs18\cf0\b0\i0\ul0\strike0
of\f3\fs18\cf0\b0\i0\ul0\strike0 meperidine\f3\fs18\cf0\b0\i0\ul0\strike0 (r
igors),\f3\fs18\cf0\b0\i0\ul0\strike0 acetaminophen\par\pard\plain\li1021\sl-23
0\f3\fs18\cf0\b0\i0\ul0\strike0 (\f3\fs18\cf0\b0\i0\ul0\strike0 f\f3\fs18\cf0\b
0\i0\ul0\strike0 e\f3\fs18\cf0\b0\i0\ul0\strike0 ve\f3\fs18\cf0\b0\i0\ul0\stri
ke0 r\f3\fs18\cf0\b0\i0\ul0\strike0 s\f3\fs18\cf0\b0\i0\ul0\strike0 )\f3\fs18
\cf0\b0\i0\ul0\strike0 ,\f3\fs18\cf0\b0\i0\ul0\strike0 d\f3\fs18\cf0\b0\i0\ul0
\strike0 i\f3\fs18\cf0\b0\i0\ul0\strike0 p\f3\fs18\cf0\b0\i0\ul0\strike0 h\f3
\fs18\cf0\b0\i0\ul0\strike0 e\f3\fs18\cf0\b0\i0\ul0\strike0 n\f3\fs18\cf0\b0\i
0\ul0\strike0 h\f3\fs18\cf0\b0\i0\ul0\strike0 y\f3\fs18\cf0\b0\i0\ul0\strike0
d\f3\fs18\cf0\b0\i0\ul0\strike0 r\f3\fs18\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0
\b0\i0\ul0\strike0 m\f3\fs18\cf0\b0\i0\ul0\strike0 i\f3\fs18\cf0\b0\i0\ul0\str
ike0 n\f3\fs18\cf0\b0\i0\ul0\strike0 e\f3\fs18\cf0\b0\i0\ul0\strike0 (\f3\fs1
8\cf0\b0\i0\ul0\strike0 r\f3\fs18\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\b0\i0\ul
0\strike0 s\f3\fs18\cf0\b0\i0\ul0\strike0 h\f3\fs18\cf0\b0\i0\ul0\strike0 )\f
3\fs18\cf0\b0\i0\ul0\strike0 ,\f3\fs18\cf0\b0\i0\ul0\strike0 i\f3\fs18\cf0\b0\
i0\ul0\strike0 n\f3\fs18\cf0\b0\i0\ul0\strike0 t\f3\fs18\cf0\b0\i0\ul0\strike0
r\f3\fs18\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\b0\i0\ul0\strike0 ve\f3\fs18\c
f0\b0\i0\ul0\strike0 n\f3\fs18\cf0\b0\i0\ul0\strike0 o\f3\fs18\cf0\b0\i0\ul0\s
trike0 u\f3\fs18\cf0\b0\i0\ul0\strike0 s\par\pard\plain\li1021\sl-230\f3\fs18\
cf0\b0\i0\ul0\strike0 hydration\f3\fs18\cf0\b0\i0\ul0\strike0 (hypotension),\f3
\fs18\cf0\b0\i0\ul0\strike0 and\f3\fs18\cf0\b0\i0\ul0\strike0 supplemental\f3\
fs18\cf0\b0\i0\ul0\strike0 oxygen\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i
0\ul0\strike0 (hypoxaemia).\f3\fs10\cf0\b0\i0\ul0\strike0 11\f3\fs18\cf0\b0\i0\
ul0\strike0 Haemodynamic\f3\fs18\cf0\b0\i0\ul0\strike0 and/or\f3\fs18\cf0\b0\i
0\ul0\strike0 respiratory\par\pard\plain\li1021\sl-229\f3\fs18\cf0\b0\i0\ul0\st
rike0 compromise\f3\fs18\cf0\b0\i0\ul0\strike0 can\f3\fs18\cf0\b0\i0\ul0\strike
0 result\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 admit
tances\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\f
s18\cf0\b0\i0\ul0\strike0 intensive\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0
\i0\ul0\strike0 care\f3\fs18\cf0\b0\i0\ul0\strike0 unit,\f3\fs18\cf0\b0\i0\ul0\
strike0 vasopressor\f3\fs18\cf0\b0\i0\ul0\strike0 support,\f3\fs18\cf0\b0\i0\u
l0\strike0 and\f3\fs18\cf0\b0\i0\ul0\strike0 even,\f3\fs18\cf0\b0\i0\ul0\strik
e0 although\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 infreque
ntly,\f3\fs18\cf0\b0\i0\ul0\strike0 intubation.\f3\fs18\cf0\b0\i0\ul0\strike0
Under\f3\fs18\cf0\b0\i0\ul0\strike0 life-threatening\par\pard\plain\li1021\sl-2
30\f3\fs18\cf0\b0\i0\ul0\strike0 circumstances,\f3\fs18\cf0\b0\i0\ul0\strike0 i
t\f3\fs18\cf0\b0\i0\ul0\strike0 is\f3\fs18\cf0\b0\i0\ul0\strike0 recommended\f
3\fs18\cf0\b0\i0\ul0\strike0 that\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf
0\b0\i0\ul0\strike0 ATG\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\stri
ke0 infusion\f3\fs18\cf0\b0\i0\ul0\strike0 is\f3\fs18\cf0\b0\i0\ul0\strike0 sl
owed\f3\fs18\cf0\b0\i0\ul0\strike0 or\f3\fs18\cf0\b0\i0\ul0\strike0 briefly\f3
\fs18\cf0\b0\i0\ul0\strike0 stopped\f3\fs18\cf0\b0\i0\ul0\strike0 till\f3\fs18

\cf0\b0\i0\ul0\strike0 severe\f3\fs18\cf0\b0\i0\ul0\strike0 signs\par\pard\pla
in\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 and\f3\fs18\cf0\b0\i0\ul0\strike0
symptoms\f3\fs18\cf0\b0\i0\ul0\strike0 recede.\f3\fs18\cf0\b0\i0\ul0\strike0
ATG\f3\fs18\cf0\b0\i0\ul0\strike0 may\f3\fs18\cf0\b0\i0\ul0\strike0 be\f3\fs1
8\cf0\b0\i0\ul0\strike0 reinitiated\f3\fs18\cf0\b0\i0\ul0\strike0 at\f3\fs18\c
f0\b0\i0\ul0\strike0 a\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strik
e0 normal\f3\fs18\cf0\b0\i0\ul0\strike0 or\f3\fs18\cf0\b0\i0\ul0\strike0 slowe
r\f3\fs18\cf0\b0\i0\ul0\strike0 infusion\f3\fs18\cf0\b0\i0\ul0\strike0 rate\f3
\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\b0\
i0\ul0\strike0 monitored\f3\fs18\cf0\b0\i0\ul0\strike0 setting,\par\pard\plain
\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 occasionally\f3\fs18\cf0\b0\i0\ul0\
strike0 over\f3\fs18\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\b0\i0\ul0\strike0 24
\f3\fs18\cf0\b0\i0\ul0\strike0 hour\f3\fs18\cf0\b0\i0\ul0\strike0 period,\f3\f
s18\cf0\b0\i0\ul0\strike0 subject\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0
\b0\i0\ul0\strike0 the\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strik
e0 severity\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 the
\f3\fs18\cf0\b0\i0\ul0\strike0 reactions.\f3\fs18\cf0\b0\i0\ul0\strike0 ATG\f3
\fs18\cf0\b0\i0\ul0\strike0 may\f3\fs18\cf0\b0\i0\ul0\strike0 be\f3\fs18\cf0\b
0\i0\ul0\strike0 infused\f3\fs18\cf0\b0\i0\ul0\strike0 even\par\pard\plain\li1
021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 if\f3\fs18\cf0\b0\i0\ul0\strike0 patie
nts\f3\fs18\cf0\b0\i0\ul0\strike0 experience\f3\fs18\cf0\b0\i0\ul0\strike0 mil
d\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 moderate\f3\f
s18\cf0\b0\i0\ul0\strike0 elevation\f3\fs18\cf0\b0\i0\ul0\strike0 in\par\pard\
plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 transaminases,\f3\fs18\cf0\b0\
i0\ul0\strike0 and\f3\fs18\cf0\b0\i0\ul0\strike0 increased\f3\fs18\cf0\b0\i0\u
l0\strike0 liver\f3\fs18\cf0\b0\i0\ul0\strike0 enzymes\f3\fs18\cf0\b0\i0\ul0\s
trike0 tend\f3\fs18\cf0\b0\i0\ul0\strike0 to\par\pard\plain\li1021\sl-230\f3\f
s18\cf0\b0\i0\ul0\strike0 normalise\f3\fs18\cf0\b0\i0\ul0\strike0 over\f3\fs18\
cf0\b0\i0\ul0\strike0 several\f3\fs18\cf0\b0\i0\ul0\strike0 days.\f3\fs18\cf0\
b0\i0\ul0\strike0 Management\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i
0\ul0\strike0 infusion\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strik
e0 related\f3\fs18\cf0\b0\i0\ul0\strike0 toxicities\f3\fs18\cf0\b0\i0\ul0\strik
e0 should\f3\fs18\cf0\b0\i0\ul0\strike0 not\f3\fs18\cf0\b0\i0\ul0\strike0 com
prise\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 switching
\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 ATG\f3\fs18\cf0\b0\i
0\ul0\strike0 formulations,\f3\fs18\cf0\b0\i0\ul0\strike0 for\f3\fs18\cf0\b0\i
0\ul0\strike0 example,\f3\fs18\cf0\b0\i0\ul0\strike0 from\f3\fs18\cf0\b0\i0\ul
0\strike0 horse\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0
rabbit.\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 Moreover,\f
3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 manage\f3\fs18\c
f0\b0\i0\ul0\strike0 rising\f3\fs18\cf0\b0\i0\ul0\strike0 creatinine,\f3\fs18\
cf0\b0\i0\ul0\strike0 CsA\f3\fs18\cf0\b0\i0\ul0\strike0 can\par\pard\plain\li1
021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 be\f3\fs18\cf0\b0\i0\ul0\strike0 withh
eld\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18
\cf0\b0\i0\ul0\strike0 short\f3\fs18\cf0\b0\i0\ul0\strike0 term\f3\fs18\cf0\b0
\i0\ul0\strike0 until\f3\fs18\cf0\b0\i0\ul0\strike0 renal\f3\fs18\cf0\b0\i0\ul
0\strike0 function\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 r
ecovers.\f3\fs10\cf0\b0\i0\ul0\strike0 11\par\pard\plain\li1021\sl-257\f2\fs18\
cf0\b\i0\ul0\strike0 Cyclosporine\par\pard\plain\li1261\sl-300\f3\fs18\cf0\b0\i0
\ul0\strike0 CsA\f3\fs18\cf0\b0\i0\ul0\strike0 may\f3\fs18\cf0\b0\i0\ul0\strike
0 be\f3\fs18\cf0\b0\i0\ul0\strike0 initiated\f3\fs18\cf0\b0\i0\ul0\strike0 on
\f3\fs18\cf0\b0\i0\ul0\strike0 day\f3\fs18\cf0\b0\i0\ul0\strike0 1\f3\fs18\cf0
\b0\i0\ul0\strike0 at\f3\fs18\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\b0\i0\ul0\st
rike0 daily\f3\fs18\cf0\b0\i0\ul0\strike0 dose\f3\fs18\cf0\b0\i0\ul0\strike0
of\f3\fs18\cf0\b0\i0\ul0\strike0 10\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0
\i0\ul0\strike0 mg/kg\f3\fs18\cf0\b0\i0\ul0\strike0 (15\f3\fs18\cf0\b0\i0\ul0\s
trike0 mg/kg\f3\fs18\cf0\b0\i0\ul0\strike0 per\f3\fs18\cf0\b0\i0\ul0\strike0
day\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 children)\f
3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\b0
\i0\ul0\strike0 target\f3\fs18\cf0\b0\i0\ul0\strike0 trough\par\pard\plain\li1

021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 level\f3\fs18\cf0\b0\i0\ul0\strike0 be
tween\f3\fs18\cf0\b0\i0\ul0\strike0 200\f3\fs18\cf0\b0\i0\ul0\strike0 and\f3\f
s18\cf0\b0\i0\ul0\strike0 400\f3\fs18\cf0\b0\i0\ul0\strike0 ng/mL.\f3\fs10\cf0
\b0\i0\ul0\strike0 22\f3\fs18\cf0\b0\i0\ul0\strike0 Patient\f3\fs18\cf0\b0\i0\
ul0\strike0 frequently\par\pard\plain\li1021\sl-229\f3\fs18\cf0\b0\i0\ul0\strik
e0 develop\f3\fs18\cf0\b0\i0\ul0\strike0 hypertension\f3\fs18\cf0\b0\i0\ul0\str
ike0 during\f3\fs18\cf0\b0\i0\ul0\strike0 CsA\f3\fs18\cf0\b0\i0\ul0\strike0 t
reatment,\f3\fs18\cf0\b0\i0\ul0\strike0 and\par\pard\plain\li1021\sl-230\f3\fs1
8\cf0\b0\i0\ul0\strike0 management\f3\fs18\cf0\b0\i0\ul0\strike0 with\f3\fs18\c
f0\b0\i0\ul0\strike0 amlodipine\f3\fs18\cf0\b0\i0\ul0\strike0 is\f3\fs18\cf0\b
0\i0\ul0\strike0 recommended\f3\fs18\cf0\b0\i0\ul0\strike0 owing\par\pard\plai
n\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0
minimal\f3\fs18\cf0\b0\i0\ul0\strike0 overlap\f3\fs18\cf0\b0\i0\ul0\strike0 wi
th\f3\fs18\cf0\b0\i0\ul0\strike0 CsA\f3\fs18\cf0\b0\i0\ul0\strike0 related\f3\
fs18\cf0\b0\i0\ul0\strike0 toxicities.\f3\fs18\cf0\b0\i0\ul0\strike0 A\f3\fs18
\cf0\b0\i0\ul0\strike0 short\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0
\strike0 course\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0
azithromycin\f3\fs18\cf0\b0\i0\ul0\strike0 is\f3\fs18\cf0\b0\i0\ul0\strike0 r
ecommended\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 impr
ove\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 gingival\f3\fs18\
cf0\b0\i0\ul0\strike0 hyperplasia.\f3\fs10\cf0\b0\i0\ul0\strike0 23\f3\fs18\cf
0\b0\i0\ul0\strike0 It\f3\fs18\cf0\b0\i0\ul0\strike0 is\f3\fs18\cf0\b0\i0\ul0\
strike0 important\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strik
e0 note\f3\fs18\cf0\b0\i0\ul0\strike0 that\par\pard\plain\li1021\sl-229\f3\fs1
8\cf0\b0\i0\ul0\strike0 calcium\f3\fs18\cf0\b0\i0\ul0\strike0 channel\f3\fs18\c
f0\b0\i0\ul0\strike0 blockers\f3\fs18\cf0\b0\i0\ul0\strike0 have\f3\fs18\cf0\b
0\i0\ul0\strike0 been\f3\fs18\cf0\b0\i0\ul0\strike0 associated\f3\fs18\cf0\b0\
i0\ul0\strike0 with\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0
worsening\f3\fs18\cf0\b0\i0\ul0\strike0 gingival\f3\fs18\cf0\b0\i0\ul0\strike0
hyperplasia\f3\fs18\cf0\b0\i0\ul0\strike0 when\f3\fs18\cf0\b0\i0\ul0\strike0
combined\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 with\f3\fs18
\cf0\b0\i0\ul0\strike0 CsA.\f3\fs10\cf0\b0\i0\ul0\strike0 24\f3\fs18\cf0\b0\i0
\ul0\strike0 CsA\f3\fs18\cf0\b0\i0\ul0\strike0 may\f3\fs18\cf0\b0\i0\ul0\strik
e0 be\f3\fs18\cf0\b0\i0\ul0\strike0 continued\f3\fs18\cf0\b0\i0\ul0\strike0 d
espite\f3\fs18\cf0\b0\i0\ul0\strike0 modest\par\pard\plain\li1021\sl-229\f3\fs1
8\cf0\b0\i0\ul0\strike0 increases\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\
b0\i0\ul0\strike0 creatinine,\f3\fs18\cf0\b0\i0\ul0\strike0 with\f3\fs18\cf0\b
0\i0\ul0\strike0 careful\f3\fs18\cf0\b0\i0\ul0\strike0 monitoring\f3\fs18\cf0\
b0\i0\ul0\strike0 of\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0
the\f3\fs18\cf0\b0\i0\ul0\strike0 patient\f3\fs18\cf0\b0\i0\ul0\strike0 \u8217
?s\f3\fs18\cf0\b0\i0\ul0\strike0 renal\f3\fs18\cf0\b0\i0\ul0\strike0 function\
f3\fs18\cf0\b0\i0\ul0\strike0 and\f3\fs18\cf0\b0\i0\ul0\strike0 dose\f3\fs18\c
f0\b0\i0\ul0\strike0 modifications\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\
i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 attain\f3\fs18\cf0\b0\i0\ul0\st
rike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 desired\f3\fs18\cf0\b0\i0\ul0\strike0
CsA\f3\fs18\cf0\b0\i0\ul0\strike0 levels.\f3\fs18\cf0\b0\i0\ul0\strike0 Susta
ined\f3\fs18\cf0\b0\i0\ul0\strike0 CsA\f3\fs18\cf0\b0\i0\ul0\strike0 use\par\p
ard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 requires\f3\fs18\cf0\b0\i0
\ul0\strike0 dose\f3\fs18\cf0\b0\i0\ul0\strike0 adjustment\f3\fs18\cf0\b0\i0\u
l0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0
CsA\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs1
8\cf0\b0\i0\ul0\strike0 lower\f3\fs18\cf0\b0\i0\ul0\strike0 end\par\pard\plain
\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 t
he\f3\fs18\cf0\b0\i0\ul0\strike0 therapeutic\f3\fs18\cf0\b0\i0\ul0\strike0 ran
ge,\f3\fs18\cf0\b0\i0\ul0\strike0 optimized\f3\fs18\cf0\b0\i0\ul0\strike0 bloo
d\f3\fs18\cf0\b0\i0\ul0\strike0 pressure\par\pard\plain\li1021\sl-230\f3\fs18\c
f0\b0\i0\ul0\strike0 control,\f3\fs18\cf0\b0\i0\ul0\strike0 adequate\f3\fs18\cf
0\b0\i0\ul0\strike0 hydration\f3\fs18\cf0\b0\i0\ul0\strike0 and\f3\fs18\cf0\b0
\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 avoidance\f3\fs18\cf0\b0\i0\
ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 other\par\pard\plain\li1021\sl-23

0\f3\fs18\cf0\b0\i0\ul0\strike0 nephrotoxic\f3\fs18\cf0\b0\i0\ul0\strike0 agent
s\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 allow\f3\fs18
\cf0\b0\i0\ul0\strike0 for\f3\fs18\cf0\b0\i0\ul0\strike0 improved\f3\fs18\cf0\
b0\i0\ul0\strike0 tolerability.\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\
ul0\strike0 Temporary\f3\fs18\cf0\b0\i0\ul0\strike0 cessation\f3\fs18\cf0\b0\i0
\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 CsA\f3\fs18\cf0\b0\i0\ul0\strike
0 is\f3\fs18\cf0\b0\i0\ul0\strike0 advised\f3\fs18\cf0\b0\i0\ul0\strike0 in\f
3\fs18\cf0\b0\i0\ul0\strike0 patients\f3\fs18\cf0\b0\i0\ul0\strike0 with\par\p
ard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 severe\f3\fs18\cf0\b0\i0\u
l0\strike0 compromise\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\s
trike0 kidney\f3\fs18\cf0\b0\i0\ul0\strike0 function\f3\fs18\cf0\b0\i0\ul0\str
ike0 from\f3\fs18\cf0\b0\i0\ul0\strike0 baseline\par\pard\plain\li1021\sl-230\
f3\fs18\cf0\b0\i0\ul0\strike0 (creatinine\f3\fs18\cf0\b0\i0\ul0\strike0 >2mg/\f
3\fs18\cf0\b0\i0\ul0\strike0 mL).\f3\fs18\cf0\b0\i0\ul0\strike0 Low\f3\fs18\cf
0\b0\i0\ul0\strike0 doses\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\u
l0\strike0 CsA\f3\fs18\cf0\b0\i0\ul0\strike0 may\f3\fs18\cf0\b0\i0\ul0\strike0
be\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 reintroduced\f3\
fs18\cf0\b0\i0\ul0\strike0 at\f3\fs18\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\b0\i
0\ul0\strike0 later\f3\fs18\cf0\b0\i0\ul0\strike0 stage,\f3\fs18\cf0\b0\i0\ul0
\strike0 with\f3\fs18\cf0\b0\i0\ul0\strike0 gradual\f3\fs18\cf0\b0\i0\ul0\stri
ke0 increases\par\pard\column\plain\sl-397\par\pard\plain\li0\sl-254\f3\fs18\cf
0\b0\i0\ul0\strike0 proportionate\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\
b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 patient\f3\fs18\cf0\b0\i0\
ul0\strike0 \u8217?s\f3\fs18\cf0\b0\i0\ul0\strike0 tolerability.\f3\fs10\cf0\b0
\i0\ul0\strike0 11\par\pard\plain\li0\sl-257\f2\fs18\cf0\b\i0\ul0\strike0 G-CSF
\par\pard\plain\li239\sl-300\f3\fs18\cf0\b0\i0\ul0\strike0 Use\f3\fs18\cf0\b0\i0
\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 G-CSF\f3\fs18\cf0\b0\i0\ul0\stri
ke0 in\f3\fs18\cf0\b0\i0\ul0\strike0 combination\f3\fs18\cf0\b0\i0\ul0\strike0
with\f3\fs18\cf0\b0\i0\ul0\strike0 immunosuppression\par\pard\plain\li0\sl-23
0\f3\fs18\cf0\b0\i0\ul0\strike0 has\f3\fs18\cf0\b0\i0\ul0\strike0 not\f3\fs18\c
f0\b0\i0\ul0\strike0 shown\f3\fs18\cf0\b0\i0\ul0\strike0 any\f3\fs18\cf0\b0\i0
\ul0\strike0 benefits\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\s
trike0 terms\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 h
ematologic\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 response\f3\f
s18\cf0\b0\i0\ul0\strike0 or\f3\fs18\cf0\b0\i0\ul0\strike0 survival\f3\fs18\cf
0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 SAA\f3\fs18\cf0\b0\i0\ul0
\strike0 patients.\f3\fs10\cf0\b0\i0\ul0\strike0 25-32\f3\fs18\cf0\b0\i0\ul0\s
trike0 Hence\f3\fs18\cf0\b0\i0\ul0\strike0 it\par\pard\plain\li0\sl-229\f3\fs1
8\cf0\b0\i0\ul0\strike0 is\f3\fs18\cf0\b0\i0\ul0\strike0 not\f3\fs18\cf0\b0\i0\
ul0\strike0 recommended\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0
\strike0 use\f3\fs18\cf0\b0\i0\ul0\strike0 with\f3\fs18\cf0\b0\i0\ul0\strike0
ATG\f3\fs18\cf0\b0\i0\ul0\strike0 owing\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\f
s18\cf0\b0\i0\ul0\strike0 the\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\s
trike0 lack\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 ben
efit\f3\fs18\cf0\b0\i0\ul0\strike0 and\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs
18\cf0\b0\i0\ul0\strike0 theoretical\f3\fs18\cf0\b0\i0\ul0\strike0 risk\f3\fs1
8\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 harmful\par\pard\plai
n\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 side-effects.\f3\fs10\cf0\b0\i0\ul0\s
trike0 11\f3\fs18\cf0\b0\i0\ul0\strike0 In\f3\fs18\cf0\b0\i0\ul0\strike0 fact
,\f3\fs18\cf0\b0\i0\ul0\strike0 some\f3\fs18\cf0\b0\i0\ul0\strike0 retrospecti
ve\f3\fs18\cf0\b0\i0\ul0\strike0 studies\f3\fs18\cf0\b0\i0\ul0\strike0 have\pa
r\pard\plain\li0\sl-229\f3\fs18\cf0\b0\i0\ul0\strike0 reported\f3\fs18\cf0\b0\i0
\ul0\strike0 an\f3\fs18\cf0\b0\i0\ul0\strike0 increased\f3\fs18\cf0\b0\i0\ul0\
strike0 risk\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 c
lonal\f3\fs18\cf0\b0\i0\ul0\strike0 evolution\f3\fs18\cf0\b0\i0\ul0\strike0 wi
th\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 G-CSF\f3\fs18\cf0\b0\
i0\ul0\strike0 use,\f3\fs10\cf0\b0\i0\ul0\strike0 33-35\f3\fs18\cf0\b0\i0\ul0\
strike0 but\f3\fs18\cf0\b0\i0\ul0\strike0 this\f3\fs18\cf0\b0\i0\ul0\strike0
remains\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 be\f3\f
s18\cf0\b0\i0\ul0\strike0 confirmed.\f3\fs10\cf0\b0\i0\ul0\strike0 36\par\pard

\plain\li0\sl-229\f3\fs18\cf0\b0\i0\ul0\strike0 The\f3\fs18\cf0\b0\i0\ul0\strike
0 decision\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 try
\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 improve\f3\fs1
8\cf0\b0\i0\ul0\strike0 neutrophil\f3\fs18\cf0\b0\i0\ul0\strike0 with\f3\fs18\
cf0\b0\i0\ul0\strike0 G-CSF\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\str
ike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 select\f3\fs18\cf0\b0\i0\ul0\strike0 pat
ients\f3\fs18\cf0\b0\i0\ul0\strike0 who\f3\fs18\cf0\b0\i0\ul0\strike0 are\f3\f
s18\cf0\b0\i0\ul0\strike0 actively\f3\fs18\cf0\b0\i0\ul0\strike0 infected\f3\f
s18\cf0\b0\i0\ul0\strike0 or\f3\fs18\cf0\b0\i0\ul0\strike0 those\par\pard\plai
n\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 that\f3\fs18\cf0\b0\i0\ul0\strike0 e
xperience\f3\fs18\cf0\b0\i0\ul0\strike0 persistent\f3\fs18\cf0\b0\i0\ul0\strike
0 severe\f3\fs18\cf0\b0\i0\ul0\strike0 neutropenia\f3\fs18\cf0\b0\i0\ul0\strik
e0 (<\f3\fs18\cf0\b0\i0\ul0\strike0 200/\par\pard\plain\li0\sl-230\f3\fs18\cf0
\b0\i0\ul0\strike0 uL)\f3\fs18\cf0\b0\i0\ul0\strike0 should\f3\fs18\cf0\b0\i0\u
l0\strike0 be\f3\fs18\cf0\b0\i0\ul0\strike0 based\f3\fs18\cf0\b0\i0\ul0\strike
0 on\f3\fs18\cf0\b0\i0\ul0\strike0 clinical\f3\fs18\cf0\b0\i0\ul0\strike0 gro
unds.\f3\fs18\cf0\b0\i0\ul0\strike0 However,\par\pard\plain\li0\sl-230\f3\fs18\
cf0\b0\i0\ul0\strike0 if\f3\fs18\cf0\b0\i0\ul0\strike0 there\f3\fs18\cf0\b0\i0\
ul0\strike0 is\f3\fs18\cf0\b0\i0\ul0\strike0 no\f3\fs18\cf0\b0\i0\ul0\strike0
significant\f3\fs18\cf0\b0\i0\ul0\strike0 response,\f3\fs18\cf0\b0\i0\ul0\stri
ke0 reassessment\f3\fs18\cf0\b0\i0\ul0\strike0 and\par\pard\plain\li0\sl-230\f
3\fs18\cf0\b0\i0\ul0\strike0 discontinuation\f3\fs18\cf0\b0\i0\ul0\strike0 afte
r\f3\fs18\cf0\b0\i0\ul0\strike0 no\f3\fs18\cf0\b0\i0\ul0\strike0 more\f3\fs18\
cf0\b0\i0\ul0\strike0 than\f3\fs18\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\b0\i0\u
l0\strike0 few\f3\fs18\cf0\b0\i0\ul0\strike0 days\f3\fs18\cf0\b0\i0\ul0\strike
0 or\f3\fs18\cf0\b0\i0\ul0\strike0 weeks\par\pard\plain\li0\sl-230\f3\fs18\cf0
\b0\i0\ul0\strike0 is\f3\fs18\cf0\b0\i0\ul0\strike0 advised.\f3\fs10\cf0\b0\i0\
ul0\strike0 11\par\pard\plain\li0\sl-258\f2\fs18\cf0\b\i0\ul0\strike0 Antimicro
bial\f2\fs18\cf0\b\i0\ul0\strike0 prophylaxis\par\pard\plain\li239\sl-300\f3\fs
18\cf0\b0\i0\ul0\strike0 As\f3\fs18\cf0\b0\i0\ul0\strike0 prophylaxis\f3\fs18\c
f0\b0\i0\ul0\strike0 for\f3\fs18\cf0\b0\i\ul0\strike0 Pneumocystis\f3\fs18\cf0
\b0\i\ul0\strike0 carinii\f3\fs18\cf0\b0\i0\ul0\strike0 infections\par\pard\pl
ain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 while\f3\fs18\cf0\b0\i0\ul0\strike0
patients\f3\fs18\cf0\b0\i0\ul0\strike0 are\f3\fs18\cf0\b0\i0\ul0\strike0 on\
f3\fs18\cf0\b0\i0\ul0\strike0 therapeutic\f3\fs18\cf0\b0\i0\ul0\strike0 doses\
f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 CsA,\par\pard\p
lain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 monthly\f3\fs18\cf0\b0\i0\ul0\stri
ke0 aerosolised\f3\fs18\cf0\b0\i0\ul0\strike0 pentamidine\f3\fs18\cf0\b0\i0\ul
0\strike0 is\f3\fs18\cf0\b0\i0\ul0\strike0 suggested.\f3\fs18\cf0\b0\i0\ul0\st
rike0 The\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 basis\f3\fs18
\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 this\f3\fs18\cf0\b0\i0
\ul0\strike0 regimen\f3\fs18\cf0\b0\i0\ul0\strike0 follows\f3\fs18\cf0\b0\i0\u
l0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 observation\f3\fs18\cf0\b0\i0\ul0
\strike0 that\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 several\f
3\fs18\cf0\b0\i0\ul0\strike0 cases\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf
0\b0\i\ul0\strike0 P\f3\fs18\cf0\b0\i\ul0\strike0 carinii\f3\fs18\cf0\b0\i0\ul
0\strike0 pneumonia\f3\fs18\cf0\b0\i0\ul0\strike0 were\f3\fs18\cf0\b0\i0\ul0\s
trike0 reported\f3\fs18\cf0\b0\i0\ul0\strike0 by\par\pard\plain\li0\sl-230\f3\
fs18\cf0\b0\i0\ul0\strike0 Scheinberg\f3\fs18\cf0\b0\i0\ul0\strike0 and\f3\fs18
\cf0\b0\i0\ul0\strike0 Young\f3\fs18\cf0\b0\i0\ul0\strike0 at\f3\fs18\cf0\b0\i
0\ul0\strike0 their\f3\fs18\cf0\b0\i0\ul0\strike0 institution\f3\fs18\cf0\b0\i
0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strik
e0 late\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 1980s\f3\fs18\c
f0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 AA\f3\fs18\cf0\b0\i0\ul0
\strike0 patients\f3\fs18\cf0\b0\i0\ul0\strike0 who\f3\fs18\cf0\b0\i0\ul0\stri
ke0 were\f3\fs18\cf0\b0\i0\ul0\strike0 treated\f3\fs18\cf0\b0\i0\ul0\strike0
with\f3\fs18\cf0\b0\i0\ul0\strike0 horse\f3\fs18\cf0\b0\i0\ul0\strike0 ATG\par
\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 and\f3\fs18\cf0\b0\i0\ul0\s
trike0 CsA.\f3\fs10\cf0\b0\i0\ul0\strike0 11\f3\fs18\cf0\b0\i0\ul0\strike0 Tr
eatment\f3\fs18\cf0\b0\i0\ul0\strike0 with\f3\fs18\cf0\b0\i0\ul0\strike0 dapso

ne\f3\fs18\cf0\b0\i0\ul0\strike0 or\f3\fs18\cf0\b0\i0\ul0\strike0 atovaquone\p
ar\pard\plain\li0\sl-229\f3\fs18\cf0\b0\i0\ul0\strike0 may\f3\fs18\cf0\b0\i0\ul0
\strike0 be\f3\fs18\cf0\b0\i0\ul0\strike0 used\f3\fs18\cf0\b0\i0\ul0\strike0
when\f3\fs18\cf0\b0\i0\ul0\strike0 aerosolised\f3\fs18\cf0\b0\i0\ul0\strike0 p
entamidine\f3\fs18\cf0\b0\i0\ul0\strike0 cannot\par\pard\plain\li0\sl-230\f3\fs
18\cf0\b0\i0\ul0\strike0 be\f3\fs18\cf0\b0\i0\ul0\strike0 tolerated\f3\fs18\cf0
\b0\i0\ul0\strike0 or\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\s
trike0 very\f3\fs18\cf0\b0\i0\ul0\strike0 young\f3\fs18\cf0\b0\i0\ul0\strike0
children.\f3\fs18\cf0\b0\i0\ul0\strike0 However,\par\pard\plain\li0\sl-230\f3\
fs18\cf0\b0\i0\ul0\strike0 sulfa\f3\fs18\cf0\b0\i0\ul0\strike0 drugs\f3\fs18\cf
0\b0\i0\ul0\strike0 should\f3\fs18\cf0\b0\i0\ul0\strike0 be\f3\fs18\cf0\b0\i0\
ul0\strike0 avoided\f3\fs18\cf0\b0\i0\ul0\strike0 because\f3\fs18\cf0\b0\i0\ul
0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 their\par\pard\plain\li0\sl-230\f3\
fs18\cf0\b0\i0\ul0\strike0 myelosuppressive\f3\fs18\cf0\b0\i0\ul0\strike0 prope
rties.\f3\fs10\cf0\b0\i0\ul0\strike0 11\f3\fs18\cf0\b0\i0\ul0\strike0 While\f3
\fs18\cf0\b0\i0\ul0\strike0 antibacterial,\par\pard\plain\li0\sl-229\f3\fs18\cf
0\b0\i0\ul0\strike0 antiviral,\f3\fs18\cf0\b0\i0\ul0\strike0 and\f3\fs18\cf0\b0
\i0\ul0\strike0 antifungal\f3\fs18\cf0\b0\i0\ul0\strike0 prophylaxes\f3\fs18\c
f0\b0\i0\ul0\strike0 are\f3\fs18\cf0\b0\i0\ul0\strike0 not\f3\fs18\cf0\b0\i0\u
l0\strike0 routinely\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 ad
ministered\f3\fs18\cf0\b0\i0\ul0\strike0 with\f3\fs18\cf0\b0\i0\ul0\strike0 st
andard\f3\fs18\cf0\b0\i0\ul0\strike0 horse\f3\fs18\cf0\b0\i0\ul0\strike0 ATG/C
sA,\f3\fs18\cf0\b0\i0\ul0\strike0 they\f3\fs18\cf0\b0\i0\ul0\strike0 have\par\
pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 been\f3\fs18\cf0\b0\i0\ul0\s
trike0 used\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 th
e\f3\fs18\cf0\b0\i0\ul0\strike0 context\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs
18\cf0\b0\i0\ul0\strike0 investigational\f3\fs18\cf0\b0\i0\ul0\strike0 regimen
s\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 that\f3\fs18\cf0\b0\i0
\ul0\strike0 are\f3\fs18\cf0\b0\i0\ul0\strike0 more\f3\fs18\cf0\b0\i0\ul0\stri
ke0 immunosuppressive.\f3\fs10\cf0\b0\i0\ul0\strike0 11\par\pard\plain\li0\sl258\f2\fs18\cf0\b\i0\ul0\strike0 Response\f2\fs18\cf0\b\i0\ul0\strike0 and\f2\f
s18\cf0\b\i0\ul0\strike0 Follow-Up\par\pard\plain\li239\sl-300\f3\fs18\cf0\b0\i
0\ul0\strike0 Most\f3\fs18\cf0\b0\i0\ul0\strike0 AA\f3\fs18\cf0\b0\i0\ul0\strik
e0 patients\f3\fs18\cf0\b0\i0\ul0\strike0 achieve\f3\fs18\cf0\b0\i0\ul0\strike
0 some\f3\fs18\cf0\b0\i0\ul0\strike0 clinical\f3\fs18\cf0\b0\i0\ul0\strike0 b
enefit\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 from\f3\fs18\cf0\
b0\i0\ul0\strike0 IST,\f3\fs18\cf0\b0\i0\ul0\strike0 but\f3\fs18\cf0\b0\i0\ul0
\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 quality\f3\fs18\cf0\b0\i0\ul0\strik
e0 of\f3\fs18\cf0\b0\i0\ul0\strike0 response\f3\fs18\cf0\b0\i0\ul0\strike0 is
\f3\fs18\cf0\b0\i0\ul0\strike0 heterogeneous:\par\pard\plain\li0\sl-230\f3\fs18
\cf0\b0\i0\ul0\strike0 with\f3\fs18\cf0\b0\i0\ul0\strike0 current\f3\fs18\cf0\b
0\i0\ul0\strike0 regimens,\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0
\ul0\strike0 response\f3\fs18\cf0\b0\i0\ul0\strike0 rate\f3\fs18\cf0\b0\i0\ul0
\strike0 is\f3\fs18\cf0\b0\i0\ul0\strike0 about\par\pard\plain\li0\sl-230\f3\f
s18\cf0\b0\i0\ul0\strike0 60\f3\fs18\cf0\b0\i0\ul0\strike0 \u8211?70%,\f3\fs18\
cf0\b0\i0\ul0\strike0 equally\f3\fs18\cf0\b0\i0\ul0\strike0 distributed\f3\fs1
8\cf0\b0\i0\ul0\strike0 between\f3\fs18\cf0\b0\i0\ul0\strike0 CR\f3\fs18\cf0\b
0\i0\ul0\strike0 and\f3\fs18\cf0\b0\i0\ul0\strike0 PR,\par\pard\plain\li0\sl-2
30\f3\fs18\cf0\b0\i0\ul0\strike0 but\f3\fs18\cf0\b0\i0\ul0\strike0 most\f3\fs18
\cf0\b0\i0\ul0\strike0 patients\f3\fs18\cf0\b0\i0\ul0\strike0 cannot\f3\fs18\c
f0\b0\i0\ul0\strike0 be\f3\fs18\cf0\b0\i0\ul0\strike0 considered\f3\fs18\cf0\b
0\i0\ul0\strike0 cured.\f3\fs10\cf0\b0\i0\ul0\strike0 37\f3\fs18\cf0\b0\i0\ul0
\strike0 In\par\pard\plain\li0\sl-229\f3\fs18\cf0\b0\i0\ul0\strike0 fact,\f3\fs
18\cf0\b0\i0\ul0\strike0 many\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\
i0\ul0\strike0 them\f3\fs18\cf0\b0\i0\ul0\strike0 require\f3\fs18\cf0\b0\i0\ul
0\strike0 long-term\f3\fs18\cf0\b0\i0\ul0\strike0 maintenance\par\pard\plain\l
i0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 IST\f3\fs18\cf0\b0\i0\ul0\strike0 by\f3
\fs18\cf0\b0\i0\ul0\strike0 CyA\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b
0\i0\ul0\strike0 sustain\f3\fs18\cf0\b0\i0\ul0\strike0 their\f3\fs18\cf0\b0\i0
\ul0\strike0 response:\f3\fs18\cf0\b0\i0\ul0\strike0 even\f3\fs18\cf0\b0\i0\ul

0\strike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 recent\par\pard\plain\li0\sl-230\f3
\fs18\cf0\b0\i0\ul0\strike0 studies,\f3\fs18\cf0\b0\i0\ul0\strike0 CyA-dependen
cy\f3\fs18\cf0\b0\i0\ul0\strike0 ranged\f3\fs18\cf0\b0\i0\ul0\strike0 between\
f3\fs18\cf0\b0\i0\ul0\strike0 25%\f3\fs18\cf0\b0\i0\ul0\strike0 and\par\pard\p
lain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 50%\f3\fs18\cf0\b0\i0\ul0\strike0
of\f3\fs18\cf0\b0\i0\ul0\strike0 patients.\f3\fs10\cf0\b0\i0\ul0\strike0 38-4
0\f3\fs18\cf0\b0\i0\ul0\strike0 Nevertheless,\f3\fs18\cf0\b0\i0\ul0\strike0 re
lapses\f3\fs18\cf0\b0\i0\ul0\strike0 after\f3\fs18\cf0\b0\i0\ul0\strike0 an\pa
r\pard\plain\li0\sl-229\f3\fs18\cf0\b0\i0\ul0\strike0 initial\f3\fs18\cf0\b0\i0\
ul0\strike0 response\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\st
rike0 IST\f3\fs18\cf0\b0\i0\ul0\strike0 are\f3\fs18\cf0\b0\i0\ul0\strike0 fre
quent:\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 about\f3
\fs18\cf0\b0\i0\ul0\strike0 30\f3\fs18\cf0\b0\i0\ul0\strike0 \u8211?50%\par\par
d\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike
0 cases\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 disea
se\f3\fs18\cf0\b0\i0\ul0\strike0 reappears\f3\fs18\cf0\b0\i0\ul0\strike0 withi
n\f3\fs18\cf0\b0\i0\ul0\strike0 months\f3\fs18\cf0\b0\i0\ul0\strike0 or\par\pa
rd\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 years\f3\fs18\cf0\b0\i0\ul0\st
rike0 from\f3\fs18\cf0\b0\i0\ul0\strike0 IST\f3\fs18\cf0\b0\i0\ul0\strike0 di
scontinuation.\f3\fs10\cf0\b0\i0\ul0\strike0 38-40\f3\fs18\cf0\b0\i0\ul0\strike
0 In\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 most\f3\
fs18\cf0\b0\i0\ul0\strike0 recent\par\pard\plain\li0\sl-229\f3\fs18\cf0\b0\i0\u
l0\strike0 experiences,\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0
\strike0 extension\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\stri
ke0 CyA\f3\fs18\cf0\b0\i0\ul0\strike0 therapy\f3\fs18\cf0\b0\i0\ul0\strike0 b
eyond\f3\fs18\cf0\b0\i0\ul0\strike0 6\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\
i0\ul0\strike0 months\f3\fs18\cf0\b0\i0\ul0\strike0 resulted\f3\fs18\cf0\b0\i0\
ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\b0\i0\ul0\strike0
reduction\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 the\f
3\fs18\cf0\b0\i0\ul0\strike0 relapse\f3\fs18\cf0\b0\i0\ul0\strike0 rate;\f3\fs
18\cf0\b0\i0\ul0\strike0 the\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\st
rike0 general\f3\fs18\cf0\b0\i0\ul0\strike0 recommendation\f3\fs18\cf0\b0\i0\ul
0\strike0 is\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 t
aper\f3\fs18\cf0\b0\i0\ul0\strike0 CyA\f3\fs18\cf0\b0\i0\ul0\strike0 by\f3\fs1
8\cf0\b0\i0\ul0\strike0 10%\f3\fs18\cf0\b0\i0\ul0\strike0 every\par\pard\plain
\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 month,\f3\fs18\cf0\b0\i0\ul0\strike0
starting\f3\fs18\cf0\b0\i0\ul0\strike0 at\f3\fs18\cf0\b0\i0\ul0\strike0 least\
f3\fs18\cf0\b0\i0\ul0\strike0 1\f3\fs18\cf0\b0\i0\ul0\strike0 year\f3\fs18\cf0
\b0\i0\ul0\strike0 from\f3\fs18\cf0\b0\i0\ul0\strike0 IST.\f3\fs10\cf0\b0\i0\u
l0\strike0 41\f3\fs18\cf0\b0\i0\ul0\strike0 Late\f3\fs18\cf0\b0\i0\ul0\strike0
relapses\par\pard\plain\li0\sl-229\f3\fs18\cf0\b0\i0\ul0\strike0 remain\f3\fs1
8\cf0\b0\i0\ul0\strike0 possible,\f3\fs18\cf0\b0\i0\ul0\strike0 maybe\f3\fs18\
cf0\b0\i0\ul0\strike0 also\f3\fs18\cf0\b0\i0\ul0\strike0 due\f3\fs18\cf0\b0\i0
\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\b0\i0\ul0\strike0
suboptimal\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 therapeutic\
f3\fs18\cf0\b0\i0\ul0\strike0 range\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\c
f0\b0\i0\ul0\strike0 CyA\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul
0\strike0 long-term\f3\fs18\cf0\b0\i0\ul0\strike0 responders\par\pard\plain\li
0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 (due\f3\fs18\cf0\b0\i0\ul0\strike0 to\f3
\fs18\cf0\b0\i0\ul0\strike0 tolerability\f3\fs18\cf0\b0\i0\ul0\strike0 or\f3\f
s18\cf0\b0\i0\ul0\strike0 scarce\f3\fs18\cf0\b0\i0\ul0\strike0 compliance).\f3
\fs18\cf0\b0\i0\ul0\strike0 Treatment\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\
i0\ul0\strike0 failure-free\f3\fs18\cf0\b0\i0\ul0\strike0 survival\f3\fs18\cf0\
b0\i0\ul0\strike0 at\f3\fs18\cf0\b0\i0\ul0\strike0 5\f3\fs18\cf0\b0\i0\ul0\str
ike0 years\f3\fs18\cf0\b0\i0\ul0\strike0 may\f3\fs18\cf0\b0\i0\ul0\strike0 be
\f3\fs18\cf0\b0\i0\ul0\strike0 estimated\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\f
s18\cf0\b0\i0\ul0\strike0 the\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\s
trike0 range\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 30
\f3\fs18\cf0\b0\i0\ul0\strike0 \u8211?50%,\f3\fs18\cf0\b0\i0\ul0\strike0 althou
gh\f3\fs18\cf0\b0\i0\ul0\strike0 overall\f3\fs18\cf0\b0\i0\ul0\strike0 surviva

l\f3\fs18\cf0\b0\i0\ul0\strike0 remains\par\pard\plain\li0\sl-230\f3\fs18\cf0\b
0\i0\ul0\strike0 significantly\f3\fs18\cf0\b0\i0\ul0\strike0 higher\f3\fs18\cf0
\b0\i0\ul0\strike0 (55\f3\fs18\cf0\b0\i0\ul0\strike0 \u8211?85%),\f3\fs10\cf0\b
0\i0\ul0\strike0 38-40\f3\fs18\cf0\b0\i0\ul0\strike0 because\f3\fs18\cf0\b0\i0
\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 available\par\pard\plain\li0\sl229\f3\fs18\cf0\b0\i0\ul0\strike0 salvage\f3\fs18\cf0\b0\i0\ul0\strike0 treatme
nts\f3\fs18\cf0\b0\i0\ul0\strike0 (either\f3\fs18\cf0\b0\i0\ul0\strike0 furthe
r\f3\fs18\cf0\b0\i0\ul0\strike0 IST\f3\fs18\cf0\b0\i0\ul0\strike0 courses\f3\f
s18\cf0\b0\i0\ul0\strike0 or\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\st
rike0 HSCT).\f3\fs18\cf0\b0\i0\ul0\strike0 In\f3\fs18\cf0\b0\i0\ul0\strike0 re
lapsed\f3\fs18\cf0\b0\i0\ul0\strike0 patients,\f3\fs18\cf0\b0\i0\ul0\strike0 t
he\f3\fs18\cf0\b0\i0\ul0\strike0 expected\f3\fs18\cf0\b0\i0\ul0\strike0 respon
se\f3\fs18\cf0\b0\i0\ul0\strike0 rate\sect\sectd\sbkpage\pgwsxn12132\pghsxn1598
7\sected\cols2\colno1\colw10910\colsr10\colno2\colw1200\pard\plain\sl-200\par\pa
rd\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-262\par\pard\plain\li102
2\sl-152\f0\fs12\cf0\b0\i0\ul0\strike0 supplement to Journal of the association
of physicians of india \u183? published on 1st of every month 1st march, 2015\pa
r\pard\column\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\
plain\sl-207\par\pard\plain\li0\sl-228\f0\fs18\cf0\b0\i0\ul0\strike0 19\par\sect
\sected\sbknone\cols3\colno1\colw6290\colsr10\colno2\colw350\colsr10\colno3\colw
5460\pard\plain\sl-200\par\pard\plain\sl-213\par\pard\plain\li1021\sl-223\f2\fs1
8\cf0\b\i0\ul\strike0 Table 1 : India\f2\fs18\cf0\b\i0\ul0\strike0
n\f2\fs18
\cf0\b\i0\ul0\strike0 data\f2\fs18\cf0\b\i0\ul0\strike0 on\f2\fs18\cf0\b\i0\ul
0\strike0 IST\par\pard\plain\li1352\sl-250\f3\fs16\cf0\b\i0\ul0\strike0 Study\f
3\fs16\cf0\b\i0\ul0\strike0
Patient\f3\fs16\cf0\b\i0\ul0\strike0 no.
\f3\fs16\cf0\b\i0\ul0\strike0
OR\f3\fs16\cf0\b\i0\ul0\strike0
OS\f3\
fs16\cf0\b\i0\ul0\strike0
f/u\par\pard\plain\li1021\sl-202\f3\fs16\cf0\b0\i0
\ul0\strike0 George\f3\fs16\cf0\b0\i0\ul0\strike0 et\f3\fs16\cf0\b0\i0\ul0\stri
ke0 al\f3\fs8\cf0\b0\i0\ul0\strike0 48\f3\fs16\cf0\b0\i0\ul0\strike0 322\f3\f
s16\cf0\b0\i0\ul0\strike0 (Adults\f3\fs16\cf0\b0\i0\ul0\strike0 and\f3\fs16\cf
0\b0\i0\ul0\strike0 children)\f3\fs16\cf0\b0\i0\ul0\strike0 63%\f3\fs16\cf0\b0
\i0\ul0\strike0
67%\f3\fs16\cf0\b0\i0\ul0\strike0 32\f3\fs16\cf0\b0\i0\ul0\s
trike0 mths\par\pard\plain\li1021\sl-203\f3\fs16\cf0\b0\i0\ul0\strike0 Nair\f3\
fs16\cf0\b0\i0\ul0\strike0 et\f3\fs16\cf0\b0\i0\ul0\strike0 al\f3\fs8\cf0\b0\i
0\ul0\strike0 49\f3\fs16\cf0\b0\i0\ul0\strike0
120\f3\fs16\cf0\b0\i0
\ul0\strike0 adults\f3\fs16\cf0\b0\i0\ul0\strike0
85%\f3\fs16\cf0\b0\i
0\ul0\strike0
83%\f3\fs16\cf0\b0\i0\ul0\strike0 76mths\par\pard\plain\li1021
\sl-203\f3\fs16\cf0\b0\i0\ul0\strike0 Nair\f3\fs16\cf0\b0\i0\ul0\strike0 et\f3\
fs16\cf0\b0\i0\ul0\strike0 al\f3\fs8\cf0\b0\i0\ul0\strike0 50\f3\fs16\cf0\b0\i0
\ul0\strike0
40\f3\fs16\cf0\b0\i0\ul0\strike0 children\f3\fs16\cf0\b
0\i0\ul0\strike0
87%\f3\fs16\cf0\b0\i0\ul0\strike0
85%\f3\fs16\cf0\b0
\i0\ul0\strike0 5\f3\fs16\cf0\b0\i0\ul0\strike0 years\par\pard\plain\li1021\sl
-203\f3\fs16\cf0\b0\i0\ul0\strike0 George\f3\fs16\cf0\b0\i0\ul0\strike0 et\f3\f
s16\cf0\b0\i0\ul0\strike0 al\f3\fs8\cf0\b0\i0\ul0\strike0 51\f3\fs16\cf0\b0\i0\
ul0\strike0
70\f3\fs16\cf0\b0\i0\ul0\strike0 children\f3\fs16\cf0\b0\i
0\ul0\strike0
43%\f3\fs16\cf0\b0\i0\ul0\strike0
37%\f3\fs16\cf0\b0\i0
\ul0\strike0 38mths\par\pard\plain\li1021\sl-203\f3\fs16\cf0\b0\i0\ul0\strike0
Sharma\f3\fs16\cf0\b0\i0\ul0\strike0 et\f3\fs16\cf0\b0\i0\ul0\strike0 al\f3\fs
8\cf0\b0\i0\ul0\strike0 52\f3\fs16\cf0\b0\i0\ul0\strike0
35\f3\fs16\cf0
\b0\i0\ul0\strike0 children\f3\fs16\cf0\b0\i0\ul0\strike0
50%\f3\fs16\c
f0\b0\i0\ul0\strike0
-\f3\fs16\cf0\b0\i0\ul0\strike0
40mths\par\pard\plai
n\li1021\sl-252\f3\fs16\cf0\b0\i0\ul0\strike0 OR-Overall\f3\fs16\cf0\b0\i0\ul0\s
trike0 Response;\f3\fs16\cf0\b0\i0\ul0\strike0 OS-Overall\f3\fs16\cf0\b0\i0\ul
0\strike0 Survival;\f3\fs16\cf0\b0\i0\ul0\strike0 f/u-Follow\f3\fs16\cf0\b0\i0
\ul0\strike0 up\par\pard\plain\li1021\sl-359\f3\fs18\cf0\b0\i0\ul0\strike0 to\f
3\fs18\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\b0\i0\ul0\strike0 second\f3\fs18\cf
0\b0\i0\ul0\strike0 IST\f3\fs18\cf0\b0\i0\ul0\strike0 is\f3\fs18\cf0\b0\i0\ul0
\strike0 50\f3\fs18\cf0\b0\i0\ul0\strike0 \u8211?70%,\f3\fs18\cf0\b0\i0\ul0\str
ike0 proving\f3\fs18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0
principle\f3\fs18\cf0\b0\i0\ul0\strike0 that\par\pard\plain\li1021\sl-230\f3\fs
18\cf0\b0\i0\ul0\strike0 standard\f3\fs18\cf0\b0\i0\ul0\strike0 IST\f3\fs18\cf0
\b0\i0\ul0\strike0 may\f3\fs18\cf0\b0\i0\ul0\strike0 be\f3\fs18\cf0\b0\i0\ul0\
strike0 insufficient\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\st
rike0 some\f3\fs18\cf0\b0\i0\ul0\strike0 patients\f3\fs10\cf0\b0\i0\ul0\strike
0 42-44\f3\fs18\cf0\b0\i0\ul0\strike0 .\par\pard\plain\li1021\sl-230\f3\fs18\cf
0\b0\i0\ul0\strike0 In\f3\fs18\cf0\b0\i0\ul0\strike0 case\f3\fs18\cf0\b0\i0\ul0
\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 further\f3\fs18\cf0\b0\i0\ul0\strike
0 relapses,\f3\fs18\cf0\b0\i0\ul0\strike0 even\f3\fs18\cf0\b0\i0\ul0\strike0
a\f3\fs18\cf0\b0\i0\ul0\strike0 third\f3\fs18\cf0\b0\i0\ul0\strike0 course\f3\
fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 ATG\par\pard\plain
\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 may\f3\fs18\cf0\b0\i0\ul0\strike0
be\f3\fs18\cf0\b0\i0\ul0\strike0 considered,\f3\fs18\cf0\b0\i0\ul0\strike0 alt
hough\f3\fs18\cf0\b0\i0\ul0\strike0 this\f3\fs18\cf0\b0\i0\ul0\strike0 strateg
y\f3\fs18\cf0\b0\i0\ul0\strike0 is\f3\fs18\cf0\b0\i0\ul0\strike0 usually\par\p
ard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 useless\f3\fs18\cf0\b0\i0\
ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\strike0 refractory\f3\fs18\cf0\b0\i0\ul0\
strike0 patients\f3\fs10\cf0\b0\i0\ul0\strike0 45\f3\fs18\cf0\b0\i0\ul0\strike
0 .\f3\fs18\cf0\b0\i0\ul0\strike0 However,\f3\fs18\cf0\b0\i0\ul0\strike0 given
\f3\fs18\cf0\b0\i0\ul0\strike0 the\par\pard\plain\li1021\sl-229\f3\fs18\cf0\b0\
i0\ul0\strike0 increased\f3\fs18\cf0\b0\i0\ul0\strike0 risk\f3\fs18\cf0\b0\i0\u
l0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 systemic\f3\fs18\cf0\b0\i0\ul0\str
ike0 reactions,\f3\fs18\cf0\b0\i0\ul0\strike0 all\f3\fs18\cf0\b0\i0\ul0\strike
0 these\f3\fs18\cf0\b0\i0\ul0\strike0 patients\par\pard\plain\li1021\sl-230\f3
\fs18\cf0\b0\i0\ul0\strike0 are\f3\fs18\cf0\b0\i0\ul0\strike0 seeming\f3\fs18\c
f0\b0\i0\ul0\strike0 candidates\f3\fs18\cf0\b0\i0\ul0\strike0 for\f3\fs18\cf0\
b0\i0\ul0\strike0 alternative\f3\fs18\cf0\b0\i0\ul0\strike0 experimental\par\p
ard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 IST.\f3\fs18\cf0\b0\i0\ul0
\strike0 Beside\f3\fs18\cf0\b0\i0\ul0\strike0 refractoriness\f3\fs18\cf0\b0\i0
\ul0\strike0 and\f3\fs18\cf0\b0\i0\ul0\strike0 relapses,\f3\fs18\cf0\b0\i0\ul0
\strike0 it\f3\fs18\cf0\b0\i0\ul0\strike0 has\f3\fs18\cf0\b0\i0\ul0\strike0 t
o\f3\fs18\cf0\b0\i0\ul0\strike0 be\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\
i0\ul0\strike0 noted\f3\fs18\cf0\b0\i0\ul0\strike0 that\f3\fs18\cf0\b0\i0\ul0\s
trike0 clonal\f3\fs18\cf0\b0\i0\ul0\strike0 evolution\f3\fs18\cf0\b0\i0\ul0\st
rike0 accounts\f3\fs18\cf0\b0\i0\ul0\strike0 for\f3\fs18\cf0\b0\i0\ul0\strike0
about\f3\fs18\cf0\b0\i0\ul0\strike0 10\f3\fs18\cf0\b0\i0\ul0\strike0 \u8211?1
5%\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\
i0\ul0\strike0 treatment-failures\f3\fs10\cf0\b0\i0\ul0\strike0 38,46\f3\fs18\
cf0\b0\i0\ul0\strike0 and\f3\fs18\cf0\b0\i0\ul0\strike0 solid\f3\fs18\cf0\b0\i
0\ul0\strike0 tumours\f3\fs18\cf0\b0\i0\ul0\strike0 account\f3\fs18\cf0\b0\i0\
ul0\strike0 for\par\pard\plain\li1021\sl-229\f3\fs18\cf0\b0\i0\ul0\strike0 an\f
3\fs18\cf0\b0\i0\ul0\strike0 additional\f3\fs18\cf0\b0\i0\ul0\strike0 10%.\f3\
fs10\cf0\b0\i0\ul0\strike0 47\par\pard\plain\li1021\sl-434\f2\fs26\cf0\b\i0\ul0
\strike0 Indian\f2\fs26\cf0\b\i0\ul0\strike0 Data\par\pard\plain\li1261\sl-393\
f3\fs18\cf0\b0\i0\ul0\strike0 We\f3\fs18\cf0\b0\i0\ul0\strike0 have\f3\fs18\cf0
\b0\i0\ul0\strike0 limited\f3\fs18\cf0\b0\i0\ul0\strike0 Indian\f3\fs18\cf0\b0
\i0\ul0\strike0 data\f3\fs18\cf0\b0\i0\ul0\strike0 published\f3\fs18\cf0\b0\i0
\ul0\strike0 on\f3\fs18\cf0\b0\i0\ul0\strike0 IST\f3\fs18\cf0\b0\i0\ul0\strike
0 in\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 AA\f3\fs18\cf0\
b0\i0\ul0\strike0 summarized\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i
0\ul0\strike0 Table\f3\fs18\cf0\b0\i0\ul0\strike0 1.\f3\fs18\cf0\b0\i0\ul0\str
ike0 One\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 the\f
3\fs18\cf0\b0\i0\ul0\strike0 largest\f3\fs18\cf0\b0\i0\ul0\strike0 adult\par\p
ard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 studies\f3\fs18\cf0\b0\i0\
ul0\strike0 conducted\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\ul0\s
trike0 322\f3\fs18\cf0\b0\i0\ul0\strike0 patients\f3\fs18\cf0\b0\i0\ul0\strike
0 showed\f3\fs18\cf0\b0\i0\ul0\strike0 an\f3\fs18\cf0\b0\i0\ul0\strike0 overa
ll\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 response\f3\fs18\c
f0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 63\f3\fs18\cf0\b0\i0\ul0
\strike0 %\f3\fs18\cf0\b0\i0\ul0\strike0 with\f3\fs18\cf0\b0\i0\ul0\strike0 a
n\f3\fs18\cf0\b0\i0\ul0\strike0 overall\f3\fs18\cf0\b0\i0\ul0\strike0 survival

\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 67%\f3\fs18\cf
0\b0\i0\ul0\strike0 at\f3\fs18\cf0\b0\i0\ul0\strike0 a\par\pard\plain\li1021\s
l-230\f3\fs18\cf0\b0\i0\ul0\strike0 median\f3\fs18\cf0\b0\i0\ul0\strike0 follow
\f3\fs18\cf0\b0\i0\ul0\strike0 up\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0
\b0\i0\ul0\strike0 32\f3\fs18\cf0\b0\i0\ul0\strike0 months.\f3\fs10\cf0\b0\i0\
ul0\strike0 48\f3\fs18\cf0\b0\i0\ul0\strike0 Data\f3\fs18\cf0\b0\i0\ul0\strike
0 from\f3\fs18\cf0\b0\i0\ul0\strike0 another\par\pard\plain\li1021\sl-229\f3\f
s18\cf0\b0\i0\ul0\strike0 centre\f3\fs18\cf0\b0\i0\ul0\strike0 on\f3\fs18\cf0\b
0\i0\ul0\strike0 120\f3\fs18\cf0\b0\i0\ul0\strike0 patients\f3\fs18\cf0\b0\i0\
ul0\strike0 reported\f3\fs18\cf0\b0\i0\ul0\strike0 an\f3\fs18\cf0\b0\i0\ul0\st
rike0 overall\f3\fs18\cf0\b0\i0\ul0\strike0 response\f3\fs18\cf0\b0\i0\ul0\str
ike0 rate\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18
\cf0\b0\i0\ul0\strike0 85%\f3\fs18\cf0\b0\i0\ul0\strike0 at\f3\fs18\cf0\b0\i0\
ul0\strike0 6\f3\fs18\cf0\b0\i0\ul0\strike0 months\f3\fs18\cf0\b0\i0\ul0\strik
e0 with\f3\fs18\cf0\b0\i0\ul0\strike0 an\f3\fs18\cf0\b0\i0\ul0\strike0 overal
l\f3\fs18\cf0\b0\i0\ul0\strike0 survival\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\f
s18\cf0\b0\i0\ul0\strike0 83%\f3\fs18\cf0\b0\i0\ul0\strike0 at\par\pard\plain\
li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 76\f3\fs18\cf0\b0\i0\ul0\strike0 mo
nths.\f3\fs10\cf0\b0\i0\ul0\strike0 49\f3\fs18\cf0\b0\i0\ul0\strike0 Paediatri
c\f3\fs18\cf0\b0\i0\ul0\strike0 data\f3\fs18\cf0\b0\i0\ul0\strike0 on\f3\fs18\
cf0\b0\i0\ul0\strike0 40\f3\fs18\cf0\b0\i0\ul0\strike0 patients\f3\fs18\cf0\b0
\i0\ul0\strike0 is\f3\fs18\cf0\b0\i0\ul0\strike0 available\par\pard\plain\li10
21\sl-229\f3\fs18\cf0\b0\i0\ul0\strike0 from\f3\fs18\cf0\b0\i0\ul0\strike0 the\
f3\fs18\cf0\b0\i0\ul0\strike0 same\f3\fs18\cf0\b0\i0\ul0\strike0 centre\f3\fs1
8\cf0\b0\i0\ul0\strike0 with\f3\fs18\cf0\b0\i0\ul0\strike0 an\f3\fs18\cf0\b0\i
0\ul0\strike0 overall\f3\fs18\cf0\b0\i0\ul0\strike0 response\f3\fs18\cf0\b0\i0
\ul0\strike0 rate\f3\fs18\cf0\b0\i0\ul0\strike0 of\par\pard\plain\li1021\sl-23
0\f3\fs18\cf0\b0\i0\ul0\strike0 87.9%\f3\fs18\cf0\b0\i0\ul0\strike0 and\f3\fs18
\cf0\b0\i0\ul0\strike0 overall\f3\fs18\cf0\b0\i0\ul0\strike0 survival\f3\fs18\
cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 90%\f3\fs18\cf0\b0\i0\u
l0\strike0 at\f3\fs18\cf0\b0\i0\ul0\strike0 24\f3\fs18\cf0\b0\i0\ul0\strike0
months\f3\fs18\cf0\b0\i0\ul0\strike0 and\par\pard\plain\li1021\sl-230\f3\fs18\c
f0\b0\i0\ul0\strike0 85%\f3\fs18\cf0\b0\i0\ul0\strike0 at\f3\fs18\cf0\b0\i0\ul0
\strike0 5\f3\fs18\cf0\b0\i0\ul0\strike0 years.\f3\fs10\cf0\b0\i0\ul0\strike0
50\f3\fs18\cf0\b0\i0\ul0\strike0 However,\f3\fs18\cf0\b0\i0\ul0\strike0 data\
f3\fs18\cf0\b0\i0\ul0\strike0 from\f3\fs18\cf0\b0\i0\ul0\strike0 other\f3\fs18
\cf0\b0\i0\ul0\strike0 centres\par\pard\plain\li1021\sl-229\f3\fs18\cf0\b0\i0\u
l0\strike0 do\f3\fs18\cf0\b0\i0\ul0\strike0 not\f3\fs18\cf0\b0\i0\ul0\strike0
show\f3\fs18\cf0\b0\i0\ul0\strike0 such\f3\fs18\cf0\b0\i0\ul0\strike0 high\f3\
fs18\cf0\b0\i0\ul0\strike0 response\f3\fs18\cf0\b0\i0\ul0\strike0 rates\f3\fs1
8\cf0\b0\i0\ul0\strike0 as\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18\cf0\b0\i0\
ul0\strike0 an\f3\fs18\cf0\b0\i0\ul0\strike0 Indian\par\pard\plain\li1021\sl-2
30\f3\fs18\cf0\b0\i0\ul0\strike0 study\f3\fs18\cf0\b0\i0\ul0\strike0 in\f3\fs18
\cf0\b0\i0\ul0\strike0 70\f3\fs18\cf0\b0\i0\ul0\strike0 children,\f3\fs18\cf0\
b0\i0\ul0\strike0 which\f3\fs18\cf0\b0\i0\ul0\strike0 described\f3\fs18\cf0\b0
\i0\ul0\strike0 a\f3\fs18\cf0\b0\i0\ul0\strike0 response\f3\fs18\cf0\b0\i0\ul0
\strike0 rate\par\pard\plain\li1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\
fs18\cf0\b0\i0\ul0\strike0 43%\f3\fs18\cf0\b0\i0\ul0\strike0 and\f3\fs18\cf0\b
0\i0\ul0\strike0 an\f3\fs18\cf0\b0\i0\ul0\strike0 overall\f3\fs18\cf0\b0\i0\ul
0\strike0 survival\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\stri
ke0 37%.\f3\fs10\cf0\b0\i0\ul0\strike0 51\f3\fs18\cf0\b0\i0\ul0\strike0 Anoth
er\f3\fs18\cf0\b0\i0\ul0\strike0 study\par\pard\plain\li1021\sl-229\f3\fs18\cf0
\b0\i0\ul0\strike0 on\f3\fs18\cf0\b0\i0\ul0\strike0 35\f3\fs18\cf0\b0\i0\ul0\st
rike0 children\f3\fs18\cf0\b0\i0\ul0\strike0 showed\f3\fs18\cf0\b0\i0\ul0\stri
ke0 a\f3\fs18\cf0\b0\i0\ul0\strike0 response\f3\fs18\cf0\b0\i0\ul0\strike0 ra
te\f3\fs18\cf0\b0\i0\ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 50%\f3\fs18\
cf0\b0\i0\ul0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 first\par\pard\plain\li
1021\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 course\f3\fs18\cf0\b0\i0\ul0\strike0
of\f3\fs18\cf0\b0\i0\ul0\strike0 ATG,\f3\fs18\cf0\b0\i0\ul0\strike0 with\f3\fs
18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 response\f3\fs18\cf

0\b0\i0\ul0\strike0 going\f3\fs18\cf0\b0\i0\ul0\strike0 up\f3\fs18\cf0\b0\i0\u
l0\strike0 to\f3\fs18\cf0\b0\i0\ul0\strike0 57%\par\pard\plain\li1021\sl-230\f
3\fs18\cf0\b0\i0\ul0\strike0 when\f3\fs18\cf0\b0\i0\ul0\strike0 a\f3\fs18\cf0\b
0\i0\ul0\strike0 second\f3\fs18\cf0\b0\i0\ul0\strike0 course\f3\fs18\cf0\b0\i0
\ul0\strike0 was\f3\fs18\cf0\b0\i0\ul0\strike0 included.\f3\fs10\cf0\b0\i0\ul0
\strike0 52\par\pard\plain\li1021\sl-434\f2\fs26\cf0\b\i0\ul0\strike0 Reference
s\par\pard\column\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\p
ard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-274\par\pard\plain\li0\
sl-192\f1\fs16\cf0\b0\i0\ul0\strike0 7.\par\pard\plain\sl-200\par\pard\plain\sl200\par\pard\plain\sl-258\par\pard\plain\li0\sl-192\f1\fs16\cf0\b0\i0\ul0\strike
0 8.\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\
plain\sl-258\par\pard\plain\li0\sl-192\f1\fs16\cf0\b0\i0\ul0\strike0 9.\par\pard
\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-258\
par\pard\plain\li0\sl-192\f1\fs16\charscalex80\cf0\b0\i0\ul0\strike0 10.\par\par
d\plain\sl-200\par\pard\plain\sl-258\par\pard\plain\li0\sl-192\f1\fs16\charscale
x80\cf0\b0\i0\ul0\strike0 11.\par\pard\plain\sl-258\par\pard\plain\li0\sl-192\f1
\fs16\charscalex80\cf0\b0\i0\ul0\strike0 12.\par\pard\plain\sl-200\par\pard\plai
n\sl-200\par\pard\plain\sl-258\par\pard\plain\li0\sl-192\f1\fs16\charscalex80\cf
0\b0\i0\ul0\strike0 13.\par\pard\plain\sl-200\par\pard\plain\sl-258\par\pard\pla
in\li0\sl-192\f1\fs16\charscalex80\cf0\b0\i0\ul0\strike0 14.\par\pard\plain\sl-2
00\par\pard\plain\sl-258\par\pard\plain\li0\sl-192\f1\fs16\charscalex80\cf0\b0\i
0\ul0\strike0 15.\par\pard\plain\sl-258\par\pard\plain\li0\sl-192\f1\fs16\charsc
alex80\cf0\b0\i0\ul0\strike0 16.\par\pard\plain\sl-200\par\pard\plain\sl-200\par
\pard\plain\sl-258\par\pard\plain\li0\sl-192\f1\fs16\charscalex80\cf0\b0\i0\ul0\
strike0 17.\par\pard\column\plain\sl-200\par\pard\plain\sl-224\par\pard\plain\li
0\sl-192\f2\fs16\cf0\b0\i\ul0\strike0 et\f2\fs16\cf0\b0\i\ul0\strike0 al.\f1\fs
16\cf0\b0\i0\ul0\strike0 Immunosuppressive\f1\fs16\cf0\b0\i0\ul0\strike0 thera
py\f1\fs16\cf0\b0\i0\ul0\strike0 of\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\
fs16\cf0\b0\i0\ul0\strike0 anemia:\f1\fs16\cf0\b0\i0\ul0\strike0 results\f1\fs
16\cf0\b0\i0\ul0\strike0 of\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\str
ike0 a\f1\fs16\cf0\b0\i0\ul0\strike0 prospective,\f1\fs16\cf0\b0\i0\ul0\strike0
randomized\f1\fs16\cf0\b0\i0\ul0\strike0 trial\f1\fs16\cf0\b0\i0\ul0\strike0
of\f1\fs16\cf0\b0\i0\ul0\strike0 antithymocyte\f1\fs16\cf0\b0\i0\ul0\strike0
globulin\f1\fs16\cf0\b0\i0\ul0\strike0 (ATG),\par\pard\plain\li0\sl-200\f1\fs16
\cf0\b0\i0\ul0\strike0 methylprednisolone,\f1\fs16\cf0\b0\i0\ul0\strike0 and\f1
\fs16\cf0\b0\i0\ul0\strike0 oxymetholone\f1\fs16\cf0\b0\i0\ul0\strike0 to\f1\f
s16\cf0\b0\i0\ul0\strike0 ATG,\f1\fs16\cf0\b0\i0\ul0\strike0 very\f1\fs16\cf0\
b0\i0\ul0\strike0 high-dose\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\str
ike0 methylprednisolone,\f1\fs16\cf0\b0\i0\ul0\strike0 and\f1\fs16\cf0\b0\i0\ul
0\strike0 oxymetholone.\f2\fs16\cf0\b0\i\ul0\strike0 Blood\f1\fs16\cf0\b0\i0\u
l0\strike0 1992;79:2566\u8211?2571.\par\pard\plain\li0\sl-250\f1\fs16\cf0\b0\i0
\ul0\strike0 Champlin\f1\fs16\cf0\b0\i0\ul0\strike0 RE,\f1\fs16\cf0\b0\i0\ul0\s
trike0 Ho\f1\fs16\cf0\b0\i0\ul0\strike0 WG,\f1\fs16\cf0\b0\i0\ul0\strike0 Fei
g\f1\fs16\cf0\b0\i0\ul0\strike0 SA,\f1\fs16\cf0\b0\i0\ul0\strike0 Winston\f1\f
s16\cf0\b0\i0\ul0\strike0 DJ,\f1\fs16\cf0\b0\i0\ul0\strike0 Lenarsky\f1\fs16\c
f0\b0\i0\ul0\strike0 C,\f1\fs16\cf0\b0\i0\ul0\strike0 Gale\f1\fs16\cf0\b0\i0\u
l0\strike0 RP.\f1\fs16\cf0\b0\i0\ul0\strike0 Do\par\pard\plain\li0\sl-200\f1\f
s16\cf0\b0\i0\ul0\strike0 androgens\f1\fs16\cf0\b0\i0\ul0\strike0 enhance\f1\fs
16\cf0\b0\i0\ul0\strike0 the\f1\fs16\cf0\b0\i0\ul0\strike0 response\f1\fs16\cf
0\b0\i0\ul0\strike0 to\f1\fs16\cf0\b0\i0\ul0\strike0 antithymocyte\f1\fs16\cf0
\b0\i0\ul0\strike0 globulin\f1\fs16\cf0\b0\i0\ul0\strike0 in\par\pard\plain\li
0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 patients\f1\fs16\cf0\b0\i0\ul0\strike0 w
ith\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anemi
a?\f1\fs16\cf0\b0\i0\ul0\strike0 A\f1\fs16\cf0\b0\i0\ul0\strike0 prospective\f
1\fs16\cf0\b0\i0\ul0\strike0 randomized\f1\fs16\cf0\b0\i0\ul0\strike0 trial.\f
2\fs16\cf0\b0\i\ul0\strike0 Blood\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\u
l0\strike0 1985;66:184\u8211?188.\par\pard\plain\li0\sl-250\f1\fs16\cf0\b0\i0\ul
0\strike0 Bacigalupo\f1\fs16\cf0\b0\i0\ul0\strike0 A,\f1\fs16\cf0\b0\i0\ul0\str
ike0 Chaple\f1\fs16\cf0\b0\i0\ul0\strike0 M,\f1\fs16\cf0\b0\i0\ul0\strike0 Ho
ws\f1\fs16\cf0\b0\i0\ul0\strike0 J,\f1\fs16\cf0\b0\i0\ul0\strike0 Van\f1\fs16\

cf0\b0\i0\ul0\strike0 Lint\f1\fs16\cf0\b0\i0\ul0\strike0 MT,\f1\fs16\cf0\b0\i0
\ul0\strike0 McCann\f1\fs16\cf0\b0\i0\ul0\strike0 S,\f1\fs16\cf0\b0\i0\ul0\str
ike0 Milligan\f1\fs16\cf0\b0\i0\ul0\strike0 D,\f2\fs16\cf0\b0\i\ul0\strike0 e
t\par\pard\plain\li0\sl-200\f2\fs16\cf0\b0\i\ul0\strike0 al.\f1\fs16\cf0\b0\i0\u
l0\strike0 Treatment\f1\fs16\cf0\b0\i0\ul0\strike0 of\f1\fs16\cf0\b0\i0\ul0\st
rike0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anaemia\f1\fs16\cf0\b0\i0\ul0\str
ike0 (AA)\f1\fs16\cf0\b0\i0\ul0\strike0 with\f1\fs16\cf0\b0\i0\ul0\strike0 an
tilymphocyte\f1\fs16\cf0\b0\i0\ul0\strike0 globulin\par\pard\plain\li0\sl-200\f
1\fs16\cf0\b0\i0\ul0\strike0 (ATG)\f1\fs16\cf0\b0\i0\ul0\strike0 and\f1\fs16\cf
0\b0\i0\ul0\strike0 methylprednisolone\f1\fs16\cf0\b0\i0\ul0\strike0 (MPred)\f
1\fs16\cf0\b0\i0\ul0\strike0 with\f1\fs16\cf0\b0\i0\ul0\strike0 or\f1\fs16\cf0
\b0\i0\ul0\strike0 without\f1\fs16\cf0\b0\i0\ul0\strike0 androgens:\par\pard\p
lain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 a\f1\fs16\cf0\b0\i0\ul0\strike0 r
andomized\f1\fs16\cf0\b0\i0\ul0\strike0 trial\f1\fs16\cf0\b0\i0\ul0\strike0 fr
om\f1\fs16\cf0\b0\i0\ul0\strike0 the\f1\fs16\cf0\b0\i0\ul0\strike0 EBMT\f1\fs1
6\cf0\b0\i0\ul0\strike0 SAA\f1\fs16\cf0\b0\i0\ul0\strike0 working\f1\fs16\cf0\
b0\i0\ul0\strike0 party.\f2\fs16\cf0\b0\i\ul0\strike0 British\f2\fs16\cf0\b0\i
\ul0\strike0 Journal\par\pard\plain\li0\sl-200\f2\fs16\cf0\b0\i\ul0\strike0 of\
f2\fs16\cf0\b0\i\ul0\strike0 Haematology\f1\fs16\cf0\b0\i0\ul0\strike0 1993;83
:145\u8211?151.\par\pard\plain\li0\sl-250\f1\fs16\cf0\b0\i0\ul0\strike0 Frickhof
en\f1\fs16\cf0\b0\i0\ul0\strike0 N,\f1\fs16\cf0\b0\i0\ul0\strike0 Kaltwasser\f
1\fs16\cf0\b0\i0\ul0\strike0 JP,\f1\fs16\cf0\b0\i0\ul0\strike0 Schrezenmeier\f
1\fs16\cf0\b0\i0\ul0\strike0 H,\f1\fs16\cf0\b0\i0\ul0\strike0 Raghavachar\f1\f
s16\cf0\b0\i0\ul0\strike0 A,\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\st
rike0 Vogt\f1\fs16\cf0\b0\i0\ul0\strike0 HG,\f1\fs16\cf0\b0\i0\ul0\strike0 Her
rmann\f1\fs16\cf0\b0\i0\ul0\strike0 F,\f2\fs16\cf0\b0\i\ul0\strike0 et\f2\fs16
\cf0\b0\i\ul0\strike0 al\f1\fs16\cf0\b0\i0\ul0\strike0 .\f1\fs16\cf0\b0\i0\ul0\
strike0 Treatment\f1\fs16\cf0\b0\i0\ul0\strike0 of\f1\fs16\cf0\b0\i0\ul0\strik
e0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anemia\f1\fs16\cf0\b0\i0\ul0\strike0
with\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 antilymphocyte\f1
\fs16\cf0\b0\i0\ul0\strike0 globulin\f1\fs16\cf0\b0\i0\ul0\strike0 and\f1\fs16
\cf0\b0\i0\ul0\strike0 methylprednisolone\f1\fs16\cf0\b0\i0\ul0\strike0 with\f
1\fs16\cf0\b0\i0\ul0\strike0 or\f1\fs16\cf0\b0\i0\ul0\strike0 without\par\pard
\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 cyclosporine.\f1\fs16\cf0\b0\i0\
ul0\strike0 The\f1\fs16\cf0\b0\i0\ul0\strike0 German\f1\fs16\cf0\b0\i0\ul0\str
ike0 Aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 Anemia\f1\fs16\cf0\b0\i0\ul0\strik
e0 Study\f1\fs16\cf0\b0\i0\ul0\strike0 Group.\f2\fs16\cf0\b0\i\ul0\strike0 Ne
w\f2\fs16\cf0\b0\i\ul0\strike0 England\par\pard\plain\li0\sl-200\f2\fs16\cf0\b0
\i\ul0\strike0 Journal\f2\fs16\cf0\b0\i\ul0\strike0 of\f2\fs16\cf0\b0\i\ul0\str
ike0 Medicine\f1\fs16\cf0\b0\i0\ul0\strike0 1991;324:1297\u8211?1304.\par\pard
\plain\li0\sl-250\f1\fs16\cf0\b0\i0\ul0\strike0 Risitano\f1\fs16\cf0\b0\i0\ul0\s
trike0 AM.\f1\fs16\cf0\b0\i0\ul0\strike0 Immunosuppressive\f1\fs16\cf0\b0\i0\u
l0\strike0 therapies\f1\fs16\cf0\b0\i0\ul0\strike0 in\f1\fs16\cf0\b0\i0\ul0\st
rike0 the\f1\fs16\cf0\b0\i0\ul0\strike0 management\f1\fs16\cf0\b0\i0\ul0\strik
e0 of\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 immune-mediated\f
1\fs16\cf0\b0\i0\ul0\strike0 marrow\f1\fs16\cf0\b0\i0\ul0\strike0 failures\f1\
fs16\cf0\b0\i0\ul0\strike0 in\f1\fs16\cf0\b0\i0\ul0\strike0 adults:\f1\fs16\cf
0\b0\i0\ul0\strike0 where\f1\fs16\cf0\b0\i0\ul0\strike0 we\f1\fs16\cf0\b0\i0\u
l0\strike0 stand\f1\fs16\cf0\b0\i0\ul0\strike0 and\par\pard\plain\li0\sl-200\f
1\fs16\cf0\b0\i0\ul0\strike0 where\f1\fs16\cf0\b0\i0\ul0\strike0 we\f1\fs16\cf0
\b0\i0\ul0\strike0 are\f1\fs16\cf0\b0\i0\ul0\strike0 going.\f2\fs16\cf0\b0\i\u
l0\strike0 British\f2\fs16\cf0\b0\i\ul0\strike0 Journal\f2\fs16\cf0\b0\i\ul0\s
trike0 of\f2\fs16\cf0\b0\i\ul0\strike0 Haematology\f1\fs16\cf0\b0\i0\ul0\strik
e0 2010;152:127\u8211?140.\par\pard\plain\li0\sl-250\f1\fs16\cf0\b0\i0\ul0\stri
ke0 Scheinberg\f1\fs16\cf0\b0\i0\ul0\strike0 P\f1\fs16\cf0\b0\i0\ul0\strike0 a
nd\f1\fs16\cf0\b0\i0\ul0\strike0 Young\f1\fs16\cf0\b0\i0\ul0\strike0 N.\f1\fs1
6\cf0\b0\i0\ul0\strike0 How\f1\fs16\cf0\b0\i0\ul0\strike0 I\f1\fs16\cf0\b0\i0\
ul0\strike0 treat\f1\fs16\cf0\b0\i0\ul0\strike0 acquired\f1\fs16\cf0\b0\i0\ul0
\strike0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anemia.\par\pard\plain\li0\sl-
200\f2\fs16\cf0\b0\i\ul0\strike0 Blood\f1\fs16\cf0\b0\i0\ul0\strike0 2012;120:1

185-96.\par\pard\plain\li0\sl-250\f1\fs16\cf0\b0\i0\ul0\strike0 Rosenfeld\f1\fs1
6\cf0\b0\i0\ul0\strike0 SJ,\f1\fs16\cf0\b0\i0\ul0\strike0 Kimball\f1\fs16\cf0\
b0\i0\ul0\strike0 J,\f1\fs16\cf0\b0\i0\ul0\strike0 Vining\f1\fs16\cf0\b0\i0\ul
0\strike0 D,\f1\fs16\cf0\b0\i0\ul0\strike0 Young\f1\fs16\cf0\b0\i0\ul0\strike0
NS.\f1\fs16\cf0\b0\i0\ul0\strike0 Intensive\par\pard\plain\li0\sl-200\f1\fs16
\cf0\b0\i0\ul0\strike0 immunosuppression\f1\fs16\cf0\b0\i0\ul0\strike0 with\f1\
fs16\cf0\b0\i0\ul0\strike0 antithymocyte\f1\fs16\cf0\b0\i0\ul0\strike0 globuli
n\f1\fs16\cf0\b0\i0\ul0\strike0 and\f1\fs16\cf0\b0\i0\ul0\strike0 cyclosporine
\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 as\f1\fs16\cf0\b0\i0\ul
0\strike0 treatment\f1\fs16\cf0\b0\i0\ul0\strike0 for\f1\fs16\cf0\b0\i0\ul0\st
rike0 severe\f1\fs16\cf0\b0\i0\ul0\strike0 acquired\f1\fs16\cf0\b0\i0\ul0\stri
ke0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anemia.\f2\fs16\cf0\b0\i\ul0\strike
0 Blood\f1\fs16\cf0\b0\i0\ul0\strike0 1995;85:3058\u8211?\par\pard\plain\li0\s
l-200\f1\fs16\cf0\b0\i0\ul0\strike0 3065.\par\pard\plain\li0\sl-250\f1\fs16\cf0\
b0\i0\ul0\strike0 Marsh,\f1\fs16\cf0\b0\i0\ul0\strike0 J.\f1\fs16\cf0\b0\i0\ul0
\strike0 Making\f1\fs16\cf0\b0\i0\ul0\strike0 therapeutic\f1\fs16\cf0\b0\i0\ul
0\strike0 decisions\f1\fs16\cf0\b0\i0\ul0\strike0 in\f1\fs16\cf0\b0\i0\ul0\str
ike0 adults\f1\fs16\cf0\b0\i0\ul0\strike0 with\f1\fs16\cf0\b0\i0\ul0\strike0
aplastic\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 anemia.\f2\fs16
\cf0\b0\i\ul0\strike0 Hematology\f2\fs16\cf0\b0\i\ul0\strike0 American\f2\fs16
\cf0\b0\i\ul0\strike0 Society\f2\fs16\cf0\b0\i\ul0\strike0 Hematology\f2\fs16\
cf0\b0\i\ul0\strike0 Education\f2\fs16\cf0\b0\i\ul0\strike0 Program\par\pard\p
lain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 2006:78\u8211?85.\par\pard\plain\l
i0\sl-250\f1\fs16\cf0\b0\i0\ul0\strike0 Young\f1\fs16\cf0\b0\i0\ul0\strike0 NS,
\f1\fs16\cf0\b0\i0\ul0\strike0 Calado\f1\fs16\cf0\b0\i0\ul0\strike0 RT,\f1\fs1
6\cf0\b0\i0\ul0\strike0 Scheinberg\f1\fs16\cf0\b0\i0\ul0\strike0 P.\f1\fs16\cf
0\b0\i0\ul0\strike0 Current\f1\fs16\cf0\b0\i0\ul0\strike0 concepts\f1\fs16\cf0
\b0\i0\ul0\strike0 in\f1\fs16\cf0\b0\i0\ul0\strike0 the\par\pard\plain\li0\sl200\f1\fs16\cf0\b0\i0\ul0\strike0 pathophysiology\f1\fs16\cf0\b0\i0\ul0\strike0
and\f1\fs16\cf0\b0\i0\ul0\strike0 treatment\f1\fs16\cf0\b0\i0\ul0\strike0 of\
f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anemia.\f
2\fs16\cf0\b0\i\ul0\strike0 Blood\f1\fs16\cf0\b0\i0\ul0\strike0 2006;\f1\fs16\
cf0\b0\i0\ul0\strike0 108:\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\stri
ke0 2509\u8211?2519.\par\pard\plain\li0\sl-250\f1\fs16\cf0\b0\i0\ul0\strike0 Cam
itta\f1\fs16\cf0\b0\i0\ul0\strike0 BM.\f1\fs16\cf0\b0\i0\ul0\strike0 What\f1\f
s16\cf0\b0\i0\ul0\strike0 is\f1\fs16\cf0\b0\i0\ul0\strike0 the\f1\fs16\cf0\b0\
i0\ul0\strike0 definition\f1\fs16\cf0\b0\i0\ul0\strike0 of\f1\fs16\cf0\b0\i0\u
l0\strike0 cure\f1\fs16\cf0\b0\i0\ul0\strike0 for\f1\fs16\cf0\b0\i0\ul0\strike
0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anemia?\f2\fs16\cf0\b0\i\ul0\strike0
Acta\par\pard\plain\li0\sl-200\f2\fs16\cf0\b0\i\ul0\strike0 Haematologica\f1\fs
16\cf0\b0\i0\ul0\strike0 2000;103:16\u8211?18.\par\pard\plain\li0\sl-250\f1\fs1
6\cf0\b0\i0\ul0\strike0 Rosenfeld\f1\fs16\cf0\b0\i0\ul0\strike0 S,\f1\fs16\cf0\
b0\i0\ul0\strike0 Follmann\f1\fs16\cf0\b0\i0\ul0\strike0 D,\f1\fs16\cf0\b0\i0\
ul0\strike0 Nunez\f1\fs16\cf0\b0\i0\ul0\strike0 O,\f1\fs16\cf0\b0\i0\ul0\strik
e0 Young\f1\fs16\cf0\b0\i0\ul0\strike0 NS.\f1\fs16\cf0\b0\i0\ul0\strike0 Anti
thymocyte\f1\fs16\cf0\b0\i0\ul0\strike0 globulin\par\pard\plain\li0\sl-200\f1\f
s16\cf0\b0\i0\ul0\strike0 and\f1\fs16\cf0\b0\i0\ul0\strike0 cyclosporine\f1\fs1
6\cf0\b0\i0\ul0\strike0 for\f1\fs16\cf0\b0\i0\ul0\strike0 severe\f1\fs16\cf0\b
0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anemia:\f1\fs16\cf0\b0
\i0\ul0\strike0 association\f1\fs16\cf0\b0\i0\ul0\strike0 between\par\pard\pla
in\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 hematologic\f1\fs16\cf0\b0\i0\ul0\st
rike0 response\f1\fs16\cf0\b0\i0\ul0\strike0 and\f1\fs16\cf0\b0\i0\ul0\strike0
long-term\f1\fs16\cf0\b0\i0\ul0\strike0 outcome.\f2\fs16\cf0\b0\i\ul0\strike0
The\f2\fs16\cf0\b0\i\ul0\strike0 Journal\f2\fs16\cf0\b0\i\ul0\strike0 of\f2\
fs16\cf0\b0\i\ul0\strike0 the\par\pard\plain\li0\sl-200\f2\fs16\cf0\b0\i\ul0\st
rike0 American\f2\fs16\cf0\b0\i\ul0\strike0 Medical\f2\fs16\cf0\b0\i\ul0\strike
0 Association\f1\fs16\cf0\b0\i0\ul0\strike0 2003;\f1\fs16\cf0\b0\i0\ul0\strike
0 289:\f1\fs16\cf0\b0\i0\ul0\strike0 1130\u8211?1135.\par\pard\plain\li0\sl-25
0\f1\fs16\cf0\b0\i0\ul0\strike0 Locasciulli\f1\fs16\cf0\b0\i0\ul0\strike0 A,\f1
\fs16\cf0\b0\i0\ul0\strike0 Oneto\f1\fs16\cf0\b0\i0\ul0\strike0 R,\f1\fs16\cf0

\b0\i0\ul0\strike0 Bacigalupo\f1\fs16\cf0\b0\i0\ul0\strike0 A,\f1\fs16\cf0\b0\
i0\ul0\strike0 Socie\u180?\f1\fs16\cf0\b0\i0\ul0\strike0 G,\f1\fs16\cf0\b0\i0\
ul0\strike0 Korthof\f1\fs16\cf0\b0\i0\ul0\strike0 E,\f1\fs16\cf0\b0\i0\ul0\str
ike0 Bekassy\f1\fs16\cf0\b0\i0\ul0\strike0 A,\par\pard\plain\li0\sl-200\f2\fs1
6\cf0\b0\i\ul0\strike0 et\f2\fs16\cf0\b0\i\ul0\strike0 al.\f1\fs16\cf0\b0\i0\ul
0\strike0 Severe\f1\fs16\cf0\b0\i0\ul0\strike0 Aplastic\f1\fs16\cf0\b0\i0\ul0\
strike0 Anemia\f1\fs16\cf0\b0\i0\ul0\strike0 Working\f1\fs16\cf0\b0\i0\ul0\str
ike0 Party\f1\fs16\cf0\b0\i0\ul0\strike0 of\f1\fs16\cf0\b0\i0\ul0\strike0 the
\f1\fs16\cf0\b0\i0\ul0\strike0 European\f1\fs16\cf0\b0\i0\ul0\strike0 Blood\pa
r\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 and\f1\fs16\cf0\b0\i0\ul0\
strike0 Marrow\f1\fs16\cf0\b0\i0\ul0\strike0 Transplant\f1\fs16\cf0\b0\i0\ul0\
strike0 Group.\f1\fs16\cf0\b0\i0\ul0\strike0 Outcome\f1\fs16\cf0\b0\i0\ul0\str
ike0 of\f1\fs16\cf0\b0\i0\ul0\strike0 patients\f1\fs16\cf0\b0\i0\ul0\strike0
with\f1\fs16\cf0\b0\i0\ul0\strike0 acquired\par\pard\plain\li0\sl-200\f1\fs16\c
f0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anemia\f1\fs16\cf0\
b0\i0\ul0\strike0 given\f1\fs16\cf0\b0\i0\ul0\strike0 first\f1\fs16\cf0\b0\i0\
ul0\strike0 line\f1\fs16\cf0\b0\i0\ul0\strike0 bone\f1\fs16\cf0\b0\i0\ul0\stri
ke0 marrow\f1\fs16\cf0\b0\i0\ul0\strike0 transplantation\f1\fs16\cf0\b0\i0\ul0
\strike0 or\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 immunosuppr
essive\f1\fs16\cf0\b0\i0\ul0\strike0 treatment\f1\fs16\cf0\b0\i0\ul0\strike0 i
n\f1\fs16\cf0\b0\i0\ul0\strike0 the\f1\fs16\cf0\b0\i0\ul0\strike0 last\f1\fs16
\cf0\b0\i0\ul0\strike0 decade:\f1\fs16\cf0\b0\i0\ul0\strike0 a\f1\fs16\cf0\b0\
i0\ul0\strike0 report\f1\fs16\cf0\b0\i0\ul0\strike0 from\par\sect\sected\sbkno
ne\cols4\colno1\colw1370\colsr10\colno2\colw4910\colsr10\colno3\colw350\colsr10\
colno4\colw5460\pard\plain\li1021\sl-335\f1\fs16\cf0\b0\i0\ul0\strike0 1.\par\pa
rd\plain\sl-200\par\pard\plain\sl-258\par\pard\plain\li1021\sl-192\f1\fs16\cf0\b
0\i0\ul0\strike0 2.\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\s
l-258\par\pard\plain\li1021\sl-192\f1\fs16\cf0\b0\i0\ul0\strike0 3.\par\pard\pla
in\sl-200\par\pard\plain\sl-258\par\pard\plain\li1021\sl-192\f1\fs16\cf0\b0\i0\u
l0\strike0 4.\par\pard\plain\sl-200\par\pard\plain\sl-258\par\pard\plain\li1021\
sl-192\f1\fs16\cf0\b0\i0\ul0\strike0 5.\par\pard\plain\sl-200\par\pard\plain\sl200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-258\par\pard\p
lain\li1021\sl-192\f1\fs16\cf0\b0\i0\ul0\strike0 6.\par\pard\plain\li0\sl-335\co
lumn\f1\fs16\cf0\b0\i0\ul0\strike0 Thomas\f1\fs16\cf0\b0\i0\ul0\strike0 ED,\f1\
fs16\cf0\b0\i0\ul0\strike0 Storb\f1\fs16\cf0\b0\i0\ul0\strike0 R,\f1\fs16\cf0\
b0\i0\ul0\strike0 Fefer\f1\fs16\cf0\b0\i0\ul0\strike0 A,\f1\fs16\cf0\b0\i0\ul0
\strike0 Slichter\f1\fs16\cf0\b0\i0\ul0\strike0 SJ,\f1\fs16\cf0\b0\i0\ul0\stri
ke0 Bryant\f1\fs16\cf0\b0\i0\ul0\strike0 JI,\f1\fs16\cf0\b0\i0\ul0\strike0 Bu
ckner\f1\fs16\cf0\b0\i0\ul0\strike0 CD,\f2\fs16\cf0\b0\i\ul0\strike0 et\par\pa
rd\plain\li0\sl-200\f2\fs16\cf0\b0\i\ul0\strike0 al\f1\fs16\cf0\b0\i0\ul0\strike
0 .\f1\fs16\cf0\b0\i0\ul0\strike0 Aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anaem
ia\f1\fs16\cf0\b0\i0\ul0\strike0 treated\f1\fs16\cf0\b0\i0\ul0\strike0 by\f1\f
s16\cf0\b0\i0\ul0\strike0 marrow\f1\fs16\cf0\b0\i0\ul0\strike0 transplantation
.\f2\fs16\cf0\b0\i\ul0\strike0 The\f2\fs16\cf0\b0\i\ul0\strike0 Lancet\par\par
d\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 1972;1:284\u8211?289.\par\pard\
plain\li0\sl-250\f1\fs16\cf0\b0\i0\ul0\strike0 Math\u233?\f1\fs16\cf0\b0\i0\ul0\
strike0 G.\f1\fs16\cf0\b0\i0\ul0\strike0 and\f1\fs16\cf0\b0\i0\ul0\strike0 Sc
hwarzenberg\f1\fs16\cf0\b0\i0\ul0\strike0 L.\f1\fs16\cf0\b0\i0\ul0\strike0 Tre
atment\f1\fs16\cf0\b0\i0\ul0\strike0 of\f1\fs16\cf0\b0\i0\ul0\strike0 bone\f1\
fs16\cf0\b0\i0\ul0\strike0 marrow\f1\fs16\cf0\b0\i0\ul0\strike0 aplasia\par\pa
rd\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 by\f1\fs16\cf0\b0\i0\ul0\strik
e0 mismatched\f1\fs16\cf0\b0\i0\ul0\strike0 bone\f1\fs16\cf0\b0\i0\ul0\strike0
marrow\f1\fs16\cf0\b0\i0\ul0\strike0 transplantation\f1\fs16\cf0\b0\i0\ul0\st
rike0 after\f1\fs16\cf0\b0\i0\ul0\strike0 conditioning\f1\fs16\cf0\b0\i0\ul0\s
trike0 with\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 antilymphoc
yte\f1\fs16\cf0\b0\i0\ul0\strike0 globulin\f1\fs16\cf0\b0\i0\ul0\strike0 \u821
1?\f1\fs16\cf0\b0\i0\ul0\strike0 long-term\f1\fs16\cf0\b0\i0\ul0\strike0 resul
ts.\f2\fs16\cf0\b0\i\ul0\strike0 Transplant\f2\fs16\cf0\b0\i\ul0\strike0 Proce
edings\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 1976;8:595\u8211?
602.\par\pard\plain\li0\sl-250\f1\fs16\cf0\b0\i0\ul0\strike0 Champlin\f1\fs16\cf
0\b0\i0\ul0\strike0 R,\f1\fs16\cf0\b0\i0\ul0\strike0 Ho\f1\fs16\cf0\b0\i0\ul0\
strike0 W,\f1\fs16\cf0\b0\i0\ul0\strike0 Gale\f1\fs16\cf0\b0\i0\ul0\strike0 R
P.\f1\fs16\cf0\b0\i0\ul0\strike0 Antithymocyte\f1\fs16\cf0\b0\i0\ul0\strike0 g
lobulin\f1\fs16\cf0\b0\i0\ul0\strike0 treatment\f1\fs16\cf0\b0\i0\ul0\strike0
in\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 patients\f1\fs16\cf0\
b0\i0\ul0\strike0 with\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i
0\ul0\strike0 anemia:\f1\fs16\cf0\b0\i0\ul0\strike0 a\f1\fs16\cf0\b0\i0\ul0\st
rike0 prospective\f1\fs16\cf0\b0\i0\ul0\strike0 randomized\f1\fs16\cf0\b0\i0\u
l0\strike0 trial.\f2\fs16\cf0\b0\i\ul0\strike0 New\par\pard\plain\li0\sl-200\f
2\fs16\cf0\b0\i\ul0\strike0 England\f2\fs16\cf0\b0\i\ul0\strike0 Journal\f2\fs1
6\cf0\b0\i\ul0\strike0 of\f2\fs16\cf0\b0\i\ul0\strike0 Medicine\f1\fs16\cf0\b0
\i0\ul0\strike0 1983;308:113\u8211?118.\par\pard\plain\li0\sl-250\f1\fs16\chars
calex99\cf0\b0\i0\ul0\strike0 Young\f1\fs16\charscalex99\cf0\b0\i0\ul0\strike0
N,\f1\fs16\charscalex99\cf0\b0\i0\ul0\strike0 Griffith\f1\fs16\charscalex99\cf0
\b0\i0\ul0\strike0 P,\f1\fs16\charscalex99\cf0\b0\i0\ul0\strike0 Brittain\f1\f
s16\charscalex99\cf0\b0\i0\ul0\strike0 E,\f1\fs16\charscalex99\cf0\b0\i0\ul0\st
rike0 Elfenbein\f1\fs16\charscalex99\cf0\b0\i0\ul0\strike0 G,\f1\fs16\charscal
ex99\cf0\b0\i0\ul0\strike0 Gardner\f1\fs16\charscalex99\cf0\b0\i0\ul0\strike0
F,\f1\fs16\charscalex99\cf0\b0\i0\ul0\strike0 Huang\f1\fs16\charscalex99\cf0\b0
\i0\ul0\strike0 A,\f2\fs16\charscalex99\cf0\b0\i\ul0\strike0 et\f2\fs16\charsc
alex99\cf0\b0\i\ul0\strike0 al\f1\fs16\charscalex99\cf0\b0\i0\ul0\strike0 .\par
\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 A\f1\fs16\cf0\b0\i0\ul0\str
ike0 multicenter\f1\fs16\cf0\b0\i0\ul0\strike0 trial\f1\fs16\cf0\b0\i0\ul0\str
ike0 of\f1\fs16\cf0\b0\i0\ul0\strike0 antithymocyte\f1\fs16\cf0\b0\i0\ul0\stri
ke0 globulin\f1\fs16\cf0\b0\i0\ul0\strike0 in\f1\fs16\cf0\b0\i0\ul0\strike0 a
plastic\f1\fs16\cf0\b0\i0\ul0\strike0 anemia\f1\fs16\cf0\b0\i0\ul0\strike0 and
\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 related\f1\fs16\cf0\b0\
i0\ul0\strike0 diseases.\f2\fs16\cf0\b0\i\ul0\strike0 Blood\f1\fs16\cf0\b0\i0\
ul0\strike0 1988;72:1861\u8211?1869.\par\pard\plain\li0\sl-250\f1\fs16\cf0\b0\i
0\ul0\strike0 De\f1\fs16\cf0\b0\i0\ul0\strike0 Planque\f1\fs16\cf0\b0\i0\ul0\st
rike0 MM,\f1\fs16\cf0\b0\i0\ul0\strike0 Bacigalupo\f1\fs16\cf0\b0\i0\ul0\strik
e0 A,\f1\fs16\cf0\b0\i0\ul0\strike0 Wu\u168?rsch\f1\fs16\cf0\b0\i0\ul0\strike0
A,\f1\fs16\cf0\b0\i0\ul0\strike0 Hows\f1\fs16\cf0\b0\i0\ul0\strike0 JM,\f1\f
s16\cf0\b0\i0\ul0\strike0 Devergie\f1\fs16\cf0\b0\i0\ul0\strike0 A,\par\pard\p
lain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 Frickhofen\f1\fs16\cf0\b0\i0\ul0\s
trike0 N,\f2\fs16\cf0\b0\i\ul0\strike0 et\f2\fs16\cf0\b0\i\ul0\strike0 al\f1\
fs16\cf0\b0\i0\ul0\strike0 .\f1\fs16\cf0\b0\i0\ul0\strike0 Long-term\f1\fs16\cf
0\b0\i0\ul0\strike0 followup\f1\fs16\cf0\b0\i0\ul0\strike0 of\f1\fs16\cf0\b0\i
0\ul0\strike0 severe\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\
ul0\strike0 anaemia\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 pat
ients\f1\fs16\cf0\b0\i0\ul0\strike0 treated\f1\fs16\cf0\b0\i0\ul0\strike0 with
\f1\fs16\cf0\b0\i0\ul0\strike0 antithymocyte\f1\fs16\cf0\b0\i0\ul0\strike0 glo
bulin.\f1\fs16\cf0\b0\i0\ul0\strike0 Severe\f1\fs16\cf0\b0\i0\ul0\strike0 Apla
stic\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 Anaemia\f1\fs16\cf0
\b0\i0\ul0\strike0 Working\f1\fs16\cf0\b0\i0\ul0\strike0 Party\f1\fs16\cf0\b0\
i0\ul0\strike0 of\f1\fs16\cf0\b0\i0\ul0\strike0 the\f1\fs16\cf0\b0\i0\ul0\stri
ke0 European\f1\fs16\cf0\b0\i0\ul0\strike0 Cooperative\f1\fs16\cf0\b0\i0\ul0\s
trike0 Group\f1\fs16\cf0\b0\i0\ul0\strike0 for\par\pard\plain\li0\sl-200\f1\fs
16\charscalex96\cf0\b0\i0\ul0\strike0 Bone\f1\fs16\charscalex96\cf0\b0\i0\ul0\st
rike0 Marrow\f1\fs16\charscalex96\cf0\b0\i0\ul0\strike0 Transplantation\f1\fs1
6\charscalex96\cf0\b0\i0\ul0\strike0 (EBMT).\f2\fs16\charscalex96\cf0\b0\i\ul0\
strike0 British\f2\fs16\charscalex96\cf0\b0\i\ul0\strike0 Journal\f2\fs16\char
scalex96\cf0\b0\i\ul0\strike0 of\f2\fs16\charscalex96\cf0\b0\i\ul0\strike0 Hae
matology\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 1989;73:121\u82
11?126.\par\pard\plain\li0\sl-250\f1\fs16\cf0\b0\i0\ul0\strike0 Doney\f1\fs16\cf
0\b0\i0\ul0\strike0 K,\f1\fs16\cf0\b0\i0\ul0\strike0 Pepe\f1\fs16\cf0\b0\i0\ul
0\strike0 M,\f1\fs16\cf0\b0\i0\ul0\strike0 Storb\f1\fs16\cf0\b0\i0\ul0\strike0
R,\f1\fs16\cf0\b0\i0\ul0\strike0 Bryant\f1\fs16\cf0\b0\i0\ul0\strike0 E,\f1\
fs16\cf0\b0\i0\ul0\strike0 Anasetti\f1\fs16\cf0\b0\i0\ul0\strike0 C,\f1\fs16\c
f0\b0\i0\ul0\strike0 Appelbaum\f1\fs16\cf0\b0\i0\ul0\strike0 FR,\par\pard\colu

mn\plain\sl-200\par\pard\plain\sl-258\par\pard\plain\li0\sl-192\f1\fs16\charscal
ex80\cf0\b0\i0\ul0\strike0 18.\par\pard\plain\sl-200\par\pard\plain\sl-200\par\p
ard\plain\sl-258\par\pard\plain\li0\sl-192\f1\fs16\charscalex80\cf0\b0\i0\ul0\st
rike0 19.\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-258\par\
pard\plain\li0\sl-192\f1\fs16\charscalex80\cf0\b0\i0\ul0\strike0 20.\par\pard\pl
ain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par
\pard\plain\sl-258\par\pard\plain\li0\sl-192\f1\fs16\charscalex80\cf0\b0\i0\ul0\
strike0 21.\par\pard\plain\li0\sl-200\column\f1\fs16\cf0\b0\i0\ul0\strike0 the\f
1\fs16\cf0\b0\i0\ul0\strike0 European\f1\fs16\cf0\b0\i0\ul0\strike0 Group\f1\f
s16\cf0\b0\i0\ul0\strike0 for\f1\fs16\cf0\b0\i0\ul0\strike0 Blood\f1\fs16\cf0\
b0\i0\ul0\strike0 and\f1\fs16\cf0\b0\i0\ul0\strike0 Marrow\f1\fs16\cf0\b0\i0\u
l0\strike0 Transplantation\f1\fs16\cf0\b0\i0\ul0\strike0 (EBMT).\par\pard\plai
n\li0\sl-200\f2\fs16\cf0\b0\i\ul0\strike0 Haematologica\f1\fs16\cf0\b0\i0\ul0\st
rike0 2007;\f1\fs16\cf0\b0\i0\ul0\strike0 92:\f1\fs16\cf0\b0\i0\ul0\strike0 1
1\u8211?18.\par\pard\plain\li0\sl-250\f1\fs16\cf0\b0\i0\ul0\strike0 Teramura\f1\
fs16\cf0\b0\i0\ul0\strike0 M,\f1\fs16\cf0\b0\i0\ul0\strike0 Kimura\f1\fs16\cf0
\b0\i0\ul0\strike0 A,\f1\fs16\cf0\b0\i0\ul0\strike0 Iwase\f1\fs16\cf0\b0\i0\ul
0\strike0 S,\f1\fs16\cf0\b0\i0\ul0\strike0 Yonemura\f1\fs16\cf0\b0\i0\ul0\stri
ke0 Y,\f1\fs16\cf0\b0\i0\ul0\strike0 Nakao\f1\fs16\cf0\b0\i0\ul0\strike0 S,\f
1\fs16\cf0\b0\i0\ul0\strike0 Urabe\f1\fs16\cf0\b0\i0\ul0\strike0 A,\f2\fs16\cf
0\b0\i\ul0\strike0 et\f2\fs16\cf0\b0\i\ul0\strike0 al.\par\pard\plain\li0\sl-2
00\f1\fs16\cf0\b0\i0\ul0\strike0 Treatment\f1\fs16\cf0\b0\i0\ul0\strike0 of\f1\
fs16\cf0\b0\i0\ul0\strike0 severe\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs
16\cf0\b0\i0\ul0\strike0 anemia\f1\fs16\cf0\b0\i0\ul0\strike0 with\f1\fs16\cf0
\b0\i0\ul0\strike0 antithymocyte\f1\fs16\cf0\b0\i0\ul0\strike0 globulin\par\pa
rd\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 and\f1\fs16\cf0\b0\i0\ul0\stri
ke0 cyclosporin\f1\fs16\cf0\b0\i0\ul0\strike0 A\f1\fs16\cf0\b0\i0\ul0\strike0
with\f1\fs16\cf0\b0\i0\ul0\strike0 or\f1\fs16\cf0\b0\i0\ul0\strike0 without\f
1\fs16\cf0\b0\i0\ul0\strike0 G-CSF\f1\fs16\cf0\b0\i0\ul0\strike0 in\f1\fs16\cf
0\b0\i0\ul0\strike0 adults:\f1\fs16\cf0\b0\i0\ul0\strike0 a\f1\fs16\cf0\b0\i0\
ul0\strike0 multicenter\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0
randomized\f1\fs16\cf0\b0\i0\ul0\strike0 study\f1\fs16\cf0\b0\i0\ul0\strike0
in\f1\fs16\cf0\b0\i0\ul0\strike0 Japan.\f2\fs16\cf0\b0\i\ul0\strike0 Blood\f1\
fs16\cf0\b0\i0\ul0\strike0 2007;110:1756\u8211?1761.\par\pard\plain\li0\sl-250\
f1\fs16\cf0\b0\i0\ul0\strike0 Frickhofen\f1\fs16\cf0\b0\i0\ul0\strike0 N,\f1\fs
16\cf0\b0\i0\ul0\strike0 Heimpel\f1\fs16\cf0\b0\i0\ul0\strike0 H,\f1\fs16\cf0\
b0\i0\ul0\strike0 Kaltwasser\f1\fs16\cf0\b0\i0\ul0\strike0 JP,\f1\fs16\cf0\b0\
i0\ul0\strike0 Schrezenmeier\f1\fs16\cf0\b0\i0\ul0\strike0 H.\f1\fs16\cf0\b0\i
0\ul0\strike0 German\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 Ap
lastic\f1\fs16\cf0\b0\i0\ul0\strike0 Anemia\f1\fs16\cf0\b0\i0\ul0\strike0 Stud
y\f1\fs16\cf0\b0\i0\ul0\strike0 Group.\f1\fs16\cf0\b0\i0\ul0\strike0 Antithymo
cyte\f1\fs16\cf0\b0\i0\ul0\strike0 globulin\f1\fs16\cf0\b0\i0\ul0\strike0 with
\f1\fs16\cf0\b0\i0\ul0\strike0 or\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\u
l0\strike0 without\f1\fs16\cf0\b0\i0\ul0\strike0 cyclosporin\f1\fs16\cf0\b0\i0\
ul0\strike0 A:\f1\fs16\cf0\b0\i0\ul0\strike0 11-year\f1\fs16\cf0\b0\i0\ul0\str
ike0 follow-up\f1\fs16\cf0\b0\i0\ul0\strike0 of\f1\fs16\cf0\b0\i0\ul0\strike0
a\f1\fs16\cf0\b0\i0\ul0\strike0 randomized\f1\fs16\cf0\b0\i0\ul0\strike0 tria
l\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 comparing\f1\fs16\cf0\
b0\i0\ul0\strike0 treatments\f1\fs16\cf0\b0\i0\ul0\strike0 of\f1\fs16\cf0\b0\i
0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anemia.\f2\fs16\cf0\b0\i\
ul0\strike0 Blood\f1\fs16\cf0\b0\i0\ul0\strike0 2003;101:1236\u8211?1242.\par\
pard\plain\li0\sl-250\f1\fs16\cf0\b0\i0\ul0\strike0 Marsh\f1\fs16\cf0\b0\i0\ul0\
strike0 J,\f1\fs16\cf0\b0\i0\ul0\strike0 Cavanagh\f1\fs16\cf0\b0\i0\ul0\strike
0 J,\f1\fs16\cf0\b0\i0\ul0\strike0 Darbyshire\f1\fs16\cf0\b0\i0\ul0\strike0 P
,\f1\fs16\cf0\b0\i0\ul0\strike0 Dokal\f1\fs16\cf0\b0\i0\ul0\strike0 I,\f1\fs16
\cf0\b0\i0\ul0\strike0 Gordon-Smith\f1\fs16\cf0\b0\i0\ul0\strike0 T,\f1\fs16\c
f0\b0\i0\ul0\strike0 Keidan\f1\fs16\cf0\b0\i0\ul0\strike0 J,\par\pard\plain\li
0\sl-200\f2\fs16\cf0\b0\i\ul0\strike0 et\f2\fs16\cf0\b0\i\ul0\strike0 al.\f1\fs
16\cf0\b0\i0\ul0\strike0 Guidance\f1\fs16\cf0\b0\i0\ul0\strike0 from\f1\fs16\c
f0\b0\i0\ul0\strike0 the\f1\fs16\cf0\b0\i0\ul0\strike0 BCSH\f1\fs16\cf0\b0\i0\

ul0\strike0 Aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 Anaemia\f1\fs16\cf0\b0\i0\u
l0\strike0 Writing\f1\fs16\cf0\b0\i0\ul0\strike0 Committee\par\pard\plain\li0\
sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 relating\f1\fs16\cf0\b0\i0\ul0\strike0 to\
f1\fs16\cf0\b0\i0\ul0\strike0 recent\f1\fs16\cf0\b0\i0\ul0\strike0 prospective
\f1\fs16\cf0\b0\i0\ul0\strike0 studies\f1\fs16\cf0\b0\i0\ul0\strike0 of\f1\fs1
6\cf0\b0\i0\ul0\strike0 rabbit\f1\fs16\cf0\b0\i0\ul0\strike0 antithymocyte\par
\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 globulin\f1\fs16\cf0\b0\i0\
ul0\strike0 (ATG)\f1\fs16\cf0\b0\i0\ul0\strike0 used\f1\fs16\cf0\b0\i0\ul0\str
ike0 for\f1\fs16\cf0\b0\i0\ul0\strike0 a\f1\fs16\cf0\b0\i0\ul0\strike0 first\
f1\fs16\cf0\b0\i0\ul0\strike0 course\f1\fs16\cf0\b0\i0\ul0\strike0 of\f1\fs16\
cf0\b0\i0\ul0\strike0 immunosuppressive\f1\fs16\cf0\b0\i0\ul0\strike0 therapy\
par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 (IST)\f1\fs16\cf0\b0\i0\
ul0\strike0 in\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\ul0\st
rike0 anaemia.\f1\fs16\cf0\b0\i0\ul0\strike0 Available\f1\fs16\cf0\b0\i0\ul0\s
trike0 from\f1\fs16\cf0\b0\i0\ul0\strike0 www.bchsguidelines.com.\par\pard\pla
in\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 Accessed\f1\fs16\cf0\b0\i0\ul0\strik
e0 on\f1\fs16\cf0\b0\i0\ul0\strike0 29th\f1\fs16\cf0\b0\i0\ul0\strike0 Novemb
er\f1\fs16\cf0\b0\i0\ul0\strike0 2014.\par\pard\plain\li0\sl-250\f1\fs16\cf0\b0
\i0\ul0\strike0 Marsh\f1\fs16\cf0\b0\i0\ul0\strike0 J,\f1\fs16\cf0\b0\i0\ul0\st
rike0 Socie\f1\fs16\cf0\b0\i0\ul0\strike0 G,\f1\fs16\cf0\b0\i0\ul0\strike0 Ti
chelli\f1\fs16\cf0\b0\i0\ul0\strike0 A,\f1\fs16\cf0\b0\i0\ul0\strike0 Schrezen
meier\f1\fs16\cf0\b0\i0\ul0\strike0 H, Hochsmann\f1\fs16\cf0\b0\i0\ul0\strike0
B, Risitano\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 AM,\f2\fs16
\cf0\b0\i\ul0\strike0 et\f2\fs16\cf0\b0\i\ul0\strike0 al.\f1\fs16\cf0\b0\i0\ul
0\strike0 Should\f1\fs16\cf0\b0\i0\ul0\strike0 irradiated\f1\fs16\cf0\b0\i0\ul
0\strike0 blood\f1\fs16\cf0\b0\i0\ul0\strike0 products\f1\fs16\cf0\b0\i0\ul0\s
trike0 be\f1\fs16\cf0\b0\i0\ul0\strike0 given\f1\fs16\cf0\b0\i0\ul0\strike0 r
outinely\f1\fs16\cf0\b0\i0\ul0\strike0 to\f1\fs16\cf0\b0\i0\ul0\strike0 all\pa
r\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 patients\f1\fs16\cf0\b0\i0
\ul0\strike0 with\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\ul0
\strike0 anaemia\f1\fs16\cf0\b0\i0\ul0\strike0 undergoing\f1\fs16\cf0\b0\i0\ul
0\strike0 immunosuppressive\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\str
ike0 therapy\f1\fs16\cf0\b0\i0\ul0\strike0 with\f1\fs16\cf0\b0\i0\ul0\strike0
antithymocyte\f1\fs16\cf0\b0\i0\ul0\strike0 globulin\f1\fs16\cf0\b0\i0\ul0\stri
ke0 (ATG)?\f1\fs16\cf0\b0\i0\ul0\strike0 A\f1\fs16\cf0\b0\i0\ul0\strike0 surv
ey\f1\fs16\cf0\b0\i0\ul0\strike0 from\f1\fs16\cf0\b0\i0\ul0\strike0 the
}}

}}
}}
}}

}}
}}
}}
}}

}}
}}
}}
}}
}}
}}
}}

}}
}}\sect\sectd\sbkpage\pgwsxn12132\pghsxn15987\sected\cols2\colno1\colw3390\colsr
10\colno2\colw8720\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200
\par\pard\plain\sl-207\par\pard\plain\li1021\sl-228\f0\fs18\cf0\b0\i0\ul0\strike
0 20\f0\fs12\cf0\b0\i0\ul0\strike0 \par\pard\column\plain\sl-200\par\pard\plain
\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-262\par\pard\plain\li0\sl-152\f0
\fs12\cf0\b0\i0\ul0\strike0 supplement to Journal of the association of physicia
ns of india \u183? published on 1st of every month 1st march, 2015\par\sect\sect
ed\sbknone\cols3\colno1\colw6290\colsr10\colno2\colw350\colsr10\colno3\colw5460\
pard\plain\sl-200\par\pard\plain\sl-224\par\pard\plain\li1381\sl-192\f1\fs16\cf0
\b0\i0\ul0\strike0 European\f1\fs16\cf0\b0\i0\ul0\strike0 Group\f1\fs16\cf0\b0\
i0\ul0\strike0 for\f1\fs16\cf0\b0\i0\ul0\strike0 Blood\f1\fs16\cf0\b0\i0\ul0\s
trike0 and\f1\fs16\cf0\b0\i0\ul0\strike0 Marrow\f1\fs16\cf0\b0\i0\ul0\strike0
Transplantation\f1\fs16\cf0\b0\i0\ul0\strike0 Severe\par\pard\plain\li1381\sl200\f1\fs16\cf0\b0\i0\ul0\strike0 Aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 Anaemi
a\f1\fs16\cf0\b0\i0\ul0\strike0 Working\f1\fs16\cf0\b0\i0\ul0\strike0 Party.\f
2\fs16\cf0\b0\i\ul0\strike0 British\f2\fs16\cf0\b0\i\ul0\strike0 Journal\f2\fs
16\cf0\b0\i\ul0\strike0 of\f2\fs16\cf0\b0\i\ul0\strike0 Haematology\par\pard\p
lain\li1381\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 2010;150:377-379.\par\pard\colu
mn\plain\sl-200\par\pard\plain\sl-224\par\pard\plain\li0\sl-192\f1\fs16\charscal
ex80\cf0\b0\i0\ul0\strike0 37.\par\pard\column\plain\sl-200\par\pard\plain\sl-22
4\par\pard\plain\li0\sl-192\f1\fs16\cf0\b0\i0\ul0\strike0 Maciejewski\f1\fs16\cf
0\b0\i0\ul0\strike0 JP\f1\fs16\cf0\b0\i0\ul0\strike0 and\f1\fs16\cf0\b0\i0\ul0
\strike0 Risitano\f1\fs16\cf0\b0\i0\ul0\strike0 AM.\f1\fs16\cf0\b0\i0\ul0\stri
ke0 Aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anemia:\f1\fs16\cf0\b0\i0\ul0\strik
e0 management\f1\fs16\cf0\b0\i0\ul0\strike0 of\par\pard\plain\li0\sl-200\f1\fs
16\cf0\b0\i0\ul0\strike0 adult\f1\fs16\cf0\b0\i0\ul0\strike0 patients.\f2\fs16\
cf0\b0\i\ul0\strike0 Hematology\f2\fs16\cf0\b0\i\ul0\strike0 American\f2\fs16\
cf0\b0\i\ul0\strike0 Society\f2\fs16\cf0\b0\i\ul0\strike0 of\f2\fs16\cf0\b0\i\
ul0\strike0 Hematology\f2\fs16\cf0\b0\i\ul0\strike0 Education\par\pard\plain\l
i0\sl-200\f2\fs16\cf0\b0\i\ul0\strike0 Program\f1\fs16\cf0\b0\i0\ul0\strike0 20
05:110\u8211?117.\par\sect\sected\sbknone\cols4\colno1\colw1370\colsr10\colno2\c
olw4910\colsr10\colno3\colw350\colsr10\colno4\colw5460\pard\plain\li1021\sl-250\
f1\fs16\charscalex79\cf0\b0\i0\ul0\strike0 22.\par\pard\plain\li0\sl-250\column\
f1\fs16\charscalex97\cf0\b0\i0\ul0\strike0 Scheinberg\f1\fs16\charscalex97\cf0\b
0\i0\ul0\strike0 P,\f1\fs16\charscalex97\cf0\b0\i0\ul0\strike0 Nunez\f1\fs16\c
harscalex97\cf0\b0\i0\ul0\strike0 O,\f1\fs16\charscalex97\cf0\b0\i0\ul0\strike0
Weinstein\f1\fs16\charscalex97\cf0\b0\i0\ul0\strike0 B,\f1\fs16\charscalex97\
cf0\b0\i0\ul0\strike0 Scheinberg\f1\fs16\charscalex97\cf0\b0\i0\ul0\strike0 P,
\f1\fs16\charscalex97\cf0\b0\i0\ul0\strike0 Biancotto\f1\fs16\charscalex97\cf0\
b0\i0\ul0\strike0 A,\f1\fs16\charscalex97\cf0\b0\i0\ul0\strike0 Colin\f1\fs16\
charscalex97\cf0\b0\i0\ul0\strike0 O.\par\pard\plain\li0\sl-250\column\f1\fs16\
charscalex80\cf0\b0\i0\ul0\strike0 38.\par\pard\plain\li0\sl-250\column\f1\fs16\
cf0\b0\i0\ul0\strike0 Rosenfeld\f1\fs16\cf0\b0\i0\ul0\strike0 S,\f1\fs16\cf0\b0
\i0\ul0\strike0 Follmann\f1\fs16\cf0\b0\i0\ul0\strike0 D,\f1\fs16\cf0\b0\i0\ul
0\strike0 Nunez\f1\fs16\cf0\b0\i0\ul0\strike0 O,\f1\fs16\cf0\b0\i0\ul0\strike0
Young\f1\fs16\cf0\b0\i0\ul0\strike0 NS.\f1\fs16\cf0\b0\i0\ul0\strike0 Antith
ymocyte\f1\fs16\cf0\b0\i0\ul0\strike0 globulin\par\sect\sected\sbknone\cols2\co
lno1\colw6650\colsr10\colno2\colw5460\pard\plain\li1381\sl-200\f2\fs16\cf0\b0\i\
ul0\strike0 et\f2\fs16\cf0\b0\i\ul0\strike0 al\f1\fs16\cf0\b0\i0\ul0\strike0 .\
f1\fs16\cf0\b0\i0\ul0\strike0 Horse\f1\fs16\cf0\b0\i0\ul0\strike0 versus\f1\fs
16\cf0\b0\i0\ul0\strike0 rabbit\f1\fs16\cf0\b0\i0\ul0\strike0 antithymocyte\f1
\fs16\cf0\b0\i0\ul0\strike0 globulin\f1\fs16\cf0\b0\i0\ul0\strike0 in\f1\fs16\
cf0\b0\i0\ul0\strike0 acquired\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\par\pard
\plain\li1381\sl-199\f1\fs16\cf0\b0\i0\ul0\strike0 anemia.\f2\fs16\cf0\b0\i\ul0\
strike0 New\f2\fs16\cf0\b0\i\ul0\strike0 England\f2\fs16\cf0\b0\i\ul0\strike0
Journal\f2\fs16\cf0\b0\i\ul0\strike0 of\f2\fs16\cf0\b0\i\ul0\strike0 Medicine
\f1\fs16\cf0\b0\i0\ul0\strike0 2011;365:430-\f1\fs16\cf0\b0\i0\ul0\strike0 438
.\par\pard\plain\li1055\sl-250\f1\fs16\cf0\b0\i0\ul0\strike0 23.\f1\fs16\cf0\b0\
i0\ul0\strike0 Tokg\u246?z\f1\fs16\cf0\b0\i0\ul0\strike0 B, Sari\f1\fs16\cf0\b
0\i0\ul0\strike0 HI, Yildiz\f1\fs16\cf0\b0\i0\ul0\strike0 O, Aslan\f1\fs16\cf0
\b0\i0\ul0\strike0 S, Sipahio\u287?lu\f1\fs16\cf0\b0\i0\ul0\strike0 M, Okten\f
1\fs16\cf0\b0\i0\ul0\strike0 T, \f2\fs16\cf0\b0\i\ul0\strike0 et\f2\fs16\cf0\b0
\i\ul0\strike0 al.\f1\fs16\cf0\b0\i0\ul0\strike0 Effects\par\pard\plain\li0\sl
-200\column\f1\fs16\cf0\b0\i0\ul0\strike0 and\f1\fs16\cf0\b0\i0\ul0\strike0 cyc
losporine\f1\fs16\cf0\b0\i0\ul0\strike0 for\f1\fs16\cf0\b0\i0\ul0\strike0 seve
re\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anemia
:\f1\fs16\cf0\b0\i0\ul0\strike0 association\f1\fs16\cf0\b0\i0\ul0\strike0 betw
een\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 hematologic\f1\fs16\
cf0\b0\i0\ul0\strike0 response\f1\fs16\cf0\b0\i0\ul0\strike0 and\f1\fs16\cf0\b
0\i0\ul0\strike0 long-term\f1\fs16\cf0\b0\i0\ul0\strike0 outcome.\f2\fs16\cf0\
b0\i\ul0\strike0 The\f2\fs16\cf0\b0\i\ul0\strike0 Journal\f2\fs16\cf0\b0\i\ul0
\strike0 of\f2\fs16\cf0\b0\i\ul0\strike0 the\par\pard\plain\li0\sl-200\f2\fs16
\cf0\b0\i\ul0\strike0 American\f2\fs16\cf0\b0\i\ul0\strike0 Medical\f2\fs16\cf0
\b0\i\ul0\strike0 Association\f1\fs16\cf0\b0\i0\ul0\strike0 2003;289:1130\u821
1?\f1\fs16\cf0\b0\i0\ul0\strike0 1135.\par\sect\sected\sbknone\cols3\colno1\col
w6290\colsr10\colno2\colw350\colsr10\colno3\colw5460\pard\plain\li1381\sl-200\f1
\fs16\cf0\b0\i0\ul0\strike0 of\f1\fs16\cf0\b0\i0\ul0\strike0 azithromycin\f1\fs
16\cf0\b0\i0\ul0\strike0 on\f1\fs16\cf0\b0\i0\ul0\strike0 cyclosporine-induced
\f1\fs16\cf0\b0\i0\ul0\strike0 gingival\f1\fs16\cf0\b0\i0\ul0\strike0 hyperpla
sia\f1\fs16\cf0\b0\i0\ul0\strike0 in\f1\fs16\cf0\b0\i0\ul0\strike0 renal\par\p
ard\plain\li1381\sl-200\f1\fs16\charscalex99\cf0\b0\i0\ul0\strike0 transplant\f1
\fs16\charscalex99\cf0\b0\i0\ul0\strike0 patients.\f2\fs16\charscalex99\cf0\b0\
i\ul0\strike0 Transplantation\f2\fs16\charscalex99\cf0\b0\i\ul0\strike0 Procee
dings\f1\fs16\charscalex99\cf0\b0\i0\ul0\strike0 2004;\f1\fs16\charscalex99\cf0
\b0\i0\ul0\strike0 36:\f1\fs16\charscalex99\cf0\b0\i0\ul0\strike0 2699-2702\f4
\fs16\charscalex99\cf0\b0\i0\ul0\strike0 .\par\pard\plain\li0\sl-200\column\f1\f
s16\charscalex80\cf0\b0\i0\ul0\strike0 39.\par\pard\plain\li0\sl-200\column\f1\f
s16\cf0\b0\i0\ul0\strike0 Marsh\f1\fs16\cf0\b0\i0\ul0\strike0 J.\f1\fs16\cf0\b0
\i0\ul0\strike0 Making\f1\fs16\cf0\b0\i0\ul0\strike0 therapeutic\f1\fs16\cf0\b
0\i0\ul0\strike0 decisions\f1\fs16\cf0\b0\i0\ul0\strike0 in\f1\fs16\cf0\b0\i0\
ul0\strike0 adults\f1\fs16\cf0\b0\i0\ul0\strike0 with\f1\fs16\cf0\b0\i0\ul0\st
rike0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anemia.\par\pard\plain\li0\sl-200
\f2\fs16\cf0\b0\i\ul0\strike0 Hematology\f2\fs16\cf0\b0\i\ul0\strike0 American\
f2\fs16\cf0\b0\i\ul0\strike0 Society\f2\fs16\cf0\b0\i\ul0\strike0 Hematology\f
2\fs16\cf0\b0\i\ul0\strike0 Education\f2\fs16\cf0\b0\i\ul0\strike0 Program\par
\sect\sected\sbknone\cols3\colno1\colw1370\colsr10\colno2\colw5270\colsr10\colno
3\colw5460\pard\plain\li1021\sl-250\f1\fs16\charscalex79\cf0\b0\i0\ul0\strike0 2
4.\par\pard\plain\li0\sl-250\column\f1\fs16\cf0\b0\i0\ul0\strike0 Lo\u180?pez-Pi
ntor\f1\fs16\cf0\b0\i0\ul0\strike0 RM,\f1\fs16\cf0\b0\i0\ul0\strike0 Hernandez
\f1\fs16\cf0\b0\i0\ul0\strike0 G,\f1\fs16\cf0\b0\i0\ul0\strike0 de\f1\fs16\cf0
\b0\i0\ul0\strike0 Arriba\f1\fs16\cf0\b0\i0\ul0\strike0 L,\f1\fs16\cf0\b0\i0\u
l0\strike0 Morales\f1\fs16\cf0\b0\i0\ul0\strike0 JM,\f1\fs16\cf0\b0\i0\ul0\str
ike0 Jimenez\par\pard\plain\li0\sl-200\column\f1\fs16\cf0\b0\i0\ul0\strike0 200
6:78\u8211?85.\par\sect\sected\sbknone\cols3\colno1\colw6290\colsr10\colno2\colw
350\colsr10\colno3\colw5460\pard\plain\li1381\sl-200\f1\fs16\cf0\b0\i0\ul0\strik
e0 C,\f1\fs16\cf0\b0\i0\ul0\strike0 de\f1\fs16\cf0\b0\i0\ul0\strike0 Andres\f1
\fs16\cf0\b0\i0\ul0\strike0 A.\f1\fs16\cf0\b0\i0\ul0\strike0 Amlodipine\f1\fs1
6\cf0\b0\i0\ul0\strike0 and\f1\fs16\cf0\b0\i0\ul0\strike0 nifedipine\f1\fs16\c
f0\b0\i0\ul0\strike0 used\f1\fs16\cf0\b0\i0\ul0\strike0 with\f1\fs16\cf0\b0\i0
\ul0\strike0 cyclosporine\par\pard\plain\li1381\sl-200\f1\fs16\cf0\b0\i0\ul0\st
rike0 induce\f1\fs16\cf0\b0\i0\ul0\strike0 different\f1\fs16\cf0\b0\i0\ul0\stri
ke0 effects\f1\fs16\cf0\b0\i0\ul0\strike0 on\f1\fs16\cf0\b0\i0\ul0\strike0 gi
ngival\f1\fs16\cf0\b0\i0\ul0\strike0 enlargement.\f2\fs16\cf0\b0\i\ul0\strike0
Transplantation\par\pard\plain\li1381\sl-200\f2\fs16\cf0\b0\i\ul0\strike0 Proce
edings\f1\fs16\cf0\b0\i0\ul0\strike0 2009;41:2351-2353.\par\pard\plain\li0\sl-2
00\column\f1\fs16\charscalex80\cf0\b0\i0\ul0\strike0 40.\par\pard\plain\li0\sl-2
00\column\f1\fs16\cf0\b0\i0\ul0\strike0 Bacigalupo\f1\fs16\cf0\b0\i0\ul0\strike0
A.\f1\fs16\cf0\b0\i0\ul0\strike0 Aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anem
ia:\f1\fs16\cf0\b0\i0\ul0\strike0 pathogenesis\f1\fs16\cf0\b0\i0\ul0\strike0 a
nd\f1\fs16\cf0\b0\i0\ul0\strike0 treatment.\par\pard\plain\li0\sl-199\f2\fs16\c
f0\b0\i\ul0\strike0 Hematology\f2\fs16\cf0\b0\i\ul0\strike0 American\f2\fs16\cf
0\b0\i\ul0\strike0 Society\f2\fs16\cf0\b0\i\ul0\strike0 of\f2\fs16\cf0\b0\i\ul
0\strike0 Hematology\f2\fs16\cf0\b0\i\ul0\strike0 Education\f2\fs16\cf0\b0\i\u
l0\strike0 Program\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 2007
:23\u8211?28.\par\sect\sected\sbknone\cols4\colno1\colw1370\colsr10\colno2\colw4
910\colsr10\colno3\colw350\colsr10\colno4\colw5460\pard\plain\li1021\sl-250\f1\f
s16\charscalex79\cf0\b0\i0\ul0\strike0 25.\par\pard\plain\sl-200\par\pard\plain\
sl-200\par\pard\plain\sl-200\par\pard\plain\sl-258\par\pard\plain\li1021\sl-192\
f1\fs16\charscalex79\cf0\b0\i0\ul0\strike0 26.\par\pard\plain\sl-200\par\pard\pl
ain\sl-258\par\pard\plain\li1021\sl-192\f1\fs16\charscalex79\cf0\b0\i0\ul0\strik
e0 27.\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\par
d\plain\sl-258\par\pard\plain\li1021\sl-192\f1\fs16\charscalex79\cf0\b0\i0\ul0\s
trike0 28.\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-258\par
\pard\plain\li1021\sl-192\f1\fs16\charscalex79\cf0\b0\i0\ul0\strike0 29.\par\par
d\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-258\par\pard\plain\li1021
\sl-192\f1\fs16\charscalex79\cf0\b0\i0\ul0\strike0 30.\par\pard\plain\sl-200\par
\pard\plain\sl-200\par\pard\plain\sl-258\par\pard\plain\li1021\sl-192\f1\fs16\ch
arscalex79\cf0\b0\i0\ul0\strike0 31.\par\pard\plain\sl-200\par\pard\plain\sl-200
\par\pard\plain\sl-258\par\pard\plain\li1021\sl-192\f1\fs16\charscalex79\cf0\b0\
i0\ul0\strike0 32.\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl
-200\par\pard\plain\sl-200\par\pard\plain\sl-258\par\pard\plain\li1021\sl-192\f1
\fs16\charscalex79\cf0\b0\i0\ul0\strike0 33.\par\pard\plain\sl-200\par\pard\plai
n\sl-200\par\pard\plain\sl-258\par\pard\plain\li1021\sl-192\f1\fs16\charscalex79
\cf0\b0\i0\ul0\strike0 34.\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\
plain\sl-258\par\pard\plain\li1021\sl-192\f1\fs16\charscalex79\cf0\b0\i0\ul0\str
ike0 35.\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-258\par\p
ard\plain\li1021\sl-192\f1\fs16\charscalex79\cf0\b0\i0\ul0\strike0 36.\par\pard\
plain\li0\sl-250\column\f1\fs16\charscalex99\cf0\b0\i0\ul0\strike0 Kojima\f1\fs1
6\charscalex99\cf0\b0\i0\ul0\strike0 S,\f1\fs16\charscalex99\cf0\b0\i0\ul0\stri
ke0 Hibi\f1\fs16\charscalex99\cf0\b0\i0\ul0\strike0 S,\f1\fs16\charscalex99\cf
0\b0\i0\ul0\strike0 Kosaka\f1\fs16\charscalex99\cf0\b0\i0\ul0\strike0 Y,\f1\fs
16\charscalex99\cf0\b0\i0\ul0\strike0 Yamamoto\f1\fs16\charscalex99\cf0\b0\i0\u
l0\strike0 M, Tsuchida\f1\fs16\charscalex99\cf0\b0\i0\ul0\strike0 M, Mugishima
\f1\fs16\charscalex99\cf0\b0\i0\ul0\strike0 H,\par\pard\plain\li0\sl-200\f2\fs1
6\cf0\b0\i\ul0\strike0 et\f2\fs16\cf0\b0\i\ul0\strike0 al.\f1\fs16\cf0\b0\i0\ul
0\strike0 .\f1\fs16\cf0\b0\i0\ul0\strike0 Immunosuppressive\f1\fs16\cf0\b0\i0\

ul0\strike0 therapy\f1\fs16\cf0\b0\i0\ul0\strike0 using\f1\fs16\cf0\b0\i0\ul0\
strike0 antithymocyte\f1\fs16\cf0\b0\i0\ul0\strike0 globulin,\par\pard\plain\l
i0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 cyclosporine,\f1\fs16\cf0\b0\i0\ul0\stri
ke0 and\f1\fs16\cf0\b0\i0\ul0\strike0 danazol\f1\fs16\cf0\b0\i0\ul0\strike0 w
ith\f1\fs16\cf0\b0\i0\ul0\strike0 or\f1\fs16\cf0\b0\i0\ul0\strike0 without\f1\
fs16\cf0\b0\i0\ul0\strike0 human\f1\fs16\cf0\b0\i0\ul0\strike0 granulocyte\par
\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 colony-stimulating\f1\fs16\
cf0\b0\i0\ul0\strike0 factor\f1\fs16\cf0\b0\i0\ul0\strike0 in\f1\fs16\cf0\b0\i
0\ul0\strike0 children\f1\fs16\cf0\b0\i0\ul0\strike0 with\f1\fs16\cf0\b0\i0\ul
0\strike0 acquired\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\ul
0\strike0 anemia.\par\pard\plain\li0\sl-200\f2\fs16\cf0\b0\i\ul0\strike0 Blood\
f1\fs16\cf0\b0\i0\ul0\strike0 2000;96:2049-2054.\par\pard\plain\li0\sl-250\f1\f
s16\charscalex97\cf0\b0\i0\ul0\strike0 Zheng\f1\fs16\charscalex97\cf0\b0\i0\ul0\
strike0 Y,\f1\fs16\charscalex97\cf0\b0\i0\ul0\strike0 Liu\f1\fs16\charscalex97
\cf0\b0\i0\ul0\strike0 Y,\f1\fs16\charscalex97\cf0\b0\i0\ul0\strike0 Chu\f1\fs
16\charscalex97\cf0\b0\i0\ul0\strike0 Y.\f1\fs16\charscalex97\cf0\b0\i0\ul0\str
ike0 Immunosuppressive\f1\fs16\charscalex97\cf0\b0\i0\ul0\strike0 therapy\f1\f
s16\charscalex97\cf0\b0\i0\ul0\strike0 for\f1\fs16\charscalex97\cf0\b0\i0\ul0\s
trike0 acquired\f1\fs16\charscalex97\cf0\b0\i0\ul0\strike0 severe\par\pard\pla
in\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\ul0\strik
e0 anemia\f1\fs16\cf0\b0\i0\ul0\strike0 (SAA):\f1\fs16\cf0\b0\i0\ul0\strike0
a\f1\fs16\cf0\b0\i0\ul0\strike0 prospective\f1\fs16\cf0\b0\i0\ul0\strike0 comp
arison\f1\fs16\cf0\b0\i0\ul0\strike0 of\f1\fs16\cf0\b0\i0\ul0\strike0 four\f1\
fs16\cf0\b0\i0\ul0\strike0 different\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i
0\ul0\strike0 regimens.\f2\fs16\cf0\b0\i\ul0\strike0 Experimental\f2\fs16\cf0\b
0\i\ul0\strike0 Hematology\f1\fs16\cf0\b0\i0\ul0\strike0 2006;\f1\fs16\cf0\b0\
i0\ul0\strike0 34:826-831.\par\pard\plain\li0\sl-250\f1\fs16\cf0\b0\i0\ul0\stri
ke0 Gluckman\f1\fs16\cf0\b0\i0\ul0\strike0 E,\f1\fs16\cf0\b0\i0\ul0\strike0 Ro
kicka-Milewska\f1\fs16\cf0\b0\i0\ul0\strike0 R,\f1\fs16\cf0\b0\i0\ul0\strike0
Hann\f1\fs16\cf0\b0\i0\ul0\strike0 I,\f1\fs16\cf0\b0\i0\ul0\strike0 Nikiforaki
s\f1\fs16\cf0\b0\i0\ul0\strike0 E, Tavakoli\par\pard\plain\li0\sl-200\f1\fs16\c
f0\b0\i0\ul0\strike0 F, Cohen-Scali\f1\fs16\cf0\b0\i0\ul0\strike0 S,\f2\fs16\cf
0\b0\i\ul0\strike0 et\f2\fs16\cf0\b0\i\ul0\strike0 al.\f1\fs16\cf0\b0\i0\ul0\s
trike0 Results\f1\fs16\cf0\b0\i0\ul0\strike0 and\f1\fs16\cf0\b0\i0\ul0\strike0
follow-up\f1\fs16\cf0\b0\i0\ul0\strike0 of\f1\fs16\cf0\b0\i0\ul0\strike0 a\f
1\fs16\cf0\b0\i0\ul0\strike0 phase\f1\fs16\cf0\b0\i0\ul0\strike0 III\f1\fs16\c
f0\b0\i0\ul0\strike0 randomized\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0
\strike0 study\f1\fs16\cf0\b0\i0\ul0\strike0 of\f1\fs16\cf0\b0\i0\ul0\strike0
recombinant\f1\fs16\cf0\b0\i0\ul0\strike0 human-granulocyte\f1\fs16\cf0\b0\i0\u
l0\strike0 stimulating\f1\fs16\cf0\b0\i0\ul0\strike0 factor\f1\fs16\cf0\b0\i0\
ul0\strike0 as\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 support\
f1\fs16\cf0\b0\i0\ul0\strike0 for\f1\fs16\cf0\b0\i0\ul0\strike0 immunosuppress
ive\f1\fs16\cf0\b0\i0\ul0\strike0 therapy\f1\fs16\cf0\b0\i0\ul0\strike0 in\f1\
fs16\cf0\b0\i0\ul0\strike0 patients\f1\fs16\cf0\b0\i0\ul0\strike0 with\f1\fs16
\cf0\b0\i0\ul0\strike0 severe\par\pard\plain\li0\sl-200\f1\fs16\charscalex96\cf
0\b0\i0\ul0\strike0 aplastic\f1\fs16\charscalex96\cf0\b0\i0\ul0\strike0 anaemia
.\f2\fs16\charscalex96\cf0\b0\i\ul0\strike0 British\f2\fs16\charscalex96\cf0\b0
\i\ul0\strike0 Journal\f2\fs16\charscalex96\cf0\b0\i\ul0\strike0 of\f2\fs16\ch
arscalex96\cf0\b0\i\ul0\strike0 Haematology\f1\fs16\charscalex96\cf0\b0\i0\ul0\
strike0 2002;119:1075-1082.\par\pard\plain\li0\sl-250\f1\fs16\cf0\b0\i0\ul0\str
ike0 Gordon-Smith\f1\fs16\cf0\b0\i0\ul0\strike0 EC,\f1\fs16\cf0\b0\i0\ul0\strik
e0 Yandle\f1\fs16\cf0\b0\i0\ul0\strike0 A,\f1\fs16\cf0\b0\i0\ul0\strike0 Miln
e\f1\fs16\cf0\b0\i0\ul0\strike0 A,\f1\fs16\cf0\b0\i0\ul0\strike0 Speck\f1\fs16
\cf0\b0\i0\ul0\strike0 B, Marmont\f1\fs16\cf0\b0\i0\ul0\strike0 A, Willemze\pa
r\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 R,\f2\fs16\cf0\b0\i\ul0\st
rike0 et\f2\fs16\cf0\b0\i\ul0\strike0 al\f1\fs16\cf0\b0\i0\ul0\strike0 .\f1\fs
16\cf0\b0\i0\ul0\strike0 Randomised\f1\fs16\cf0\b0\i0\ul0\strike0 placebo\f1\f
s16\cf0\b0\i0\ul0\strike0 controlled\f1\fs16\cf0\b0\i0\ul0\strike0 study\f1\fs
16\cf0\b0\i0\ul0\strike0 of\f1\fs16\cf0\b0\i0\ul0\strike0 RH-GM-CSF\par\pard\p
lain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 following\f1\fs16\cf0\b0\i0\ul0\st
rike0 ALG\f1\fs16\cf0\b0\i0\ul0\strike0 in\f1\fs16\cf0\b0\i0\ul0\strike0 the\
f1\fs16\cf0\b0\i0\ul0\strike0 treatment\f1\fs16\cf0\b0\i0\ul0\strike0 of\f1\fs
16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anaemia.\f2\fs
16\cf0\b0\i\ul0\strike0 Bone\f2\fs16\cf0\b0\i\ul0\strike0 Marrow\par\pard\plai
n\li0\sl-200\f2\fs16\cf0\b0\i\ul0\strike0 Transplantation\f1\fs16\cf0\b0\i0\ul0\
strike0 1991;7:78-80.\par\pard\plain\li0\sl-250\f1\fs16\charscalex97\cf0\b0\i0\
ul0\strike0 Shao\f1\fs16\charscalex97\cf0\b0\i0\ul0\strike0 Z,\f1\fs16\charscal
ex97\cf0\b0\i0\ul0\strike0 Chu\f1\fs16\charscalex97\cf0\b0\i0\ul0\strike0 Y,\f
1\fs16\charscalex97\cf0\b0\i0\ul0\strike0 Zhang\f1\fs16\charscalex97\cf0\b0\i0\
ul0\strike0 Y,\f1\fs16\charscalex97\cf0\b0\i0\ul0\strike0 Chen\f1\fs16\charsca
lex97\cf0\b0\i0\ul0\strike0 G,\f1\fs16\charscalex97\cf0\b0\i0\ul0\strike0 Zhen
g\f1\fs16\charscalex97\cf0\b0\i0\ul0\strike0 Y.\f1\fs16\charscalex97\cf0\b0\i0\
ul0\strike0 Treatment\f1\fs16\charscalex97\cf0\b0\i0\ul0\strike0 of\f1\fs16\ch
arscalex97\cf0\b0\i0\ul0\strike0 severe\f1\fs16\charscalex97\cf0\b0\i0\ul0\stri
ke0 aplastic\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 anemia\f1\
fs16\cf0\b0\i0\ul0\strike0 with\f1\fs16\cf0\b0\i0\ul0\strike0 an\f1\fs16\cf0\b
0\i0\ul0\strike0 immunosuppressive\f1\fs16\cf0\b0\i0\ul0\strike0 agent\f1\fs16
\cf0\b0\i0\ul0\strike0 plus\f1\fs16\cf0\b0\i0\ul0\strike0 recombinant\par\pard
\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 human\f1\fs16\cf0\b0\i0\ul0\stri
ke0 granulocyte-macrophage\f1\fs16\cf0\b0\i0\ul0\strike0 colony-stimulating\f1
\fs16\cf0\b0\i0\ul0\strike0 factor\f1\fs16\cf0\b0\i0\ul0\strike0 and\par\pard\
plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 erythropoietin.\f2\fs16\cf0\b0\i\
ul0\strike0 American\f2\fs16\cf0\b0\i\ul0\strike0 Journal\f2\fs16\cf0\b0\i\ul0
\strike0 of\f2\fs16\cf0\b0\i\ul0\strike0 Hematology\f1\fs16\cf0\b0\i0\ul0\stri
ke0 1998;59:185-191.\par\pard\plain\li0\sl-250\f1\fs16\charscalex96\cf0\b0\i0\u
l0\strike0 Teramura\f1\fs16\charscalex96\cf0\b0\i0\ul0\strike0 M,\f1\fs16\chars
calex96\cf0\b0\i0\ul0\strike0 Kimura\f1\fs16\charscalex96\cf0\b0\i0\ul0\strike0
A,\f1\fs16\charscalex96\cf0\b0\i0\ul0\strike0 Iwase\f1\fs16\charscalex96\cf0\
b0\i0\ul0\strike0 S,\f1\fs16\charscalex96\cf0\b0\i0\ul0\strike0 Yonemura\f1\fs
16\charscalex96\cf0\b0\i0\ul0\strike0 Y, Nakao\f1\fs16\charscalex96\cf0\b0\i0\u
l0\strike0 S, Urabe\f1\fs16\charscalex96\cf0\b0\i0\ul0\strike0 A\f2\fs16\chars
calex96\cf0\b0\i\ul0\strike0 ,\f2\fs16\charscalex96\cf0\b0\i\ul0\strike0 et\f2\
fs16\charscalex96\cf0\b0\i\ul0\strike0 al\f1\fs16\charscalex96\cf0\b0\i0\ul0\st
rike0 .\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 Treatment\f1\fs1
6\cf0\b0\i0\ul0\strike0 of\f1\fs16\cf0\b0\i0\ul0\strike0 severe\f1\fs16\cf0\b0
\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anemia\f1\fs16\cf0\b0\i
0\ul0\strike0 with\f1\fs16\cf0\b0\i0\ul0\strike0 antithymocyte\f1\fs16\cf0\b0\
i0\ul0\strike0 globulin\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0
and\f1\fs16\cf0\b0\i0\ul0\strike0 cyclosporin\f1\fs16\cf0\b0\i0\ul0\strike0 A
\f1\fs16\cf0\b0\i0\ul0\strike0 with\f1\fs16\cf0\b0\i0\ul0\strike0 or\f1\fs16\c
f0\b0\i0\ul0\strike0 without\f1\fs16\cf0\b0\i0\ul0\strike0 G-CSF\f1\fs16\cf0\b
0\i0\ul0\strike0 in\f1\fs16\cf0\b0\i0\ul0\strike0 adults:\f1\fs16\cf0\b0\i0\ul
0\strike0 a\f1\fs16\cf0\b0\i0\ul0\strike0 multicenter\par\pard\plain\li0\sl-20
0\f1\fs16\cf0\b0\i0\ul0\strike0 randomized\f1\fs16\cf0\b0\i0\ul0\strike0 study\
f1\fs16\cf0\b0\i0\ul0\strike0 in\f1\fs16\cf0\b0\i0\ul0\strike0 Japan.\f2\fs16\
cf0\b0\i\ul0\strike0 Blood\f1\fs16\cf0\b0\i0\ul0\strike0 2007;110:1756-1761.\p
ar\pard\plain\li0\sl-250\f1\fs16\charscalex96\cf0\b0\i0\ul0\strike0 Fu\u168?\f1\
fs16\charscalex96\cf0\b0\i0\ul0\strike0 hrer\f1\fs16\charscalex96\cf0\b0\i0\ul0
\strike0 M,\f1\fs16\charscalex96\cf0\b0\i0\ul0\strike0 Rampf\f1\fs16\charscale
x96\cf0\b0\i0\ul0\strike0 U,\f1\fs16\charscalex96\cf0\b0\i0\ul0\strike0 Bauman
n\f1\fs16\charscalex96\cf0\b0\i0\ul0\strike0 I,\f1\fs16\charscalex96\cf0\b0\i0\
ul0\strike0 Faldum\f1\fs16\charscalex96\cf0\b0\i0\ul0\strike0 A, Niemeyer\f1\f
s16\charscalex96\cf0\b0\i0\ul0\strike0 C, Janka-Schaub\par\pard\plain\li0\sl-20
0\f1\fs16\cf0\b0\i0\ul0\strike0 G, \f2\fs16\cf0\b0\i\ul0\strike0 et\f2\fs16\cf0\
b0\i\ul0\strike0 al.\f1\fs16\cf0\b0\i0\ul0\strike0 Immunosuppressive\f1\fs16\c
f0\b0\i0\ul0\strike0 therapy\f1\fs16\cf0\b0\i0\ul0\strike0 for\f1\fs16\cf0\b0\
i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anemia\f1\fs16\cf0\b0\i0
\ul0\strike0 in\f1\fs16\cf0\b0\i0\ul0\strike0 children:\par\pard\plain\li0\sl200\f1\fs16\cf0\b0\i0\ul0\strike0 a\f1\fs16\cf0\b0\i0\ul0\strike0 more\f1\fs16\
cf0\b0\i0\ul0\strike0 severe\f1\fs16\cf0\b0\i0\ul0\strike0 disease\f1\fs16\cf0

\b0\i0\ul0\strike0 predicts\f1\fs16\cf0\b0\i0\ul0\strike0 better\f1\fs16\cf0\b
0\i0\ul0\strike0 survival.\f2\fs16\cf0\b0\i\ul0\strike0 Blood\f1\fs16\cf0\b0\i
0\ul0\strike0 2005;106:2102-\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\st
rike0 2104.\par\pard\plain\li0\sl-250\f1\fs16\charscalex99\cf0\b0\i0\ul0\strike0
Tichelli\f1\fs16\charscalex99\cf0\b0\i0\ul0\strike0 A,\f1\fs16\charscalex99\cf
0\b0\i0\ul0\strike0 Schrezenmeier\f1\fs16\charscalex99\cf0\b0\i0\ul0\strike0 H
,\f1\fs16\charscalex99\cf0\b0\i0\ul0\strike0 Socie\u180?\f1\fs16\charscalex99\c
f0\b0\i0\ul0\strike0 G,\f1\fs16\charscalex99\cf0\b0\i0\ul0\strike0 Marsh\f1\fs
16\charscalex99\cf0\b0\i0\ul0\strike0 J, Bacigalupo\f1\fs16\charscalex99\cf0\b0
\i0\ul0\strike0 A, D\u252?hrsen\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0
\strike0 U,\f2\fs16\cf0\b0\i\ul0\strike0 et\f2\fs16\cf0\b0\i\ul0\strike0 al.\f
1\fs16\cf0\b0\i0\ul0\strike0 A\f1\fs16\cf0\b0\i0\ul0\strike0 randomized\f1\fs1
6\cf0\b0\i0\ul0\strike0 controlled\f1\fs16\cf0\b0\i0\ul0\strike0 study\f1\fs16
\cf0\b0\i0\ul0\strike0 in\f1\fs16\cf0\b0\i0\ul0\strike0 patients\f1\fs16\cf0\b
0\i0\ul0\strike0 with\f1\fs16\cf0\b0\i0\ul0\strike0 newly\par\pard\plain\li0\s
l-200\f1\fs16\cf0\b0\i0\ul0\strike0 diagnosed\f1\fs16\cf0\b0\i0\ul0\strike0 sev
ere\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anemi
a\f1\fs16\cf0\b0\i0\ul0\strike0 receiving\f1\fs16\cf0\b0\i0\ul0\strike0 antith
ymocyte\f1\fs16\cf0\b0\i0\ul0\strike0 globulin\par\pard\plain\li0\sl-200\f1\fs1
6\charscalex97\cf0\b0\i0\ul0\strike0 (ATG),\f1\fs16\charscalex97\cf0\b0\i0\ul0\s
trike0 cyclosporine,\f1\fs16\charscalex97\cf0\b0\i0\ul0\strike0 with\f1\fs16\c
harscalex97\cf0\b0\i0\ul0\strike0 or\f1\fs16\charscalex97\cf0\b0\i0\ul0\strike0
without\f1\fs16\charscalex97\cf0\b0\i0\ul0\strike0 G-CSF:\f1\fs16\charscalex9
7\cf0\b0\i0\ul0\strike0 a\f1\fs16\charscalex97\cf0\b0\i0\ul0\strike0 study\f1\
fs16\charscalex97\cf0\b0\i0\ul0\strike0 of\f1\fs16\charscalex97\cf0\b0\i0\ul0\s
trike0 the\f1\fs16\charscalex97\cf0\b0\i0\ul0\strike0 SAAWorking\par\pard\plai
n\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 Party\f1\fs16\cf0\b0\i0\ul0\strike0
of\f1\fs16\cf0\b0\i0\ul0\strike0 the\f1\fs16\cf0\b0\i0\ul0\strike0 European\f1
\fs16\cf0\b0\i0\ul0\strike0 Group\f1\fs16\cf0\b0\i0\ul0\strike0 for\f1\fs16\cf
0\b0\i0\ul0\strike0 Blood\f1\fs16\cf0\b0\i0\ul0\strike0 and\f1\fs16\cf0\b0\i0\
ul0\strike0 Marrow\f1\fs16\cf0\b0\i0\ul0\strike0 Transplantation.\par\pard\pla
in\li0\sl-200\f2\fs16\cf0\b0\i\ul0\strike0 Blood\f1\fs16\cf0\b0\i0\ul0\strike0
2011;117:4434-4441.\par\pard\plain\li0\sl-250\f1\fs16\charscalex98\cf0\b0\i0\ul0
\strike0 Socie\f1\fs16\charscalex98\cf0\b0\i0\ul0\strike0 G,\f1\fs16\charscalex
98\cf0\b0\i0\ul0\strike0 Mary\f1\fs16\charscalex98\cf0\b0\i0\ul0\strike0 JY,\f
1\fs16\charscalex98\cf0\b0\i0\ul0\strike0 Schrezenmeier\f1\fs16\charscalex98\cf
0\b0\i0\ul0\strike0 H,\f1\fs16\charscalex98\cf0\b0\i0\ul0\strike0 Marsh\f1\fs1
6\charscalex98\cf0\b0\i0\ul0\strike0 J, Bacigalupo\f1\fs16\charscalex98\cf0\b0\
i0\ul0\strike0 A, Locasciulli\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\s
trike0 A,\f2\fs16\cf0\b0\i\ul0\strike0 et\f2\fs16\cf0\b0\i\ul0\strike0 al.\f1\
fs16\cf0\b0\i0\ul0\strike0 Granulocyte-stimulating\f1\fs16\cf0\b0\i0\ul0\strike
0 factor\f1\fs16\cf0\b0\i0\ul0\strike0 and\f1\fs16\cf0\b0\i0\ul0\strike0 seve
re\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anemia
:\f1\fs16\cf0\b0\i0\ul0\strike0 a\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\u
l0\strike0 survey\f1\fs16\cf0\b0\i0\ul0\strike0 by\f1\fs16\cf0\b0\i0\ul0\strike
0 the\f1\fs16\cf0\b0\i0\ul0\strike0 European\f1\fs16\cf0\b0\i0\ul0\strike0 Gr
oup\f1\fs16\cf0\b0\i0\ul0\strike0 for\f1\fs16\cf0\b0\i0\ul0\strike0 Blood\f1\f
s16\cf0\b0\i0\ul0\strike0 and\f1\fs16\cf0\b0\i0\ul0\strike0 Marrow\f1\fs16\cf0
\b0\i0\ul0\strike0 Transplantation\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\
ul0\strike0 (EBMT).\f2\fs16\cf0\b0\i\ul0\strike0 Blood\f1\fs16\cf0\b0\i0\ul0\st
rike0 2007;109:2794-2796.\par\pard\plain\li0\sl-250\f1\fs16\cf0\b0\i0\ul0\strik
e0 Ohara\f1\fs16\cf0\b0\i0\ul0\strike0 A,\f1\fs16\cf0\b0\i0\ul0\strike0 Kojima
\f1\fs16\cf0\b0\i0\ul0\strike0 S,\f1\fs16\cf0\b0\i0\ul0\strike0 Hamajima\f1\fs
16\cf0\b0\i0\ul0\strike0 N,\f1\fs16\cf0\b0\i0\ul0\strike0 Tsuchida\f1\fs16\cf0
\b0\i0\ul0\strike0 M, Imashuku\f1\fs16\cf0\b0\i0\ul0\strike0 S, Ohta\f1\fs16\c
f0\b0\i0\ul0\strike0 S.\f2\fs16\cf0\b0\i\ul0\strike0 et\par\pard\plain\li0\sl200\f2\fs16\cf0\b0\i\ul0\strike0 al.\f1\fs16\cf0\b0\i0\ul0\strike0 Myelodysplas
tic\f1\fs16\cf0\b0\i0\ul0\strike0 syndrome\f1\fs16\cf0\b0\i0\ul0\strike0 and\f
1\fs16\cf0\b0\i0\ul0\strike0 acute\f1\fs16\cf0\b0\i0\ul0\strike0 myelogenous\f
1\fs16\cf0\b0\i0\ul0\strike0 leukemia\f1\fs16\cf0\b0\i0\ul0\strike0 as\par\par

d\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 a\f1\fs16\cf0\b0\i0\ul0\strike0
late\f1\fs16\cf0\b0\i0\ul0\strike0 clonal\f1\fs16\cf0\b0\i0\ul0\strike0 comp
lication\f1\fs16\cf0\b0\i0\ul0\strike0 in\f1\fs16\cf0\b0\i0\ul0\strike0 childr
en\f1\fs16\cf0\b0\i0\ul0\strike0 with\f1\fs16\cf0\b0\i0\ul0\strike0 acquired\f
1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anemia.\pa
r\pard\plain\li0\sl-200\f2\fs16\cf0\b0\i\ul0\strike0 Blood\f1\fs16\cf0\b0\i0\ul0
\strike0 1997;90:1009-1013.\par\pard\plain\li0\sl-250\f1\fs16\charscalex98\cf0\
b0\i0\ul0\strike0 Kaito\f1\fs16\charscalex98\cf0\b0\i0\ul0\strike0 K,\f1\fs16\c
harscalex98\cf0\b0\i0\ul0\strike0 Kobayashi\f1\fs16\charscalex98\cf0\b0\i0\ul0\
strike0 M,\f1\fs16\charscalex98\cf0\b0\i0\ul0\strike0 Katayama\f1\fs16\charsca
lex98\cf0\b0\i0\ul0\strike0 T,\f1\fs16\charscalex98\cf0\b0\i0\ul0\strike0 Masu
oka\f1\fs16\charscalex98\cf0\b0\i0\ul0\strike0 H, Shimada\f1\fs16\charscalex98\
cf0\b0\i0\ul0\strike0 T, Nishiwaki\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\
ul0\strike0 K,\f2\fs16\cf0\b0\i\ul0\strike0 et\f2\fs16\cf0\b0\i\ul0\strike0 al
.\f1\fs16\cf0\b0\i0\ul0\strike0 Long-term\f1\fs16\cf0\b0\i0\ul0\strike0 admini
stration\f1\fs16\cf0\b0\i0\ul0\strike0 of\f1\fs16\cf0\b0\i0\ul0\strike0 G-CSF\
f1\fs16\cf0\b0\i0\ul0\strike0 for\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs
16\cf0\b0\i0\ul0\strike0 anaemia\f1\fs16\cf0\b0\i0\ul0\strike0 is\par\pard\pla
in\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 closely\f1\fs16\cf0\b0\i0\ul0\strike
0 related\f1\fs16\cf0\b0\i0\ul0\strike0 to\f1\fs16\cf0\b0\i0\ul0\strike0 the\
f1\fs16\cf0\b0\i0\ul0\strike0 early\f1\fs16\cf0\b0\i0\ul0\strike0 evolution\f1
\fs16\cf0\b0\i0\ul0\strike0 of\f1\fs16\cf0\b0\i0\ul0\strike0 monosomy\f1\fs16\
cf0\b0\i0\ul0\strike0 7\f1\fs16\cf0\b0\i0\ul0\strike0 MDS\f1\fs16\cf0\b0\i0\ul
0\strike0 in\f1\fs16\cf0\b0\i0\ul0\strike0 adults.\par\pard\plain\li0\sl-200\f
2\fs16\cf0\b0\i\ul0\strike0 British\f2\fs16\cf0\b0\i\ul0\strike0 Journal\f2\fs1
6\cf0\b0\i\ul0\strike0 of\f2\fs16\cf0\b0\i\ul0\strike0 Haematology\f1\fs16\cf0
\b0\i0\ul0\strike0 1998;103:297-303.\par\pard\plain\li0\sl-250\f1\fs16\charscal
ex89\cf0\b0\i0\ul0\strike0 Locasciulli\f1\fs16\charscalex89\cf0\b0\i0\ul0\strike
0 A,\f1\fs16\charscalex89\cf0\b0\i0\ul0\strike0 Arcese\f1\fs16\charscalex89\cf
0\b0\i0\ul0\strike0 W,\f1\fs16\charscalex89\cf0\b0\i0\ul0\strike0 Locatelli\f1
\fs16\charscalex89\cf0\b0\i0\ul0\strike0 F,\f1\fs16\charscalex89\cf0\b0\i0\ul0\
strike0 Di\f1\fs16\charscalex89\cf0\b0\i0\ul0\strike0 Bona\f1\fs16\charscalex8
9\cf0\b0\i0\ul0\strike0 E,\f1\fs16\charscalex89\cf0\b0\i0\ul0\strike0 Bacigalu
po\f1\fs16\charscalex89\cf0\b0\i0\ul0\strike0 A.\f1\fs16\charscalex89\cf0\b0\i0
\ul0\strike0 Treatment\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0
of\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anaemi
a\f1\fs16\cf0\b0\i0\ul0\strike0 with\f1\fs16\cf0\b0\i0\ul0\strike0 granulocyte
-colony\f1\fs16\cf0\b0\i0\ul0\strike0 stimulating\f1\fs16\cf0\b0\i0\ul0\strike0
factor\f1\fs16\cf0\b0\i0\ul0\strike0 and\par\pard\plain\li0\sl-200\f1\fs16\cf
0\b0\i0\ul0\strike0 risk\f1\fs16\cf0\b0\i0\ul0\strike0 of\f1\fs16\cf0\b0\i0\ul0
\strike0 malignancy:\f1\fs16\cf0\b0\i0\ul0\strike0 Italian\f1\fs16\cf0\b0\i0\u
l0\strike0 Aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 Anaemia\f1\fs16\cf0\b0\i0\ul
0\strike0 Study\f1\fs16\cf0\b0\i0\ul0\strike0 Group.\f2\fs16\cf0\b0\i\ul0\stri
ke0 The\f2\fs16\cf0\b0\i\ul0\strike0 Lancet\par\pard\plain\li0\sl-200\f1\fs16\
cf0\b0\i0\ul0\strike0 2001;357:43-44.\par\pard\plain\li0\sl-250\column\f1\fs16\c
harscalex80\cf0\b0\i0\ul0\strike0 41.\par\pard\plain\sl-200\par\pard\plain\sl-20
0\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-258\par\pard\pla
in\li0\sl-192\f1\fs16\charscalex80\cf0\b0\i0\ul0\strike0 42.\par\pard\plain\sl-2
00\par\pard\plain\sl-200\par\pard\plain\sl-258\par\pard\plain\li0\sl-192\f1\fs16
\charscalex80\cf0\b0\i0\ul0\strike0 43.\par\pard\plain\sl-200\par\pard\plain\sl200\par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-258\par\pard\p
lain\li0\sl-192\f1\fs16\charscalex80\cf0\b0\i0\ul0\strike0 44.\par\pard\plain\sl
-200\par\pard\plain\sl-200\par\pard\plain\sl-258\par\pard\plain\li0\sl-192\f1\fs
16\charscalex80\cf0\b0\i0\ul0\strike0 45.\par\pard\plain\sl-200\par\pard\plain\s
l-200\par\pard\plain\sl-258\par\pard\plain\li0\sl-192\f1\fs16\charscalex80\cf0\b
0\i0\ul0\strike0 46.\par\pard\plain\sl-200\par\pard\plain\sl-258\par\pard\plain\
li0\sl-192\f1\fs16\charscalex80\cf0\b0\i0\ul0\strike0 47.\par\pard\plain\sl-200\
par\pard\plain\sl-200\par\pard\plain\sl-200\par\pard\plain\sl-258\par\pard\plain
\li0\sl-192\f1\fs16\charscalex80\cf0\b0\i0\ul0\strike0 48.\par\pard\plain\sl-200
\par\pard\plain\sl-200\par\pard\plain\sl-258\par\pard\plain\li0\sl-192\f1\fs16\c
harscalex80\cf0\b0\i0\ul0\strike0 49.\par\pard\plain\sl-200\par\pard\plain\sl-25
8\par\pard\plain\li0\sl-192\f1\fs16\charscalex80\cf0\b0\i0\ul0\strike0 50.\par\p
ard\plain\sl-200\par\pard\plain\sl-258\par\pard\plain\li0\sl-192\f1\fs16\charsca
lex80\cf0\b0\i0\ul0\strike0 51.\par\pard\plain\sl-200\par\pard\plain\sl-200\par\
pard\plain\sl-200\par\pard\plain\sl-258\par\pard\plain\li0\sl-192\f1\fs16\charsc
alex80\cf0\b0\i0\ul0\strike0 52.\par\pard\plain\li0\sl-250\column\f1\fs16\cf0\b0
\i0\ul0\strike0 Saracco\f1\fs16\cf0\b0\i0\ul0\strike0 P,\f1\fs16\cf0\b0\i0\ul0\
strike0 Quarello\f1\fs16\cf0\b0\i0\ul0\strike0 P,\f1\fs16\cf0\b0\i0\ul0\strike
0 Iori\f1\fs16\cf0\b0\i0\ul0\strike0 AP,\f1\fs16\cf0\b0\i0\ul0\strike0 Zecca\
f1\fs16\cf0\b0\i0\ul0\strike0 M.,\f1\fs16\cf0\b0\i0\ul0\strike0 Longoni,\f1\fs
16\cf0\b0\i0\ul0\strike0 D,\f1\fs16\cf0\b0\i0\ul0\strike0 Svahn\f1\fs16\cf0\b0
\i0\ul0\strike0 J.\f2\fs16\cf0\b0\i\ul0\strike0 et\f2\fs16\cf0\b0\i\ul0\strike
0 al.\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 Bone\f1\fs16\cf0\
b0\i0\ul0\strike0 Marrow\f1\fs16\cf0\b0\i0\ul0\strike0 Failure\f1\fs16\cf0\b0\
i0\ul0\strike0 Study\f1\fs16\cf0\b0\i0\ul0\strike0 Group\f1\fs16\cf0\b0\i0\ul0
\strike0 of\f1\fs16\cf0\b0\i0\ul0\strike0 the\f1\fs16\cf0\b0\i0\ul0\strike0 A
IEOP\f1\fs16\cf0\b0\i0\ul0\strike0 (Italian\f1\fs16\cf0\b0\i0\ul0\strike0 Asso
ciation\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 of\f1\fs16\cf0\b
0\i0\ul0\strike0 Paediatric\f1\fs16\cf0\b0\i0\ul0\strike0 Haematology\f1\fs16\
cf0\b0\i0\ul0\strike0 Oncology).\f1\fs16\cf0\b0\i0\ul0\strike0 Cyclosporin\f1\
fs16\cf0\b0\i0\ul0\strike0 A\f1\fs16\cf0\b0\i0\ul0\strike0 response\f1\fs16\cf
0\b0\i0\ul0\strike0 and\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0
dependence\f1\fs16\cf0\b0\i0\ul0\strike0 in\f1\fs16\cf0\b0\i0\ul0\strike0 chi
ldren\f1\fs16\cf0\b0\i0\ul0\strike0 with\f1\fs16\cf0\b0\i0\ul0\strike0 acquire
d\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anaemia
:\f1\fs16\cf0\b0\i0\ul0\strike0 a\f1\fs16\cf0\b0\i0\ul0\strike0 multicentre\pa
r\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 retrospective\f1\fs16\cf0\
b0\i0\ul0\strike0 study\f1\fs16\cf0\b0\i0\ul0\strike0 with\f1\fs16\cf0\b0\i0\u
l0\strike0 long-term\f1\fs16\cf0\b0\i0\ul0\strike0 observation\f1\fs16\cf0\b0\
i0\ul0\strike0 follow-up.\f2\fs16\cf0\b0\i\ul0\strike0 British\par\pard\plain\
li0\sl-200\f2\fs16\cf0\b0\i\ul0\strike0 Journal\f2\fs16\cf0\b0\i\ul0\strike0 of
\f2\fs16\cf0\b0\i\ul0\strike0 Haematology\f1\fs16\cf0\b0\i0\ul0\strike0 2008;1
40:197\u8211?205.\par\pard\plain\li0\sl-250\f1\fs16\cf0\b0\i0\ul0\strike0 Tichel
li\f1\fs16\cf0\b0\i0\ul0\strike0 A,\f1\fs16\cf0\b0\i0\ul0\strike0 Passweg\f1\f
s16\cf0\b0\i0\ul0\strike0 J,\f1\fs16\cf0\b0\i0\ul0\strike0 Nissen\f1\fs16\cf0\
b0\i0\ul0\strike0 C,\f1\fs16\cf0\b0\i0\ul0\strike0 Bargetzi\f1\fs16\cf0\b0\i0\
ul0\strike0 M,\f1\fs16\cf0\b0\i0\ul0\strike0 Hoffmann\f1\fs16\cf0\b0\i0\ul0\st
rike0 T,\f1\fs16\cf0\b0\i0\ul0\strike0 Wodnar-\par\pard\plain\li0\sl-200\f1\fs
16\cf0\b0\i0\ul0\strike0 Filipowicz\f1\fs16\cf0\b0\i0\ul0\strike0 A,\f2\fs16\cf
0\b0\i\ul0\strike0 et\f2\fs16\cf0\b0\i\ul0\strike0 al\f1\fs16\cf0\b0\i0\ul0\st
rike0 .\f1\fs16\cf0\b0\i0\ul0\strike0 Repeated\f1\fs16\cf0\b0\i0\ul0\strike0 t
reatment\f1\fs16\cf0\b0\i0\ul0\strike0 with\f1\fs16\cf0\b0\i0\ul0\strike0 hors
e\f1\fs16\cf0\b0\i0\ul0\strike0 antilymphocyte\par\pard\plain\li0\sl-200\f1\fs1
6\cf0\b0\i0\ul0\strike0 globulin\f1\fs16\cf0\b0\i0\ul0\strike0 for\f1\fs16\cf0\
b0\i0\ul0\strike0 severe\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0
\i0\ul0\strike0 anaemia.\f2\fs16\cf0\b0\i\ul0\strike0 British\f2\fs16\cf0\b0\i
\ul0\strike0 Journal\f2\fs16\cf0\b0\i\ul0\strike0 of\f2\fs16\cf0\b0\i\ul0\stri
ke0 Haematology\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 1998;\f
1\fs16\cf0\b0\i0\ul0\strike0 100:\f1\fs16\cf0\b0\i0\ul0\strike0 393\u8211?400.
\par\pard\plain\li0\sl-250\f1\fs16\cf0\b0\i0\ul0\strike0 Di\f1\fs16\cf0\b0\i0\ul
0\strike0 Bona\f1\fs16\cf0\b0\i0\ul0\strike0 E,\f1\fs16\cf0\b0\i0\ul0\strike0
Rodeghiero\f1\fs16\cf0\b0\i0\ul0\strike0 F,\f1\fs16\cf0\b0\i0\ul0\strike0 Bru
no\f1\fs16\cf0\b0\i0\ul0\strike0 B,\f1\fs16\cf0\b0\i0\ul0\strike0 Gabbas\f1\fs
16\cf0\b0\i0\ul0\strike0 A,\f1\fs16\cf0\b0\i0\ul0\strike0 Foa\f1\fs16\cf0\b0\i
0\ul0\strike0 P,\f1\fs16\cf0\b0\i0\ul0\strike0 Locasciulli\f1\fs16\cf0\b0\i0\u
l0\strike0 A,\par\pard\plain\li0\sl-200\f2\fs16\cf0\b0\i\ul0\strike0 et\f2\fs16
\cf0\b0\i\ul0\strike0 al.\f1\fs16\cf0\b0\i0\ul0\strike0 Rabbit\f1\fs16\cf0\b0\
i0\ul0\strike0 antithymocyte\f1\fs16\cf0\b0\i0\ul0\strike0 globulin\f1\fs16\cf
0\b0\i0\ul0\strike0 (r-ATG)\f1\fs16\cf0\b0\i0\ul0\strike0 plus\f1\fs16\cf0\b0\
i0\ul0\strike0 cyclosporine\f1\fs16\cf0\b0\i0\ul0\strike0 and\par\pard\plain\l

i0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 granulocyte\f1\fs16\cf0\b0\i0\ul0\strike
0 colony\f1\fs16\cf0\b0\i0\ul0\strike0 stimulating\f1\fs16\cf0\b0\i0\ul0\strik
e0 factor\f1\fs16\cf0\b0\i0\ul0\strike0 is\f1\fs16\cf0\b0\i0\ul0\strike0 an\f
1\fs16\cf0\b0\i0\ul0\strike0 effective\f1\fs16\cf0\b0\i0\ul0\strike0 treatment
\f1\fs16\cf0\b0\i0\ul0\strike0 for\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\
ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anaemia\f1\fs16\cf0\b0\i0\ul
0\strike0 patients\f1\fs16\cf0\b0\i0\ul0\strike0 unresponsive\f1\fs16\cf0\b0\i
0\ul0\strike0 to\f1\fs16\cf0\b0\i0\ul0\strike0 a\f1\fs16\cf0\b0\i0\ul0\strike0
first\f1\fs16\cf0\b0\i0\ul0\strike0 course\f1\fs16\cf0\b0\i0\ul0\strike0 of\
f1\fs16\cf0\b0\i0\ul0\strike0 intensive\par\pard\plain\li0\sl-200\f1\fs16\cf0\b
0\i0\ul0\strike0 immunosuppressive\f1\fs16\cf0\b0\i0\ul0\strike0 therapy.\f1\fs
16\cf0\b0\i0\ul0\strike0 Gruppo\f1\fs16\cf0\b0\i0\ul0\strike0 Italiano\f1\fs16
\cf0\b0\i0\ul0\strike0 Trapianto\f1\fs16\cf0\b0\i0\ul0\strike0 di\f1\fs16\cf0\
b0\i0\ul0\strike0 Midollo\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strik
e0 Osseo\f1\fs16\cf0\b0\i0\ul0\strike0 (GITMO).\f2\fs16\cf0\b0\i\ul0\strike0 B
ritish\f2\fs16\cf0\b0\i\ul0\strike0 Journal\f2\fs16\cf0\b0\i\ul0\strike0 of\f2
\fs16\cf0\b0\i\ul0\strike0 Haematology\f1\fs16\cf0\b0\i0\ul0\strike0 1999;107:
330\u8211?334.\par\pard\plain\li0\sl-250\f1\fs16\cf0\b0\i0\ul0\strike0 Scheinber
g\f1\fs16\cf0\b0\i0\ul0\strike0 P,\f1\fs16\cf0\b0\i0\ul0\strike0 Nunez\f1\fs16
\cf0\b0\i0\ul0\strike0 O,\f1\fs16\cf0\b0\i0\ul0\strike0 Young\f1\fs16\cf0\b0\i
0\ul0\strike0 NS.\f1\fs16\cf0\b0\i0\ul0\strike0 Re-treatment\f1\fs16\cf0\b0\i0
\ul0\strike0 with\f1\fs16\cf0\b0\i0\ul0\strike0 rabbit\par\pard\plain\li0\sl-2
00\f1\fs16\cf0\b0\i0\ul0\strike0 antithymocyte\f1\fs16\cf0\b0\i0\ul0\strike0 gl
obulin\f1\fs16\cf0\b0\i0\ul0\strike0 and\f1\fs16\cf0\b0\i0\ul0\strike0 ciclosp
orin\f1\fs16\cf0\b0\i0\ul0\strike0 for\f1\fs16\cf0\b0\i0\ul0\strike0 patients\
f1\fs16\cf0\b0\i0\ul0\strike0 with\f1\fs16\cf0\b0\i0\ul0\strike0 relapsed\par\
pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 or\f1\fs16\cf0\b0\i0\ul0\str
ike0 refractory\f1\fs16\cf0\b0\i0\ul0\strike0 severe\f1\fs16\cf0\b0\i0\ul0\str
ike0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anaemia.\f2\fs16\cf0\b0\i\ul0\stri
ke0 British\f2\fs16\cf0\b0\i\ul0\strike0 Journal\f2\fs16\cf0\b0\i\ul0\strike0
of\f2\fs16\cf0\b0\i\ul0\strike0 Haematology\par\pard\plain\li0\sl-200\f1\fs16\
cf0\b0\i0\ul0\strike0 2006;133:622\u8211?627.\par\pard\plain\li0\sl-250\f1\fs16\
cf0\b0\i0\ul0\strike0 Gupta\f1\fs16\cf0\b0\i0\ul0\strike0 V,\f1\fs16\cf0\b0\i0\
ul0\strike0 Gordon-\f1\fs16\cf0\b0\i0\ul0\strike0 Smith\f1\fs16\cf0\b0\i0\ul0\
strike0 EC,\f1\fs16\cf0\b0\i0\ul0\strike0 Cook\f1\fs16\cf0\b0\i0\ul0\strike0
G,\f1\fs16\cf0\b0\i0\ul0\strike0 Parker\f1\fs16\cf0\b0\i0\ul0\strike0 A,\f1\fs
16\cf0\b0\i0\ul0\strike0 Duguid\f1\fs16\cf0\b0\i0\ul0\strike0 JK,\f2\fs16\cf0\
b0\i\ul0\strike0 et\f2\fs16\cf0\b0\i\ul0\strike0 al.\f1\fs16\cf0\b0\i0\ul0\str
ike0 A\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 third\f1\fs16\cf
0\b0\i0\ul0\strike0 course\f1\fs16\cf0\b0\i0\ul0\strike0 of\f1\fs16\cf0\b0\i0\
ul0\strike0 anti-thymocyte\f1\fs16\cf0\b0\i0\ul0\strike0 globulin\f1\fs16\cf0\
b0\i0\ul0\strike0 in\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\
ul0\strike0 anaemia\f1\fs16\cf0\b0\i0\ul0\strike0 is\f1\fs16\cf0\b0\i0\ul0\str
ike0 only\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 beneficial\f1
\fs16\cf0\b0\i0\ul0\strike0 in\f1\fs16\cf0\b0\i0\ul0\strike0 previous\f1\fs16\
cf0\b0\i0\ul0\strike0 responders.\f2\fs16\cf0\b0\i\ul0\strike0 British\f2\fs16
\cf0\b0\i\ul0\strike0 Journal\f2\fs16\cf0\b0\i\ul0\strike0 of\f2\fs16\cf0\b0\i
\ul0\strike0 Haematology\f1\fs16\cf0\b0\i0\ul0\strike0 2005;\par\pard\plain\li
0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 129:\f1\fs16\cf0\b0\i0\ul0\strike0 110\u
8211?117.\par\pard\plain\li0\sl-250\f1\fs16\cf0\b0\i0\ul0\strike0 Locasciulli\f1
\fs16\cf0\b0\i0\ul0\strike0 A,\f1\fs16\cf0\b0\i0\ul0\strike0 Arcese\f1\fs16\cf
0\b0\i0\ul0\strike0 W,\f1\fs16\cf0\b0\i0\ul0\strike0 Locatelli\f1\fs16\cf0\b0\
i0\ul0\strike0 F,\f1\fs16\cf0\b0\i0\ul0\strike0 DiBona\f1\fs16\cf0\b0\i0\ul0\s
trike0 E,\f1\fs16\cf0\b0\i0\ul0\strike0 Bacigalupo\f1\fs16\cf0\b0\i0\ul0\strik
e0 A.\f1\fs16\cf0\b0\i0\ul0\strike0 Treatment\par\pard\plain\li0\sl-200\f1\fs1
6\cf0\b0\i0\ul0\strike0 of\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b
0\i0\ul0\strike0 anaemia\f1\fs16\cf0\b0\i0\ul0\strike0 with\f1\fs16\cf0\b0\i0\
ul0\strike0 granulocyte-colony\f1\fs16\cf0\b0\i0\ul0\strike0 stimulating\f1\fs
16\cf0\b0\i0\ul0\strike0 factor\f1\fs16\cf0\b0\i0\ul0\strike0 and\par\pard\pla
in\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 risk\f1\fs16\cf0\b0\i0\ul0\strike0
of\f1\fs16\cf0\b0\i0\ul0\strike0 malignancy.\f2\fs16\cf0\b0\i\ul0\strike0 The\
f2\fs16\cf0\b0\i\ul0\strike0 Lancet\f1\fs16\cf0\b0\i0\ul0\strike0 2001;357:43\
u8211?44.\par\pard\plain\li0\sl-250\f1\fs16\cf0\b0\i0\ul0\strike0 Socie\u180?\f1
\fs16\cf0\b0\i0\ul0\strike0 G,\f1\fs16\cf0\b0\i0\ul0\strike0 Henry-Amar\f1\fs1
6\cf0\b0\i0\ul0\strike0 M,\f1\fs16\cf0\b0\i0\ul0\strike0 Bacigalupo\f1\fs16\cf
0\b0\i0\ul0\strike0 A,\f1\fs16\cf0\b0\i0\ul0\strike0 Hows\f1\fs16\cf0\b0\i0\ul
0\strike0 J,\f1\fs16\cf0\b0\i0\ul0\strike0 Tichelli\f1\fs16\cf0\b0\i0\ul0\stri
ke0 A,\f1\fs16\cf0\b0\i0\ul0\strike0 Ljungman\f1\fs16\cf0\b0\i0\ul0\strike0 P
,\par\pard\plain\li0\sl-200\f2\fs16\cf0\b0\i\ul0\strike0 et\f2\fs16\cf0\b0\i\ul0
\strike0 al.\f1\fs16\cf0\b0\i0\ul0\strike0 Malignant\f1\fs16\cf0\b0\i0\ul0\str
ike0 tumors\f1\fs16\cf0\b0\i0\ul0\strike0 occurring\f1\fs16\cf0\b0\i0\ul0\stri
ke0 after\f1\fs16\cf0\b0\i0\ul0\strike0 treatment\f1\fs16\cf0\b0\i0\ul0\strike
0 of\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 ane
mia.\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 European\f1\fs16\cf
0\b0\i0\ul0\strike0 Bone\f1\fs16\cf0\b0\i0\ul0\strike0 Marrow\f1\fs16\cf0\b0\i
0\ul0\strike0 Transplantation-Severe\f1\fs16\cf0\b0\i0\ul0\strike0 Aplastic\f1
\fs16\cf0\b0\i0\ul0\strike0 Anaemia\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0
\ul0\strike0 Working\f1\fs16\cf0\b0\i0\ul0\strike0 Party.\f2\fs16\cf0\b0\i\ul0\
strike0 The\f2\fs16\cf0\b0\i\ul0\strike0 New\f2\fs16\cf0\b0\i\ul0\strike0 Eng
land\f2\fs16\cf0\b0\i\ul0\strike0 Journal\f2\fs16\cf0\b0\i\ul0\strike0 of\f2\f
s16\cf0\b0\i\ul0\strike0 Medicine\f1\fs16\cf0\b0\i0\ul0\strike0 1993;329:1152\
u8211?\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 1157.\par\pard\pl
ain\li0\sl-250\f1\fs16\cf0\b0\i0\ul0\strike0 George\f1\fs16\cf0\b0\i0\ul0\strike
0 B,\f1\fs16\cf0\b0\i0\ul0\strike0 Mathews\f1\fs16\cf0\b0\i0\ul0\strike0 V,\f
1\fs16\cf0\b0\i0\ul0\strike0 Lakshmi\f1\fs16\cf0\b0\i0\ul0\strike0 KM,\f1\fs16
\cf0\b0\i0\ul0\strike0 Ahmed\f1\fs16\cf0\b0\i0\ul0\strike0 R,\f1\fs16\cf0\b0\i
0\ul0\strike0 Abraham\f1\fs16\cf0\b0\i0\ul0\strike0 A,\f1\fs16\cf0\b0\i0\ul0\s
trike0 Srivastava\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 A.\f1
\fs16\cf0\b0\i0\ul0\strike0 Response\f1\fs16\cf0\b0\i0\ul0\strike0 to\f1\fs16\
cf0\b0\i0\ul0\strike0 Immunosuppressive\f1\fs16\cf0\b0\i0\ul0\strike0 Therapy\
f1\fs16\cf0\b0\i0\ul0\strike0 with\f1\fs16\cf0\b0\i0\ul0\strike0 Antithymocyte
\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 Globulin\f1\fs16\cf0\b0
\i0\ul0\strike0 (ATG)\f1\fs16\cf0\b0\i0\ul0\strike0 In\f1\fs16\cf0\b0\i0\ul0\s
trike0 Older\f1\fs16\cf0\b0\i0\ul0\strike0 Patients\f1\fs16\cf0\b0\i0\ul0\stri
ke0 with\f1\fs16\cf0\b0\i0\ul0\strike0 Aplastic\f1\fs16\cf0\b0\i0\ul0\strike0
Anemia.\f2\fs16\cf0\b0\i\ul0\strike0 Blood\f1\fs16\cf0\b0\i0\ul0\strike0 (ASH
\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 Annual\f1\fs16\cf0\b0\i
0\ul0\strike0 Meeting\f1\fs16\cf0\b0\i0\ul0\strike0 Abstracts)\f1\fs16\cf0\b0\
i0\ul0\strike0 2011;\f1\fs16\cf0\b0\i0\ul0\strike0 118:\f1\fs16\cf0\b0\i0\ul0\
strike0 Abstract\f1\fs16\cf0\b0\i0\ul0\strike0 4374\par\pard\plain\li0\sl-250\
f1\fs16\cf0\b0\i0\ul0\strike0 Nair\f1\fs16\cf0\b0\i0\ul0\strike0 V, \f1\fs16\cf
0\b0\i0\ul0\strike0 Sharma\f1\fs16\cf0\b0\i0\ul0\strike0 A, \f1\fs16\cf0\b0\i0
\ul0\strike0 Das\f1\fs16\cf0\b0\i0\ul0\strike0 S, \f1\fs16\cf0\b0\i0\ul0\strik
e0 Sondhi\f1\fs16\cf0\b0\i0\ul0\strike0 V, \f1\fs16\cf0\b0\i0\ul0\strike0 Sha
rma\f1\fs16\cf0\b0\i0\ul0\strike0 S.\f1\fs16\cf0\b0\i0\ul0\strike0 Immunosupre
ssive\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 therapy\f1\fs16\cf
0\b0\i0\ul0\strike0 in\f1\fs16\cf0\b0\i0\ul0\strike0 adults\f1\fs16\cf0\b0\i0\
ul0\strike0 with\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\ul0\
strike0 anemia-single\f1\fs16\cf0\b0\i0\ul0\strike0 institution\f1\fs16\cf0\b0
\i0\ul0\strike0 experience\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\stri
ke0 from\f1\fs16\cf0\b0\i0\ul0\strike0 India.\f2\fs16\cf0\b0\i\ul0\strike0 Pos
tgraduate\f2\fs16\cf0\b0\i\ul0\strike0 Medical\f2\fs16\cf0\b0\i\ul0\strike0 Jo
urnal\f1\fs16\cf0\b0\i0\ul0\strike0 2013;89:508-515.\par\pard\plain\li0\sl-250\
f1\fs16\cf0\b0\i0\ul0\strike0 Nair\f1\fs16\cf0\b0\i0\ul0\strike0 V,\f1\fs16\cf0
\b0\i0\ul0\strike0 Sondhi\f1\fs16\cf0\b0\i0\ul0\strike0 V,\f1\fs16\cf0\b0\i0\u
l0\strike0 Sharma\f1\fs16\cf0\b0\i0\ul0\strike0 A,\f1\fs16\cf0\b0\i0\ul0\strik
e0 Das\f1\fs16\cf0\b0\i0\ul0\strike0 S,\f1\fs16\cf0\b0\i0\ul0\strike0 Sharma\
f1\fs16\cf0\b0\i0\ul0\strike0 S.\f1\fs16\cf0\b0\i0\ul0\strike0 Survival\f1\fs1
6\cf0\b0\i0\ul0\strike0 after\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\s
trike0 imunosupressive\f1\fs16\cf0\b0\i0\ul0\strike0 therapy\f1\fs16\cf0\b0\i0\

ul0\strike0 in\f1\fs16\cf0\b0\i0\ul0\strike0 children\f1\fs16\cf0\b0\i0\ul0\st
rike0 with\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike
0 anemia.\f2\fs16\cf0\b0\i\ul0\strike0 Indian\par\pard\plain\li0\sl-200\f2\fs1
6\cf0\b0\i\ul0\strike0 Pediatrics\f1\fs16\cf0\b0\i0\ul0\strike0 2011;49:371-376
.\par\pard\plain\li0\sl-250\f1\fs16\cf0\b0\i0\ul0\strike0 George\f1\fs16\cf0\b0\
i0\ul0\strike0 B,\f1\fs16\cf0\b0\i0\ul0\strike0 Mathews\f1\fs16\cf0\b0\i0\ul0\
strike0 V,Viswabandya\f1\fs16\cf0\b0\i0\ul0\strike0 A,\f1\fs16\cf0\b0\i0\ul0\s
trike0 Lakshmi\f1\fs16\cf0\b0\i0\ul0\strike0 KM,\f1\fs16\cf0\b0\i0\ul0\strike0
Srivastava\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 A,Chandy\f1
\fs16\cf0\b0\i0\ul0\strike0 M.\f1\fs16\cf0\b0\i0\ul0\strike0 Allogeneic\f1\fs1
6\cf0\b0\i0\ul0\strike0 stem\f1\fs16\cf0\b0\i0\ul0\strike0 cell\f1\fs16\cf0\b0
\i0\ul0\strike0 transplantation\f1\fs16\cf0\b0\i0\ul0\strike0 is\f1\fs16\cf0\b
0\i0\ul0\strike0 superior\f1\fs16\cf0\b0\i0\ul0\strike0 to\par\pard\plain\li0\
sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 immunosuppressive\f1\fs16\cf0\b0\i0\ul0\str
ike0 therapy\f1\fs16\cf0\b0\i0\ul0\strike0 in\f1\fs16\cf0\b0\i0\ul0\strike0 I
ndian\f1\fs16\cf0\b0\i0\ul0\strike0 children\f1\fs16\cf0\b0\i0\ul0\strike0 wit
h\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\b0\i0\ul0\strike0 anemia\
par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 -\f1\fs16\cf0\b0\i0\ul0\
strike0 a\f1\fs16\cf0\b0\i0\ul0\strike0 single\f1\fs16\cf0\b0\i0\ul0\strike0
center\f1\fs16\cf0\b0\i0\ul0\strike0 analysis\f1\fs16\cf0\b0\i0\ul0\strike0 of
\f1\fs16\cf0\b0\i0\ul0\strike0 100\f1\fs16\cf0\b0\i0\ul0\strike0 patients.\f2\
fs16\cf0\b0\i\ul0\strike0 Pediatric\f2\fs16\cf0\b0\i\ul0\strike0 Haematology\f
2\fs16\cf0\b0\i\ul0\strike0 and\par\pard\plain\li0\sl-200\f2\fs16\cf0\b0\i\ul0\
strike0 Oncology\f1\fs16\cf0\b0\i0\ul0\strike0 2010;27:122-131.\par\pard\plain\
li0\sl-250\f1\fs16\cf0\b0\i0\ul0\strike0 Sharma\f1\fs16\cf0\b0\i0\ul0\strike0 R
,\f1\fs16\cf0\b0\i0\ul0\strike0 Chandra\f1\fs16\cf0\b0\i0\ul0\strike0 J,\f1\fs
16\cf0\b0\i0\ul0\strike0 Sharma\f1\fs16\cf0\b0\i0\ul0\strike0 S,\f1\fs16\cf0\b
0\i0\ul0\strike0 Pemde\f1\fs16\cf0\b0\i0\ul0\strike0 H,\f1\fs16\cf0\b0\i0\ul0\
strike0 Singh\f1\fs16\cf0\b0\i0\ul0\strike0 V.\f1\fs16\cf0\b0\i0\ul0\strike0
Antithymocyte\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 globulin\f
1\fs16\cf0\b0\i0\ul0\strike0 and\f1\fs16\cf0\b0\i0\ul0\strike0 cyclosporine\f1
\fs16\cf0\b0\i0\ul0\strike0 in\f1\fs16\cf0\b0\i0\ul0\strike0 children\f1\fs16\
cf0\b0\i0\ul0\strike0 with\f1\fs16\cf0\b0\i0\ul0\strike0 aplastic\f1\fs16\cf0\
b0\i0\ul0\strike0 anemia\f1\fs16\cf0\b0\i0\ul0\strike0 \u8211?\f1\fs16\cf0\b0\
i0\ul0\strike0 A\par\pard\plain\li0\sl-200\f1\fs16\cf0\b0\i0\ul0\strike0 develo
ping\f1\fs16\cf0\b0\i0\ul0\strike0 country\f1\fs16\cf0\b0\i0\ul0\strike0 exper
ience.\f2\fs16\cf0\b0\i\ul0\strike0 Journal\f2\fs16\cf0\b0\i\ul0\strike0 of\f2
\fs16\cf0\b0\i\ul0\strike0 Pediatric\f2\fs16\cf0\b0\i\ul0\strike0 Haematology/
\par\pard\plain\li0\sl-200\f2\fs16\cf0\b0\i\ul0\strike0 Oncology\f1\fs16\cf0\b0\
i0\ul0\strike0 2012;34:93-95.}

04 Immunosuppressive Therapy For Aplastic

Transféré par

Informations du document

Titre original

Copyright

Formats disponibles

Partager ce document

Partager ou intégrer le document

Options de partage

Avez-vous trouvé ce document utile ?

Ce contenu est-il inapproprié ?

Droits d'auteur :

Formats disponibles

04 Immunosuppressive Therapy For Aplastic

Transféré par

Droits d'auteur :

Formats disponibles

{\rtf\ansi\deff0{\fonttbl{\f0 Garamond;}{\f1 Times New Roman;}{\f2 Segoe UI;}{\f

3 Palatino Linotype;}{\f4 Helvetica;}}{\colortbl\red0\green0\blue0;\red255\green

i0\ul0\strike0 IST\f2\fs26\cf0\b\i0\ul0\strike0 for\f2\fs26\cf0\b\i0\ul0\strik

b0\i0\ul0\strike0 52%\f3\fs18\cf0\b0\i0\ul0\strike0 and\f3\fs18\cf0\b0\i0\ul0\

0\b0\i0\ul0\strike0 g\f3\fs18\cf0\b0\i0\ul0\strike0 e\f3\fs18\cf0\b0\i0\ul0\st

\ul0\strike0 (\f3\fs18\cf0\b0\i0\ul0\strike0 e\f3\fs18\cf0\b0\i0\ul0\strike0 v

\strike0 years,\f3\fs18\cf0\b0\i0\ul0\strike0 but\f3\fs18\cf0\b0\i0\ul0\strike

{\sp{\sn posrelh}{\sv 1}}

\f3\fs18\cf0\b0\i0\ul0\strike0 ,\f3\fs18\cf0\b0\i0\ul0\strike0 AT\f3\fs18\cf0\

f3\fs18\cf0\b0\i0\ul0\strike0 Pharmacia\f3\fs18\cf0\b0\i0\ul0\strike0 and\f3\f

s18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 British\f3\fs18\cf

0\strike0 skin\par\pard\plain\li0\sl-230\f3\fs18\cf0\b0\i0\ul0\strike0 test\f3\

ke0 infections\f3\fs18\cf0\b0\i0\ul0\strike0 is\f3\fs18\cf0\b0\i0\ul0\strike0

i0\ul0\strike0 initiated\f3\fs18\cf0\b0\i0\ul0\strike0 on\f3\fs18\cf0\b0\i0\ul

\fs18\cf0\b0\i0\ul0\strike0 stopped\f3\fs18\cf0\b0\i0\ul0\strike0 till\f3\fs18

\i0\ul0\strike0 target\f3\fs18\cf0\b0\i0\ul0\strike0 trough\par\pard\plain\li1

ul0\strike0 of\f3\fs18\cf0\b0\i0\ul0\strike0 other\par\pard\plain\li1021\sl-23

s18\cf0\b0\i0\ul0\strike0 confirmed.\f3\fs10\cf0\b0\i0\ul0\strike0 36\par\pard

eatment\f3\fs18\cf0\b0\i0\ul0\strike0 with\f3\fs18\cf0\b0\i0\ul0\strike0 dapso

\ul0\strike0 response:\f3\fs18\cf0\b0\i0\ul0\strike0 even\f3\fs18\cf0\b0\i0\ul

gh\f3\fs18\cf0\b0\i0\ul0\strike0 overall\f3\fs18\cf0\b0\i0\ul0\strike0 surviva

n\f3\fs18\cf0\b0\i0\ul0\strike0 overall\f3\fs18\cf0\b0\i0\ul0\strike0 survival

18\cf0\b0\i0\ul0\strike0 the\f3\fs18\cf0\b0\i0\ul0\strike0 response\f3\fs18\cf

ws\f1\fs16\cf0\b0\i0\ul0\strike0 J,\f1\fs16\cf0\b0\i0\ul0\strike0 Van\f1\fs16\

200\f2\fs16\cf0\b0\i\ul0\strike0 Blood\f1\fs16\cf0\b0\i0\ul0\strike0 2012;120:1

\fs16\cf0\b0\i0\ul0\strike0 Oneto\f1\fs16\cf0\b0\i0\ul0\strike0 R,\f1\fs16\cf0

f0\b0\i0\ul0\strike0 Appelbaum\f1\fs16\cf0\b0\i0\ul0\strike0 FR,\par\pard\colu

f0\b0\i0\ul0\strike0 the\f1\fs16\cf0\b0\i0\ul0\strike0 BCSH\f1\fs16\cf0\b0\i0\

{\sp{\sn shapePath}{\sv 4}}

{\sp{\sn fBehindDocument}{\sv 1}}

{\sp{\sn fFillOK}{\sv 0}}

{\sp{\sn fLayoutInCell}{\sv 1}}

0\strike0 .\f1\fs16\cf0\b0\i0\ul0\strike0 Immunosuppressive\f1\fs16\cf0\b0\i0\

cf0\b0\i0\ul0\strike0 severe\f1\fs16\cf0\b0\i0\ul0\strike0 disease\f1\fs16\cf0

1\fs16\cf0\b0\i0\ul0\strike0 leukemia\f1\fs16\cf0\b0\i0\ul0\strike0 as\par\par

i0\ul0\strike0 cyclosporine\f1\fs16\cf0\b0\i0\ul0\strike0 and\par\pard\plain\l

trike0 imunosupressive\f1\fs16\cf0\b0\i0\ul0\strike0 therapy\f1\fs16\cf0\b0\i0\

Vous aimerez peut-être aussi